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Abstract
The neuronal ceroid lipofuscinoses (NCLs, Batten Disease) are a group of 
lysosomal storage disorders caused by mutations in known and unknown 
proteins with different cellular locations. Mutations in the CLN6 gene cause a 
type of variant late infantile NCL (vLINCL). The CLN6 protein is located in the 
ER and how mutations in CLN6 cause accumulation of storage material in the 
lysosome is unclear. The aims of this thesis were to establish the tools and 
techniques necessary to analyse the CLN6 protein and to utilise these to 
investigate its subcellular location, to identify proteins that interact with CLN6 
and to elucidate the early cellular responses to loss of functional vLINCL 
proteins, CLN5, CLN6 and CLN8. It was shown that CLN6 can be detected by 
Western blotting, indirect immunofluorescence and immunoprecipitation. A 
construct of CLN6 fused to horseradish peroxidase was cloned for localisation 
studies by indirect immunofluorescence and electron microscopy. CLN6 protein 
and mRNA levels could be depleted using RNA interference and this depletion 
assessed by Western blotting, indirect immunofluorescence and Q-PCR. It was 
not possible to establish whether CLN6 is located within a sub-domain of the ER 
using indirect immunofluorescence or electron microscopy. There was no effect 
on the localisation or stabilisation of wild-type or mutant CLN6 when 
proteasomal or lysosomal inhibitors were used, indicating that CLN6 does not 
traffic to the lysosome and that wild-type and mutant CLN6 were not degraded 
by ER-associated degradation. Endogenous CLN6 was identified in co- 
immunoprecipitation experiments, confirming that it may bind to itself. No other 
proteins were identified that bind to CLN6. Depletion of CLN5, CLN6 and 
CLN8 resulted in an increase in the size and a redistribution to perinuclear areas 
of late endosomes and lysosomes. An increase in long cis-Golgi structures was 
also observed in response to siRNA against CLN6 and CLN8 but not CLN5.
3
Text
Table of Contents
DECLARATION................................................................................................... 2
ABSTRACT............................................................................................................3
TABLE OF CONTENTS.......................................................................................4
T e x t ............................................................................................................................................................ 4
F i g u r e s ......................................................................................................................................................8
T a b l e s .......................................................................................................................................................9
ABBREVIATIONS.............................................................................................. 11
1. INTRODUCTION.........................................................................................15
1.1 O v e r v ie w ...................................................................................................................................... 16
1 .2  L y s o s o m a l  s t o r a g e  d is o r d e r s ..................................................................................... 17
1.3 E n d o p l a s m ic  r e t ic u l u m .................................................................................................... 18
1.3.1 Translocation............................................................................................ 19
1.3.2 Folding and post-translational modifications.......................................19
1.3.3 ER export...................................................................................................20
1.3.4 Recycling ...................................................................................................21
1.3.5 ERAD ......................................................................................................... 21
1.3.6 Calcium storage........................................................................................2 2
1.3.7 Autophagy..................................................................................................2 2
1.3.8 Lipid synthesis and transport.................................................................. 23
1 .4  L y s o s o m e ......................................................................................................................................23
1.5 N e u r o n a l  C e r o id  L ip o f u s c in o s is ...............................................................................25
1.5.1 C LN 1 ......................................................................................................... 26
1.5.2 Cathepsin D .............................................................................................. 2 7
1.5.3 C LN 2 ..........................................................................................................28
1.5.4 CLN 3 ..........................................................................................................29
1.5.5 C LN 5 ..........................................................................................................31
1.5.6 C LN 8 ..........................................................................................................32
4
1.6 CLN6..................................................................................................................34
1.6.1 Possible functions o fC L N 6 .....................................................................38
1.7 P r o je c t  a i m s ............................................................................................................................... 38
2. MATERIALS AND METHODS..................................................................39
2.1  L ist  o f  r e a g e n t s ..................................................................................................................... 3 9
2.2 A n t ib o d ie s ................................................................................................................................... 43
2.2.1 Antibody production.................................................................................43
2.2.2 Antibody purification................................................................................43
2.2.3 List o f antibodies used ..............................................................................45
2.3 C l o n in g  a n d  M o l e c u l a r  B io l o g y ............................................................................. 46
2.3.1 Restriction digest.......................................................................................46
2.3.2 Ligation......................................................................................................47
2.3.3 Site directed mutagenesis (with all primers) .........................................47
2.3.4 Transformation..........................................................................................48
2.3.5 DNA and RNA preparations....................................................................48
2.3.6 DNA sequencing........................................................................................50
2.3.7 Agarose gels.............................................................................................. 50
2.3.8 List o f constructs used ..............................................................................50
2.3.9 Q-PCR ....................................................................................................... 50
2.3.10 Primers and siRNA.................................................................................52
2.4 C e l l  c u l t u r e ............................................................................................................................. 53
2.4.1 List o f cell types/lines used ......................................................................53
2.4.2 List o f fibroblast cells lines used............................................................ 53
2.4.3 Culture conditions.................................................................................... 53
2.4.4 Transfection.............................................................................................. 54
2.4.5 Microinjection...........................................................................................54
2.5 P r o t h n  w o r k ............................................................................................................................55
2.5.1 Cell extracts.............................................................................................. 55
2.5.2 Immunoprecipitation and crosslinking...................................................56
2.5.3 SDS-PAGE.................................................................................................57
2.5.4 Coomassie staining 1 and 2 .....................................................................57
2.5.5 Silver staining ........................................................................................... 58
2.5.6 Western blotting........................................................................................58
5
2.5.7 Mass spectrometry................................................................................... 59
2.5.8 Indirect immunofluorescence and quantitative immunofluorescence
(QuIF)..................................................................................................................59
2.5.9 TSA staining ofHRP containing cells....................................................60
2.6 E l e c t r o n  m ic r o s c o p y ............................................................................................... 60
2.6.1 DAB reaction for HRP chimeras............................................................60
2.6.2 Embedding.................................................................................................61
RESULTS.............................................................................................................62
CHAPTER 3 -  SETTING UP THE TOOLS AND TECHNIQUES............. 63
3.1 W e s t e r n  a n a l y s is .................................................................................................................. 64
3.2  CLN6 Im m u n o p r e c ip it  a t i o n .................................................................................. 68
3.3  In d ir e c t  im m u n o f l u o r e s c e n c e .................................................................................... 71
3 .4  CLN6-HRP c h im e r a ...................................................................................................73
3.5 CLN6 R N A i.................................................................................................................... 77
6.3 C h a p t e r  3 S u m m a r y .............................................................................................................81
CHAPTER 4 -  CLN6 LOCALISATION..........................................................82
4.1 CLN6 CO-LOCALISATION STUDY WITHIN THE ENDOPLASMIC RETICULUM 
USING IMMUNOFLUORESCENCE MICROSCOPY............................................................... 83
4 .2  CLN6-H R P d is t r ib u t io n  w it h in  t h e  e n d o p l a s m ic  r e t ic u l u m ................ 92
4.3 C LN 6 TRAFFICKING IN RESPONSE TO LYSOSOMAL AND PROTEASOMAL 
INHIBITORS.............................................................................................................................100
4 .4  C h a p t e r  4  S u m m a r y .......................................................................................................... 105
CHAPTER 5 -  CLN6 INTERACTORS......................................................... 106
5.1 CO-IMMUNOPRECIPIT ATION 1 ...................................................................................107
5.1.1 Band 2 ...................................................................................................... 110
5.1.2 Band 3 ...................................................................................................... 110
5.1.3 Band 5 ...................................................................................................... 110
5.1.4 Band 7.......................................................................................................I l l
5.2 CO-IMMUNOPRECIPITATION 2 ...................................................................................113
5.3 Co-IMMUNOPRECIPITATION 3 ...................................................................................117
5 .4  C h a p t e r  5 S u m m a r y .......................................................................................................... 120
6
CHAPTER 6 -  SIRNA SCREEN OF VLINCL PROTEINS....................... 121
6.1 siRNA a g a i n s t  CLN5 a n d  CLN 8 ................................................................................122
6.2 SiRNA a g a i n s t  CLN5, CLN6 a n d  C L N 8................................................... 125
6.2.1 Lamp-1......................................................................................................126
6.2.2 C D 63 ........................................................................................................127
6.2.3 EEA1.........................................................................................................127
6.2.4 P D I ...........................................................................................................128
6.2.5 GM130..................................................................................................... 128
6.3 C h a p t e r  6 S u m m a r y .......................................................................................................... 138
7. DISCUSSION..................................................................................................139
7.1 S u m m a r y  o f  f i n d i n g s .........................................................................................................140
7.2  L o c a l i s a t i o n  o f  CLN6 ......................................................................................................142
7.2.1 Co-localisation study within the endoplasmic reticulum using 
immunofluorescence microscopy....................................................................142
7.2.2 CLN6-HRP distribution within the endoplasmic reticulum ..............143
7.2.3 CLN6 trafficking in response to lysosomal andproteasomal inhibitors 
............................................................................................................................143
7.2.4 Future work............................................................................................. 144
7.3 CLN6 BINDING PARTNERS................................................................................. 146
7.4 SiRNA SCREEN OF VLINCL PROTEINS............................................................ 149
7.4.1 Lamp-1 and CD63.................................................................................. 149
7.4.2 GM130..................................................................................................... 152
7.5 P o s s i b l e  f u n c t i o n s  o f  C LN 6........................................................................155
7.5.1 Trafficking o f proteins or lipids............................................................155
7.5.2 Golgi to ER or ER to Golgi traffic....................................................... 155
7.6  S u m m a r y  a n d  C o n c l u s i o n s ...........................................................................................157
REFERENCES...................................................................................................159
APPENDIX......................................................................................................... 181
ACKNOWLEDGEMENTS.............................................................................. 186
7
Figures
Figure 3.1.1: Sequence alignment of human, rat and mouse CLN6......................64
Figure 3.1.2: Schematic overview of production of CLN6 antibodies................. 65
Figure 3.1.3: CLN6 Western blotting....................................................................... 67
Figure 3.2: CLN6 Immunoprecipitation...................................................................70
Figure 3.3.1: CLN6 Immunofluorescence............................................................... 72
Figure 3.3.2: CLN6 shows partial co-iocalisation with Protein Disulphide
Isomerase.....................................................................................................................72
Figure 3.4.1: Mutagenesis primers used in CLN6-HRP cloning.......................... 75
Figure 3.4.2: CLN6-HRP shows partial co-localisation with CLN6 and PDI.....76
Figure 3.5.1: Alignment of CLN6 mRNA (gi 1478999) and CLN6 siRNAs......77
Figure 3.5.2: CLN6 siRNA........................................................................................79
Figure 3.5.3: CLN6 siRNA Immunofluorescence................................................... 80
Figure 4.1.1: CLN6 shows no co-localisation with Sec24-GFP........................... 87
Figure 4.1.2: CLN6 shows partial co-localisation with GFP-cytochrome b(5)
(low expression levels).............................................................................................. 88
Figure 4.1.3: CLN6 shows very little co-localisation with GFP-cytochrome b(5)
(low to medium expression levels)............................................................................89
Figure 4.1.4: CLN6 shows co-localisation with GFP-cytochrome b(5) in OSER
structures (high expression levels)............................................................................90
Figure 4.1.5: CLN6 and PDI co-localise with GFP-cytochrome b(5) in OSER
structures......................................................................................................................91
Figure 4.2.1: CLN6-HRP and CLN6 are both located in the ER.......................... 95
Figure 4.2.2: CLN6-HRP partially co-localises with CLN6 and Calreticulin.....96
Figure 4.2.3: CLN6-HRP does not co-localise with late endosomal/lysosomal
markers CD63 and Lamp-1........................................................................................97
Figure 4.2.4: CLN6-HRP throughout the ER in HEK293 cells -  EM cell 1....... 98
Figure 4.2.5: CLN6-HRP throughout the ER in HEK293 cells -  EM cell 2 ....... 99
Figure 4.3.1: Lysosomal and proteasomal inhibitor assay....................................104
Figure 5.1.1: Silver stain of CLN6 co-immunoprecipitation 1 ............................109
Figure 5.1.1.1: CLN6 does not co-immunoprecipitate hNMP65 or beta-tubulin 
 112
8
Figure 5.1.2.1: CLN6 does not co-immunoprecipitate gamma-actin.................112
Figure 5.2.1: Coomassie stain of co-immunoprecipiation 2 ................................ 116
Figure 5.2.2: CLN6 does not co-immunoprecipitate mitochondrial HSP75 116
Figure 5.3.1: Silver stain of co-immunoprecipitation 3........................................ 119
Figure 5.3.2: CLN6 does not co-immunoprecipitate actin ...................................119
Figure 6.1: siRNA CLN5, CLN6 and CLN8......................................................... 124
Figure 6.2.1.1: Lamp-1 staining of siRNA treated cells against CLN5, CLN6 and
CLN 8..........................................................................................................................130
Figure 6.2.1.2: QuIF Lamp-1............................................................................131
Figure 6.2.2: CD63 staining of siRNA treated cells against CLN5, CLN6 and
CLN 8..........................................................................................................................132
Figure 6.2.3: EEA1 staining of siRNA treated cells against CLN5, CLN6 and
CLN 8..........................................................................................................................133
Figure 6.2.4: PDI staining of siRNA treated cells against CLN5, CLN6 and
CLN 8..........................................................................................................................134
Figure 6.2.5.1: GM130 staining of siRNA treated cells against CLN5, CLN6 and
CLN 8..........................................................................................................................135
Figure 6.2.5.2: Golgi structures in siRNA treated cells against CLN5, CLN6 and
CLN 8..........................................................................................................................136
Figure 6.2.5.3: GM130 staining of cells microinjected with siRNA against
CLN5, CLN6 and CLN8................................................................................... 137
Tables
Table 2.2.3.1: Primary antibodies............................................................................. 45
Table 2.2.3.2: Secondary antibodies.........................................................................46
Table: 2.3.2: Ligations............................................................................................... 47
Table 2.3.8: Constructs used..................................................................................... 50
Table 2.4.1: Cell types/lines used..............................................................................53
Table 2.4.2: Fibroblast cell lines used......................................................................53
Table 2.4.4: Transfections.......................................................................................... 54
Table: 2.5.2: Cross-linkers.........................................................................................56
9
Table 3.1: Antibody peptides.....................................................................................64
Table 5.1.1: Non-denaturing lysis buffer................................................................107
Table 5.1.2: Sequencing results from co-immunoprecipitation 1 ........................108
Table 5.2.1: Cross-linking reagents for co-immunoprecipitation....................... 113
Table 5.2.2: NET and HEPES lysis buffers used in co-immunoprecipitation 2 114
Table 5.3.1: Sequencing results of co-immunoprecipitation 3 ............................117
Table 6.1: Organelle markers used in siRNA screen.............................................125
Table 9.1: t-tests (paired student’s t-test, two-tail)................................................ 182
Table 9.2 : Co-immunoprecipitation 1 raw da ta ................................................... 185
Table 9.3: Co-immunoprecipitation 2 raw data .....................................................185
Table 9.4: Co-immunoprecipitation 3 raw data .....................................................185
10
Abbreviations
ABCAl -  ATP-binding cassette transporter A1
Acetate -  sodium acetate
AMF-R -  autocrine motility factor receptor
AP -  adaptor complex
APS -  ammonium persulphate
ASA -  arylsulphatase A
ATP -  adenosine triphosphate
Azide -  sodium azide
BFA -  brefeldin A
BLOC -  biogenesis of lysosomal-related organelle complex 
BME -  beta-mercaptoethanol 
bp -  basepair
BSA -  bovine serum albumin 
Cacodylate -  sodium cacodylate 
C. elegans -  Caenorhabditis elegans
CFTR -  cystic fibrosis transmembrane conductance regulator
CHR -  chromogen
CL -  curvilinear profile
cm -  centimeter
CNS -  central nervous system
COP -  coatomer protein
CsCl -  caesium chloride
CTSD -  cathepsin D
DAB -  diamino benzedene
DDSA -  dodecenyl succinic anhydride
DMP-30 -  2,4,6 tri(dimethylamenomethyl) phenol
DMSO -  dimethyl sulphoxide
DNA -  deoxyribonucleic acid
ds -  double-stranded
dNTP -  deoxyribonucleotide triphosphate 
EDTA -  ethylene diamine tetraacetic acid
11
EGTA -  ethylene glycol tetraacetic acid
elF -  translation initiation factor
EMPR -  progressive epilepsy with mental retardation
ER -  endoplasmic reticulum
ERAD -  ER associated degradation
ERES -  ER exit site
ERGIC -  ER-Golgi intermediate compartment
f  -  final bleed
FCS -  foetal calf serum
FGE -  FGly-generating enzyme
FGly - formylglycine
FP -  fingerprint body
GFP -  green fluorescent protein
GROD -  granular osmiophilic deposit
H20  -  distilled water
HC1 -  hydrochloric acid
HDL-C -  high density lipoprotein cholesterol
hNMP -  human nuclear matrix protein
HRP -  horseradish peroxidase
HSC -  heat shock cognate protein
HSP -  heat shock protein
IF -  indirect immunofluorescence
INCL -  infantile NCL
IP -  immunoprecipiation
JNCL -  juvenile NCL
kDa - kilodalton
L -  ligation
LINCL -  late infantile NCL
LSD -  lysosomal storage disorder
MAM -  mitochondrial associated membranes of the ER
min -  minute(s)
mM -  millimolar
mm - millimeter
12
MNA -  methylnadic anhydride
MnSOD -  manganese superoxide dismutase
MRC-LMCB -  Medical Research Council Laboratory for Molecular Cell 
Biology
mRNA -  messenger RNA 
MSD -  multiple sulphatase deficiency 
mtHSP -  mitochondrial heat shock protein 
MTOC -  microtubule organising centre 
NCL -  neuronal ceroid lipofuscinosis 
NDLB -  non-denaturing lysis buffer 
NE -  nuclear envelope 
nm -  nanometer 
nt -  nucleotide
OSER -  organised smooth ER 
p -  purified antibody 
PBS -  phosphate buffered saline 
PCR -  polymerase chain reaction 
PDI -  protein disulphide isomerase 
PFA -  paraformaldehyde 
PPR -  pentatricopeptide repeat 
PPT1- palmitoyl thioesterase 1 
QC -  quality control
QuIF -  quantitative immunofluorescence
Q-PCR -  quantitative reverse transcription polymerase chain reaction
RAP -  receptor associated protein
RER -  rough ER
RL -  rectilinear body
RNA -  ribonucleic acid
RNAi -  RNA interference
RT -  room temperature
S. cerevisiae -  Saccharomyces cerevisiae
SDS -  sodium dodecyl sulphate
SER -  smooth ER
13
siRNA -  small interfering RNA
S. pombe -  Schizosaccharomyces pombe
SRP -  signal recognition particle
SUMF-1 -  sulphatase modifying factor-1
tER -  transitional ER
TGN -  trans-Golgi network
TLC -  Tram, Lag, CLN8
TMD -  transmembrane domain
TPPI -  tripeptidyl peptidase I
TSA -  tyramide signal amplification
U -  units
UCL -  University College London 
vLINCL -  variant late infantile NCL 
WB -  Western blotting 
pi -  microliter
14
1. Introduction
15
1.1 Overview
The neuronal ceroid lipofuscinoses (NCLs, Batten Disease) are a group of 
lysosomal storage disorders caused by mutations in known and unknown 
proteins with different cellular locations such as endoplasmic reticulum (ER), 
ER-Golgi intermediate compartment (ERGIC), lysosomes and elsewhere. They 
are the most common neurodegenerative disorder in children and most display 
autosomal recessive Mendelian inheritance. Mutations in the CLN6 gene cause a 
type of variant late infantile NCL (vLINCL). The CLN6 protein is located in the 
ER and it is unclear how mutations in CLN6 cause accumulation of storage 
material in the lysosome.
The introduction is divided into two sections. The first includes a brief 
introduction to lysosomal storage disorders, the endoplasmic reticulum and its 
functions and the lysosome. The second section focuses on the NCLs and 
introduces the different proteins involved, with a particular focus on the CLN6 
protein. This is followed by a description of the aims of this project.
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1.2 Lvsosomal storage disorders
Lysosomal storage disorders (LSDs) share the common phenomenon of 
accumulation of storage material in the lysosome accompanied by cellular 
pathology. Over 40 different LSDs have been described to date with different 
components of storage material and different affected cell types (Vellodi, 2005). 
They tend to be progressive, although the rate of progression is variable, and 
show almost exclusively recessive autosomal inheritance. Most LSDs result from 
a defect in a lysosomal hydrolase, leading to incomplete degradation of 
macromolecules and subsequent accumulation of these products (Futerman and 
van Meer, 2004; Winchester et al., 2000).
To date only three LSDs have been shown to be caused by a long-range effect 
between the endoplasmic reticulum and the lysosome. One of these is multiple 
sulphatase deficiency (MSD), a rare autosomal recessive LSD characterised by 
decreased activity of all known sulphatases. This family of proteins is comprised 
of eight enzymes, seven lysosomal and one microsomal, which hydrolyse 
sulphate esters (Schmidt et al., 1995). The sulphatases are post-translationally 
modified in the ER by the FGly-generating enzyme (FGE), which converts a 
cysteine residue to formylglycine (FGly). This modification is essential for the 
catalytic activity of sulphatases. A deficiency in FGE, caused by mutations in the 
sulphatase modifying factor-1 (SUMF-1) gene, results in unmodified, inactive 
sulphatases. This leads to impaired lysosomal catabolism of sulphated 
glycolipids and glycosaminoglycans (Dierks et al., 2003; Landgrebe et al., 2003; 
Schmidt et al., 1995). The other two LSDs caused by mutations in proteins 
located in the ER are variant late infantile NCL (vLINCL) caused by mutations 
in the genes CLN6 and CLN8. These will be discussed in detail below.
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1.3 Endoplasmic reticulum
The CLN6 protein has been shown to be located in the membrane of the 
endoplasmic reticulum (Heine et al., 2004; Mole et al., 2004), although its 
function in this organelle is currently unknown.
The endoplasmic reticulum (ER) is a continuous organelle, which extends 
through all parts of the cytoplasm and fulfils a number of functions. It consists of 
an interconnected membrane system with distinct sub-domains: the nuclear 
envelope (NE) and the peripheral ER, consisting of the rough ER (RER) and the 
smooth ER (SER). The NE surrounds the nucleus with two sheets of membrane, 
which connect at nuclear pores (Holmer and Worman, 2001). The peripheral ER 
is a network of sheets and tubules that are found dispersed throughout the 
cytoplasm (Voeltz et al., 2002). The simplest way of distinguishing between the 
RER and the SER is that the RER is covered with ribosomes and arranged in flat 
sheets, which have a granular appearance, while the SER lacks ribosomes and 
appears as more convoluted tubules (Shibata et al., 2006; Voeltz et al., 2006). 
The ribosomes that cover the RER associate with channels that allow entry of 
newly synthesised proteins into the ER by co-translational translocation. The 
function of the SER includes export into the exocytic pathway via transitional 
ER as well as sequestration of proteins and some cell-type specific processes. For 
example, in liver cells the SER is involved in detoxification of hydrophobic 
substances whereas in steroid producing cells a number of steps in steroid 
synthesis occur here (Voeltz et al., 2002). SER that is organised into stacks 
(organised smooth ER) has also been implicated as the site of aggregated 
misfolded protein in some pathological conditions (Dickson et al., 2002; Hewett 
et al., 2000).
The main functions of the ER are translocation of nascent proteins, folding and 
post-translational modification, export into the exocytic pathway, recycling, ER- 
associated degradation, calcium storage, autophagy and lipid synthesis and 
transport. Proteins located in the ER can be involved in one or more of these 
processes.
18
1.3.1 Translocation
As proteins are translated from messenger RNA (mRNA) on ribosomes in the 
cytoplasm, a proportion of these proteins are destined for the ER. Such proteins 
are synthesised with a signal sequence that is recognised by the signal 
recognition particle (SRP). SRP binds the signal sequence and targets the 
ribosome with the nascent polypeptide chain to the ER membrane (Walter and 
Blobel, 1980; Walter and Blobel, 1981a; Walter and Blobel, 1981b; Walter et al., 
1981). The emerging protein is inserted into the translocation channel, the Sec61 
complex, and further synthesised directly into the lumen of the ER (Kleizen and 
Braakman, 2004). This process is referred to as co-translational translocation. 
Another method of translocation was identified in yeast, although it has not yet 
been shown to exist in higher eukaryotes. This is referred to as post-translational 
translocation. Proteins that use this method are translated in the cytoplasm where 
they bind to the Sec62/63 complex in their unfolded state. This is then targeted to 
the Sec61 channel and the unfolded protein translocated with the help of the ER 
chaperone BiP (Matlack et al., 1999; Osborne et al., 2005).
1.3.2 Folding and post-translational modifications
The environment inside the ER is optimised to assist protein folding by its 
extracytosolic milieu, the presence of chaperone complexes and the opportunity 
for a number of post-translational modifications to occur. Folding takes place 
while a protein is being translocated into the ER. The quality control system 
(QC) recognises correctly folded proteins and regulates ER export to the Golgi. 
Chaperones are part of the primary QC and act as folding sensors by binding to 
misfolded proteins and retaining them in the ER. Some chaperones such as BiP 
assist in the folding of all proteins while others act on specific groups of proteins, 
such as calnexin and calreticulin that promote the folding of glycoproteins 
(Helenius et al., 1997). Chaperones can also assist in folding and perform post- 
translational modifications simultaneously. Protein disulphide isomerase (PDI) 
catalyses the oxidation, isomerisation and reduction of disulphide bonds while
19
retaining incorrectly folded proteins in the ER (Ellgaard and Helenius, 2003). A 
very important type of post-translational modification that occurs in the ER is the 
addition of N-linked core oligosaccharides to nascent proteins by the 
oligosaccharyltransferase complex. These basic glycans are further modified in 
the ER and in the Golgi (Helenius and Aebi, 2001). More recently it has been 
suggested that palmitoylation events can also occur in the ER and that this 
modification is necessary for ER export of some transmembrane proteins such as 
the nicotinic acetylcholine receptor (Drisdel et al., 2004; Lam et al., 2006).
1.3.3 ER export
Proteins that are folded correctly and have signal sequences targeting them to 
other organelles leave the ER and traffic to the Golgi apparatus. Exit from the ER 
occurs through a subdomain of the smooth, ribosome-free ER called transitional 
(t) ER or ER exit sites (ERES) (Bannykh et al., 1996; Palade, 1975; Stephens, 
2003). Here, coatomer protein (COP) II coated vesicles are generated through 
interactions between Sec 12, Sari, the Sec23/24 complex and the Sec 13/31 
complex (Antonny and Schekman, 2001; Barlowe et al., 1994). Proteins exit the 
ER either by bulk flow or through interactions with transport receptors or 
accessory proteins (Lee et al., 2004). Several proteins are involved in recruiting 
cargo proteins into COPII vesicles. These proteins are called secondary QC 
proteins and are usually specific to the family of proteins they sort. An example 
of this is the ER-Golgi intermediate compartment (ERGIC)-53 protein, which 
acts as a transport receptor for glycoproteins (Appenzeller et al., 1999). Another 
example is the receptor associated protein (RAP) which escorts members of the 
low density lipoprotein receptor family to the Golgi and prevents premature 
ligand binding (Herrmann et al., 1999). Once proteins arrive at the Golgi they 
can be further post-translationally modified and sorted for trafficking to other 
destinations in the cell (Ellgaard and Helenius, 2003).
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1.3.4 Recycling
As the ER is continuously exporting components to the ERGIC and the Golgi via 
COPII coated vesicles, it is necessary to recycle ER-resident proteins back to the 
ER. This occurs via vesicles coated with the COPI complex of proteins in a 
mechanism termed retrograde transport. Proteins traffic from the Golgi through 
the ERGIC and then back to the ER (Lee et al., 2004; Martinez-Menarguez et al., 
1999; Orci et al., 1993). ER residents have specific retention signals to facilitate 
their recognition and transport. The best-known is the KDEL sequence which is 
present on the carboxy terminus of many soluble ER proteins (Munro and 
Pelham, 1987). This signal binds to a KDEL specific receptor which can directly 
interact with the COPI coat proteins and thereby facilitate retrieval to the ER 
(Ellgaard and Helenius, 2003; Lewis and Pelham, 1990). CLN8 is an example of 
a protein recycled from the ERGIC to the ER (Lonka et al., 2000).
1.3.5 ERAD
Proteins that are unable to fold properly in the ER are eventually targeted for ER- 
associated degradation (ERAD). Firstly, substrates are recognised by chaperones 
as misfolded and targeted for retro-translocation into the cytoplasm. Retro- 
translocation has been reported to occur via the translocon channel Sec61 (Tsai 
et al., 2002). However other complexes have also been implicated in this 
mechanism, such as the Derlin-l/VIMP complex which has been shown to be 
involved in retro-translocation of proteins with misfolded luminal domains (Ye 
et al., 2004). While substrates are retro-translocated they become poly- 
ubiquitinated on the cytosolic side of the ER. This acts as the signal for 
degradation by the proteasome complex and release of the degraded components 
into the cytoplasm (Hiller et al., 1996; Romisch, 2005).
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1.3.6 Calcium storage
Calcium plays an important role in signalling and many other cellular processes, 
such as chaperone-mediated protein folding in the ER, ER overload and the 
unfolded protein response (Paschen, 2001). The ER is the main calcium storage 
compartment of the cell (Meldolesi and Pozzan, 1998). Disturbances in 
homeostasis of calcium levels are sufficient to trigger cellular damage and have 
been implicated in neuronal injury and death most likely by apoptosis and 
necrosis (Lehotsky et al., 2003).
1.3.7 Autophagv
The major degradative pathways in the cell are lysosomal degradation, cytosolic 
degradation by the proteasome and autophagy. The latter is a process involved in 
the turnover of cellular constituents such as organelles (Klionsky and Emr, 
2000). In this process, intracellular organelles such as mitochondria are first 
sequestered away from the remaining cytosol by a double membrane. The 
resulting autophagosome structure then fuses with the lysosome to form an 
autolysosome, inside which the constituents are degraded by acid hydrolases 
(Dunn, 1990). The origin of the sequestering membrane remains controversial. 
Some research suggests that it contains markers of the rough ER (Dunn, 1990). 
Others have found evidence of Golgi or post-Golgi markers (Locke and Sykes, 
1975; Yamamoto et al., 1990), while others have shown that it arises from 
crescent-shaped membranes in the cytoplasm, termed autophagosome precursors 
(Mizushima et al., 2001). The extent to which the ER is involved in autophagy 
remains unclear. It was recently reported that autophagy can be triggered by ER 
stress (Yorimitsu et al., 2006). Furthermore, recent data has shown that one of 
the proteins required for autophagy mammalian (m) Atg9 is a transmembrane 
protein that recycles between the trans-Golgi network (TGN) and late endosomes 
(Young et al., 2006). As transmembrane proteins are folded in the lumen of the 
ER and then transported to the Golgi, the ER certainly has a function in ensuring 
the availability of this and other proteins involved in autophagy.
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1.3.8 Lipid synthesis and transport
The ER is one of the sites of de novo lipid synthesis. Lipids are synthesised on 
the luminal side of the ER after which they traffic to other sites in the cell. The 
vLINCL protein CLN8 has been proposed to be have a lipid-sensing domain and 
to be involved in the activation of lipid synthesis and the synthesis of ceramide 
moieties (Winter and Ponting, 2002). Since lipids lack the conventional 
trafficking signals observed on proteins, they must have a specific sorting 
mechanism (Holthuis and Levine, 2005). Sorting along the endocytic and 
exocytic pathways has been observed for certain lipids; however, it has yet to be 
fully elucidated how this is achieved. Other modes of lipid transfer from the ER 
have been investigated more successfully. The ER comes in close contact with 
other organelles such as mitochondria, the plasma membrane, the trans-Golgi 
network, endosomes and lysosomes. Evidence has accumulated for lipid traffic 
across these so-called membrane contact sites (Holthuis and Levine, 2005).
1.4 Lvsosome
Lysosomes are membrane-bound organelles of 0.5 p,m diameter and are the 
major site of cellular degradation (de Duve, 2005; de Duve et al., 1955). 
Molecules can traffic to the lysosome from the plasma membrane via the 
endocytic pathway, from the ER and the Golgi apparatus via the biosynthetic 
pathway and through the autophagic pathway (Luzio et al., 2003; Mullins and 
Bonifacino, 2001). Lysosomes have a pH of approximately 5, which is 
maintained by the vacuolar ATPase proton pump. The pH is lower than in other 
organelles and this provides optimum conditions for lysosomal hydrolases, as 
these are less active in higher pH environments (Eskelinen et al., 2003). 
Lysosomal hydrolases metabolise macromolecules into low molecular mass 
components which pass through the lysosomal membrane into the cytoplasm 
where they are reused by the cell (Winchester et al., 2000). Lysosomes also carry 
a number of highly glycosylated integral membrane proteins in their limiting 
membrane, named lamps, limps and lgps, but they lack the mannose 6-phosphate
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receptor, which distinguishes them from endosomes (Eskelinen et al., 2003; 
Kornfeld and Mellman, 1989; Mullins and Bonifacino, 2001). Lysosomes are 
found dispersed throughout the cytoplasm and clustered in the perinuclear region 
near the microtubule organising centre (MTOC). This distribution is 
microtubule-dependent and becomes altered in response to mutations in BLOC-3 
(biogenesis of lysosomal-related organelles complex 3) and changes in 
cytoplasmic pH (Falcon-Perez et al., 2005; Heuser, 1989; Matteoni and Kreis, 
1987). In many LSDs there is a defect in the delivery or function of acid 
hydrolases, which leads to a disruption of lysosomal function and accumulation 
of undegraded material.
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1.5 Neuronal Ceroid Lipofuscinosis
The NCLs were first described almost 200 years ago by Stengel (Stengel, 1826; 
Stengel, 1982). However, it was only in 1969 that Zeman and Dyken introduced 
the name NCL to distinguish them from the gangliosidoses (Goebel, 1999; 
Zeman and Dyken, 1969). The common characteristic of the NCLs is the 
presence of autofluorescent storage material resembling ceroid and lipofuscin 
lipopigments that also accumulate during the normal ageing process. This storage 
material is observed in many tissues and cell types, but the pathological effect of 
the disease is most prominent in the central nervous system (CNS) and the eyes. 
There are several subtypes of NCL, each of which is associated with a distinct 
gene and differs according to age of onset, disease progression and severity and 
the morphological appearance of the storage material (Goebel, 1999; Wisniewski 
et al., 2001).
Age of onset was originally used to classify the NCLs into infantile, late 
infantile, juvenile, and the rare adult onset types. Genes assigned to the 
respective subtypes were CLN1, CLN2, CLN3 and CLN4. This classification has 
been adapted over the years as more genes involved in causing NCL phenotypes 
were identified. It now includes a group of variant late infantile NCL (vLINCL) 
with a similar disease phenotype, caused by mutations in the genes CLN5, CLN6, 
CLN7 or CLN8, and the most recent addition to the NCL classification Cathepsin 
D (CTSD), mutations in which cause congenital NCL. The genes for CLN4 and 
CLN7 have not yet been identified. Other mutations in mice genes have also been 
reported but not yet identified in humans.
Common pathological characteristics of NCL disease progression include 
progressive visual deterioration leading to blindness, epilepsy, intellectual and 
motor decline. Eventually all affected individuals die prematurely due to death of 
cortical neurons (Goebel, 1999).
The appearance of the storage material is characteristic for each type of NCL and 
has long been used as a diagnostic tool (Goebel, 1999). There are four main
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types of storage with some additional variant forms: granular osmiophilic 
deposits (GRODs), curvilinear profiles (CL), rectilinear bodies (RL) and 
fingerprint bodies (FP).
Changes in lysosomal pH have been reported as a result of mutations in NCL 
genes (Holopainen et al., 2001), although it has not been elucidated to date how 
this affects lysosomal function in NCL patients. Fibroblast cell lines from 
patients with mutations in CLN1, CLN3, CLN5, CLN6 and CLN8  showed 
increased lysosomal pH, with CLN6 and CLN1 being the most affected. A slight 
reduction in lysosomal pH was observed in fibroblast cells from patients with 
mutations in CLN2.
Below is a brief overview of the different forms of NCL, where the gene has 
been identified, with particular focus on the group of variant late infantile NCLs. 
CLN6 will be introduced separately in section 1.6.
1.5.1 CLN1
Mutations in CLN1 cause infantile (I)NCL (Goebel, 1999; Santavuori et al., 
1974). Mutations in CLN1 causing NCLs with later onset have also been reported 
(Bonsignore et al., 2006; Goebel, 1999; van Diggelen et al., 2001)(Mole, et al., 
2006, in press).
INCL is distinct from the other NCL types, except for congenital NCL caused by 
mutations in CTSD, in the appearance of the storage material as granular 
osmiophilic deposits (GRODs), which has been used as a diagnostic marker. The 
protein component of the storage material mainly contains saposins A and D 
(Haltia et al., 1973; Tyynela et al., 1993).
The CLN1 gene encodes the enzyme palmitoyl protein thioesterase 1 (PPT1), 
which removes palmitate groups from S-acylated proteins (Camp and Hofmann, 
1993). It is located in lysosomes in non-neuronal cells and in axons,
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synaptosomes and synaptic vesicles in neuronal cells (Ahtiainen et al., 2003; 
Hellsten et al., 1996; Lehtovirta et al., 2001; Verkruyse and Hofmann, 1996). Its 
in vivo substrates remain unknown.
Two mouse models have been generated to date. The Pptl knockout mouse 
(Gupta et al., 2001) shows disease progression similar to INCL and was used to 
show a reduction in the pool of synaptic vesicles in cortical neurons (Virmani et 
al., 2005). The P ptlA ex4  mouse (Jalanko et al., 2005) also shows disease 
progression similar to INCL. Recently a Drosophila melanogaster model with 
Pptl-deficiency was generated, which has accumulation of abnormal, non- 
GROD storage material and a reduced lifespan without evidence of 
neurodegeneration (Hickey et al., 2006).
1.5.2 Cathepsin D
Congenital NCL was first observed in White Swedish Landrace sheep and was 
found to be caused by a mutation in ovine cathepsin D (Jarplid and Haltia, 1993; 
Tyynela et al., 2000). Recently, mutations in CTSD have been shown to cause 
congenital NCL in humans as well and the storage material described as GRODs 
(Siintola et al., 2006b). This is thought to be the most aggressive form of NCL 
with the earliest age of onset (Siintola et al., 2006a). Mutations resulting in 
residual cathepsin D activity have been reported to cause NCL with onset in late 
infancy (Steinfeld et al., 2006).
Cathepsin D is an aspartic proteinase, which is localised in lysosomes. It has also 
been reported to be involved in a number of other cellular processes, such as 
apoptosis, autophagy and different types of cancer (Garcia et al., 1990; Kagedal 
et al., 2001; Liaudet-Coopman et al., 2006; Uchiyama, 2001; Vigneswaran et al., 
2000).
A cathepsin D-deficient Drosophila model was reported to have storage material 
resembling GRODs and to show modest age-dependent neurodegeneration 
(Myllykangas et al., 2005). A mouse model was originally generated to study the
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function of cathepsin D (Saftig et al., 1995) and later shown to have storage 
material resembling GRODs and fingerprint profiles (Koike et al., 2000). A 
naturally occurring mutation in cathepsin D has also been reported in American 
Bulldogs. It has residual enzymatic activity which explains the onset of disease 
in young adulthood (Awano et al., 2006b).
1.5.3 CLN2
The CLN2 gene encodes the lysosomal tripeptidyl-peptidase I (TPP-I) enzyme 
and mutations in TPP-I have been described to cause classic late infantile NCL 
(LINCL) (Sharp et al., 1997; Sleat et al., 1997). Some mutations of CLN2 can 
also cause NCL with delayed onset and slower disease progression (Sleat et al., 
1999).
The storage material appears as curvilinear profiles and the protein component 
contains mainly subunit c of the mitochondrial ATP synthase complex (Lake and 
Hall, 1993); but other components have been reported such as saposins A and D 
(Tyynela et al., 1995) and P-amyloid precursor protein (Wisniewski et al., 1990).
Fibroblast cells from INCL patients were shown to be deficient in TPP-I (Sohar 
et al., 1999; Vines and Warburton, 1999). TPP-I is a lysosomal serine-carboxyl 
peptidase that removes tripeptides from the N-terminus of small peptides but not 
large proteins (Vines and Warburton, 1999; Warburton and Bernardini, 2000). It 
is synthesised as a 67 kDa precursor form which is processed into a 46 kDa 
mature N-glycosylated protein (Ezaki et al., 1999; Golabek et al., 2003; Lin et 
al., 2001; Sleat et al., 1997). Mutants affecting conserved regions of the protein 
have been shown to remain in the ER, indicating that the mutant proteins are 
most likely misfolded (Steinfeld et al., 2004). However, a mutation in one of the 
N-glycosylation sites results in a protein that traffics normally to the lysosome 
but remains catalytically inactive. This mutation is associated with a more severe 
disease phenotype (Tsiakas et al., 2004).
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The in vivo substrates of TPP-I remain unknown, although the protein has been 
implicated in initiating the lysosomal degradation of subunit c of the 
mitochondrial ATP synthase (Ezaki et al., 2000; Ezaki et al., 1999; Ezaki et al., 
1995; Kida et al., 2001). It has furthermore been shown to be involved in the 
degradation of the neuropeptide neuromedin B, indicating that it might have a 
special function in neurons (Kopan et al., 2004). CLN2 has been reported to 
interact with CLN5 (Vesa et al., 2002).
A mouse model of Cln2 was generated, which has no detectable enzymatic 
activity and displays similar clinical features to human patients (Sleat et al., 
2004). A naturally occurring model exists in Dachshund dogs resulting from a 
mutation in the canine TPP1 gene (Awano et al., 2006a).
1.5.4 CLN3
Mutations in CLN3 cause the most common form of NCL with juvenile onset 
(JNCL). The storage material in patients resembles fingerprint profiles (Goebel, 
1999) and CLN3 patients are the only NCL patients with vacuolated 
lymphocytes (Anderson et al., 2005; Derwort and Detering, 1959). The protein is 
highly conserved and homologues have been described in mouse, rabbit, dog, 
sheep, C. elegans, S. cerevisiae and S. pombe suggesting that it has an essential 
function in eukaryotic cells (Goebel, 1999).
The CLN3 protein was predicted to be a transmembrane protein spanning the 
membrane either five (Mao et al., 2003a) or six times (Janes et al., 1996). In the 
six transmembrane model, the N- and C-termini of CLN3 have been shown to 
protrude into the cytoplasm (Kyttala et al., 2004a). The protein was shown to be 
glycosylated and different isoforms were detected in a range of 45 -  66 kDa 
depending on the glycosylation state (Ezaki et al., 2003).
Controversy still exists about the intracellular localisation of CLN3. It has been 
shown to localise to the membranes of lysosomes and late endosomes (Ezaki et 
al., 2003) and also to synaptosomes (Luiro et al., 2001) and early endosomes
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(Kyttala et al., 2004a) in neurons. CLN3 has also been shown to traffic via the 
plasma membrane (Mao et al., 2003b; Persaud-Sawin et al., 2004). Other groups 
have reported that CLN3 is localised in the Golgi apparatus, recycling 
endosomes and lipid rafts on the plasma membrane (Kremmidiotis et al., 1999; 
Persaud-Sawin et al., 2004; Rakheja et al., 2004).
Lysosomal targeting of CLN3 has been shown to be mediated by either one or 
two motifs, a dileucine motif in the second cytosolic loop (Kyttala et al., 2004a; 
Storch et al., 2004) and an unconventional motif in the C-terminal tail (Kyttala et 
al., 2004a). Conflicting data exists about the mechanism by which CLN3 traffics 
intracellularly. Trafficking has been proposed to be dependent on both of the 
adaptor complexes (AP-) 1 and AP-3 (Kyttala et al., 2004b; Mao et al., 2003b) or 
independent of them (Storch et al., 2004).
The function of CLN3 remains unknown, although it has been implicated in 
many cellular mechanisms. CLN3 has been reported to bind to the microtububule 
binding protein Hookl (Luiro et al., 2004) and also to CLN5 (Vesa et al., 2002). 
Receptor mediated endocytosis has been shown to be reduced in fibroblast cell 
lines from CLN3 patients (Luiro et al., 2004). It was also reported that the levels 
of lysosomal glycoproteins containing mannose-6-phosphate modifications, 
including TPP-I, were highly increased in brain samples from JNCL patients. 
This was accompanied by an increase in enzymatic activity of TPP-I, however 
this increase was not to the same extent as the increase in protein levels, 
indicating that there may be an accumulation of enzymatically inactive TPP-I in 
neurons of JNCL patients (Sleat et al., 1998).
The most common mutation (85% of disease chromosomes) in CLN3 is a 1 kb 
deletion that encodes a truncated protein that is retained in the ER (Jarvela et al., 
1999). It has recently been suggested that this mutant is partially functional, 
reclassifying JNCL from a loss of function to a mutation specific disease (C. 
Kitzmuller, R. Haines, S. Mole, personal communication).
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Several mouse models for CLN3 exist, the Cln3 knock-out mouse (Cln3
which is missing exons one to six (Greene et al., 1999), and the Cln3 knock-in
mouse, which is missing exons seven and eight (Cotman et al., 2002). Both
models display neurodegeneration similar to JNCL. Microarray studies on brains
from the Cln3 knock-out mouse implicated Cln3 in diverse functions such as
mitochondrial glucose metabolism, cytoskeleton and synaptosome (Luiro et al.,
2006). Mitochondrial abnormalities and changes in lysosomal size and
distribution as well as a decrease in endocytosis were observed in the Cln3
knock-in mouse (Fossale et al., 2004), and it was further shown that there was a
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disruption in the maturation of autophagic vacuoles (Cao et al., 2006). In the 
yeast model S. pombe the CLN3 homologue Btnlp has been shown to involved 
in regulating vacuole homeostasis (Gachet et al., 2005). In the S.scerevisiae 
model deleted for B tnlp, the protein has been implicated in vacuole pH 
homeostasis and arginine transport (Kim et al., 2003; Pearce et al., 1999; Pearce 
and Sherman, 1998). There is also a C. elegans model of CLN3, which is 
mutated in all three homologues of CLN3 and which displays a mild phenotype 
(de Voer et al., 2005).
1.5.5 CLN5
A rare form of vLINCL caused by mutations in CLN5 is found predominantly in 
Finland. The storage material in vLINCL patients resembles fingerprint and 
curvilinear profiles with some non-classical condensed fingerprint profiles and 
lamellar inclusions (Mole et al., 2005). CLN5 was predicted to be a 
transmembrane protein (Savukoski et al., 1998) and has been shown to be 
glycosylated and to localise to lysosomes (Isosomppi et al., 2002; Vesa et al.,
2002). CLN5 has four methionies, each of which can act as a start codon for 
translation. Conflicting data exists about the molecular weight of CLN5, whether 
it is a soluble or transmembrane protein and about the intracellular trafficking of 
CLN5 constructs modelling the most common naturally occurring mutants.
It has been reported that four isoforms of CLN5 can exist. The longest one has 
been shown to be a membrane protein and the three shorter forms soluble (Vesa
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et al., 2002), while it was shown in parallel that CLN5 only exists as a soluble 
protein (Isosomppi et al., 2002). Furthermore, has been shown that murine Cln5 
is a soluble protein which localises to lysosome in non-neuronal cells and to 
lysosomes and additional non-lysosomal compartments in neurons (Holmberg et 
al., 2004). However, more recently it has been reported that CLN5 exists as four 
integral membrane isoforms (Bessa et al., 2006). The molecular weight of the 
protein has been reported in the range of 45 to 60 kDa (Bessa et al., 2006; 
Isosomppi et al., 2002; Vesa et al., 2002). The most common disease-modelling 
mutants have been reported to localise to the lysosome but one also to the Golgi 
(Isosomppi et al., 2002; Vesa et al., 2002).
CLN5 has been reported to interact with both CLN2 and CLN3. Interaction 
between CLN5 and CLN2 was abolished with four of the most common disease 
mutants, while the interaction with CLN3 was retained (Vesa et al., 2002). It has 
also been reported that mRNA levels of CLN3 are reduced in fibroblast cell lines 
from CLN5 patients (Bessa et al., 2006).
A mouse model of CLN5 was developed (Cln5-/-) which mimics the progressive 
neurodegeneration seen in patients (Kopra et al., 2004). Naturally occurring 
models of CLN5 exist in Border collie dogs (Melville et al., 2005) and Devon 
cattle (Houweling et al., 2006a).
1.5.6 CLN8
This form of vLINCL is very varied phenotypically, ranging from a disease 
similar to vLINCL caused by mutations in CLN5  and CLN6  to what was 
originally called Northern epilepsy or progressive epilepsy with mental 
retardation (EPMR). The EPMR phenotype is to date confined to a remote 
geographic area in North-Eastern Finland and is caused by a mild mutation in 
CLN8 (Ranta et al., 1999), although it has been suggested that EPMR may occur 
in other populations as well (Hirvasniemi et al., 1994). Other variants caused by 
mutations in the CLN8 gene are Turkish vLINCL, which was originally thought 
to be linked to mutations in CLN7 (Mitchell et al., 2001; Ranta et al., 2004), and
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Italian vLINCL, which suggests that mutations in CLN8 are more widespread 
than previously thought (Cannelli et al., 2006). The storage material in CLN8 
patients varies according to the mutation and severity of the disease. Data on this 
subject is still very limited, however fingerprint profiles and mixed fingerprint 
and curvilinear profiles have been reported (Mole et al., 2005).
CLN8 was predicted to be a transmembrane protein (Ranta et al., 1999) and later 
shown to be primarily resident in the ER but also recycling between the ER and 
the ERGIC (Lonka et al., 2000). It has also been reported to have an additional 
location in neurons (Lonka et al., 2004). CLN8 is a 33 kDa protein which does 
not undergo proteolytic processing and which contains an ER-retrieval signal 
(KKRP) (Lonka et al., 2000). CLN8 can form homodimers (Heine et al., 2006, in 
press).
CLN8 is part of the TLC family of proteins, whose function has been proposed to 
be involved in the synthesis of ceramide moieties and the activation of lipid 
synthesis. Other members of this family are TRAM which is involved in 
polypeptide translocation into the ER and the S. cerevisiae Lagl which facilitates 
ER to Golgi transport of GPI-anchored proteins (Winter and Ponting, 2002). 
Mass spectrometric analysis of cerebral samples from two CLN8 patients 
revealed changes in sphingo- and phospholipid profiles, which was proposed to 
affect membrane stability, lipid peroxidation, vesicular trafficking and 
neurotransmission (Hermansson et al., 2005).
A naturally occurring mouse model called mnd exists, carrying a 1-bp insertion 
in Cln8, which is predicted to result in a truncated protein (Bronson et al., 1993; 
Ranta et al., 1999). Using this model it was shown that Cln8 may be involved in 
maturation, differentiation and survival of different neuronal populations with 
the expression of Cln8 mRNA in postnatal brains being the highest in the cortex 
and the hippocampus (Lonka et al., 2005). It was also shown that in mnd mice, 
mitochondrial associated membranes of the ER (MAM) were aberrant and a 
reduction in phospholipid biosynthetic enzyme activity was observed (Vance et
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al., 1997). Another naturally occurring model of CLN8 has been identified in 
English Setter dogs, which contain a missense mutation (Katz et al., 2005).
1.6 CLN6
Ultra-structurally vLINCL patients with mutations in CLN6 show a mixed 
pattern of variant rectilinear (RL) and fingerprint (FP) complexes accumulating 
as storage material in the brain. Pure FPs can be seen in intestinal neurons and 
curvilinear (CL), FP and RL complexes in visceral storage. Lymphocytes are not 
vacuolated as observed in CLN3 (Goebel and Wisniewski, 2004). Subunit c 
storage can be observed in brain but not in liver, adrenals and endocrine pancreas 
(Elleder et al., 1997). Lysosomal pH in fibroblast cell lines from patients is 
increased (Holopainen et al., 2001).
Age of onset in CLN6 can be very varied, ranging from as early as 18 months to 
as late as 8 years, but more commonly occurs around age 4. Patients usually 
present with visual failure or seizures. Progressive visual deterioration, loss of 
speech and intellectual decline, motor delay, ataxia, epilepsy, disarthria and 
irritability are among the most common symptoms. Loss of all motor skills 
occurs between the ages of 4 and 10 years. Patients usually die prematurely in 
the second or third decade of life (Goebel, 1999; Mole et al., 2005).
CLN6 was originally mapped to a region on human chromosome 15q22-23 by 
homozygosity mapping in two consanguineous families of Indian origin (Sharp 
et al., 1999) and the gene identified in 2002 in parallel by two groups using 
conserved haplotype markers in a Costa Rican subset of families (Gao et al.,
2002) and fine mapping and mutational analysis of candidate genes (Wheeler et 
al., 2002). Twenty-five mutations have been reported to date in families from 
different countries (Sharp et al., 2003; Siintola et al., 2005; Teixeira et al.,
2003)(www.ucl.ac.uk/ncl).
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When work for this thesis was started, very limited information was available 
about CLN6. The protein was predicted to be a 311 amino acid novel protein 
conserved among vertebrates and bearing no known functional or sequence 
homology to other known proteins. The protein has seven predicted 
transmembrane domains (TMD) with mutations found both in TMDs and 
intraorganellar loops (Gao et al., 2002; Wheeler et al., 2002). It has been shown 
in fibroblast cells and brain extracts from CLN6 patients and the OCL6 sheep 
model that there was an increase in the expression and protein levels of the 
mitochondrial reactive oxygen species stress response protein manganese 
superoxide-dismutase (MnSOD), suggesting a response to oxidative stress and 
inflammation (Heine et al., 2003).
In recent years, a number of key publications have advanced knowledge about 
CLN6. Heine, et al. first showed that overexpressed CLN6 was a resident of the 
ER, as detected by co-localisation with the rough ER marker PDI, that this 
protein had a molecular weight of 27 kDa and could form homodimers (Heine et 
al., 2004). In the same publication it was shown that in fibroblast cells from 
CLN6 patients, the OCL6 sheep and the nclf mouse, the sorting and processing 
of the lysosomal hydrolase cathepsin D was normal. Further, the activities of two 
other lysosomal enzymes, beta-hexosaminidase and aryl sulphatase A (ASA) 
were normal (Heine et al., 2004) and it had previously been reported that TPP-I 
activity was also normal in fibroblasts from CLN6 patients (Sohar et al., 1999). 
This indicated that trafficking from the ER to the lysosome was not affected by 
mutant CLN6, at least with respect to the proteins tested. However, it was shown 
that endocytosis of ASA from the plasma membrane to the lysosome was 
increased and yet its lysosomal degradation decreased, suggesting an impairment 
of lysosomal function (Heine et al., 2004).
It was then confirmed that endogenous CLN6 was also located in the ER, as 
shown by partial overlap with the rough ER marker PDI, although the molecular 
weight of the protein was reported to be slightly higher at 30 kDa (Mole et al.,
2004). In samples from two CLN6 patients, no protein could be detected by 
Western blotting. Constructs tagged with green fluorescencent protein (GFP)
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modelling some of the mutations observed in CLN6 patients as well as wild-type 
CLN6 were overexpressed. All of these constructs localised to the ER, which 
indicated that the CLN6 phenotype was not caused by mislocalisation of the 
mutant proteins, but rather by non-functional proteins. It was further suggested 
that the mutant proteins may be degraded more rapidly, however no data has 
been published about the tum-over times of CLN6 mutants to date.
Very recently, the topology, ER retention and oligomerisation of CLN6 were 
investigated further (Heine et al., 2006, in press). It was reported that the N- 
terminus of CLN6 is in the cytoplasm, the protein has an odd number of 
transmembrane domains and the C-terminus protrudes into the lumen of the ER, 
confirming the orientation of the suggested topological model (Wheeler et al., 
2002). The potential ER retention motifs in CLN6 were mutated, and it was 
shown that none of them played a role in CLN6 retention. However, the N- 
terminal 49 amino acids as well as the two most distal transmembrane domains 
were implicated in ER retention, although the residues involved in this were not 
identified. Similar results were also shown when CLN6 was overexpressed in 
primary hippocampal mouse neurons. Furthermore, in neuronal cell bodies 
CLN6 located to structures positive for the ER marker PDI. However, in 
neuronal extensions, this co-localisation was only partial, and CLN6 could also 
be detected in tubular structures negative for PDI. This is similar to the co­
localisation of endogenous CLN6 and PDI in HEK293 cells where overlap was 
only partial (Mole et al., 2004). CLN6 may therefore be located within regions of 
the ER other than PDI-positive rough ER, or in an additional location in neuronal 
cells. Furthermore, it was shown that CLN6 does not heterodimerise with the 
vLINCL ER-resident protein CLN8 and that the homodimerisation of CLN6 is 
mediated by regions in both the N- and C-termini. The same regions could be 
involved in interactions of CLN6 with other proteins.
Microarray studies of fibroblast cells lines from CLN6 patients have recently 
been reported (Teixeira et al., 2006). Twelve genes were identified and 
confirmed to be upregulated. These were grouped into the following cellular 
processes: extracellular matrix remodelling, signalling, apoptosis and
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immuno/inflammatory response. Alterations in cholesterol homeostasis and 
proteoglycan metabolism were further implicated in this data. Indeed it was 
shown in fibroblast cell lines from CLN6 patients that cholesterol and 
ganglioside GM2 accum ulated in lysosom es and that urinary 
glycosaminoglycans showed a different profile in CLN6 patients compared to 
normal control individuals.
A naturally occurring mouse model of CLN6, nclf exists which carries a 1-bp 
insertion in the murine orthologous Cln6  gene on mouse chromosome 9 
(Bronson et al., 1998; Wheeler et al., 2002). There are also two naturally 
occurring sheep models, the South Hampshire model, OCL6, and the Merino 
model, which both carry mutations in the ovine CLN6 gene (Broom et al., 1998; 
Broom et al., 1999; Cook et al., 2002; Houweling et al., 2006b; Tammen et al., 
2001). Mutations in the Merino sheep model were recently identified while 
mutations in the South Hampshire model, which was reported to have decreased 
levels of CLN6 mRNA, remain to date unknown (Tammen et al., 2006). The 
South Hampshire sheep model was originally used to show that two thirds of 
storage material in NCL was of protein origin and to identify subunit c of the 
mitochondrial ATP synthase as a major component of the storage material 
(Palmer et al., 1986a; Palmer et al., 1989; Palmer et al., 1986b). Recently it was 
shown that neurodegeneration can be detected in distinct regions of the brain of 
South Hampshire sheep before the onset of symptoms (Oswald et al., 2005). This 
was observed in the form of glial activation and did not correlate with the 
distribution of the storage material, indicating that neurodegeneration and storage 
material could be independent processes.
In summary, CLN6 is an ER-resident protein of unknown function and mutant 
forms of CLN6 cause the lysosomal storage and neurodegeneration observed in 
vLINCL. The link between the ER and the lysosome in vLINCL and the 
relationship of the vLINCL proteins to each other remain to date unknown.
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1.6.1 Possible functions of CLN6
As CLN6 is located in the ER, it is likely that it has a specific function in this 
organelle. It could be postulated that this function is not essential, otherwise 
mutations in CLN6 would lead to embryonic lethality, but instead would be 
highly specialised. The following hypotheses were proposed:
• CLN6 could be located in a sub-domain of the ER that interacts with 
mitochondria, as the storage material is in part of mitochondrial origin.
• CLN6 could be located in a sub-domain of the ER that interacts with the 
lysosome and could in this way contribute directly to a disruption in 
lysosomal homeostasis.
• CLN6 may interact with ER or other NCL proteins. CLN6 has been 
reported to interact with itself, but not with CLN8. The identification of 
an interaction partner would aid in the elucidation of its function. It may 
interact with known ER proteins, which would implicate it in one of the 
various function of the ER. It could also interact with other NCL proteins, 
in particular the other vLINCL protein CLN5 and play a role in its 
transition through the ER.
• The functions of CLN5, CLN6 and CLN8 may be functionally linked as 
they all cause the vLINCL disease phenotype. Although they are not 
located in the same organelle, they could play important roles in the same 
cellular pathway.
1.7 Project aims
The aims of this project were to establish the tools and techniques necessary to 
analyse the CLN6 protein and to utilise these to investigate in further detail its 
subcellular location, to identify proteins that interact with CLN6 and to elucidate 
the early cellular responses to loss of functional vLINCL proteins, CLN5, CLN6 
and CLN8. This would provide insight into the function of the CLN6 protein, the 
disease mechanism of vLINCL at the cellular level and the relationship between 
the vLINCL proteins.
38
2. Materials and Methods
2.1 List of reagents
Listed here are frequently used reagents, including information about the 
manufacturer they were purchased from and whether they were stored as a stock 
solution.
Acrylamide (30% acrylamide/0.8% bisacrylamide): Sigma
Agar: Sigma
Agarose: Sigma
Ammonium chloride: Sigma
Ammonium sulphate: Fisons
Ampicillin: Sigma
Antifade Gold reagent with DAPI: Molecular probes 
APS (ammonium persulphate, Sigma): 10% stock solution.
Beta-mercaptoethanol (BME): Sigma 
Butanol: Sigma 
Bromophenol blue: BDH 
BS3: Pierce
BSA aqueous (Sigma): stock solution of 2 mg/ml.
BSA powder: Sigma
CsCl (Caesium chloride): Sigma
Colloidal coomassie (Sigma): 20% stock solution
Coomassie G250: Sigma
DAB (TAAB): 3% stock in 0.05 M Tris-HCl, pH 7.6.
DDSA: TAAB
Dextran blue: Molecular Probes 
D-MEM high glucose: Gibco
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DMP-30: TAAB 
DMSO: Sigma
DNA marker: 1 kb ladder (Promega)
DSP: Pierce 
DSS: Pierce
Dynabeads: Dynal biotech (Sheep anti rabbit beads)
EDTA: Sigma 
EGTA: Sigma 
Ethanol: BDH 
Ethanolamine: Sigma 
Ethidium bromide: Sigma
FCS: Biowest 
Formaldehyde-37: Sigma
Gelatin (fish, Sigma): 20% stock
Gentamycin: Gibco
Glacial acetic acid (acetic acid): BDH
Glucose: Sigma
Gluteraldehyde: TAAB
Glycerol: Sigma
Glycine: Sigma
HEPES: Sigma 
Hydrogen peroxide: Sigma 
Hydrochloric acid (HC1): BDH
Isopropanol: BDH
LB: Sigma
Leupeptin (Merk Biosciences): stock solution of 100 mg/ml in H2Q.
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Magnesium chloride (MgCl2): Sigma 
Magnesium sulphate (MgS04): Sigma 
MEM-a with glutamax: Gibco 
Methanol: BDH
MG-132 (Merk Biosciences): stock solution of 50 mg/ml in DMSO.
MNA: TAAB 
Mowiol: Calbiochem
NP-40 (Igepal): Sigma 
NZ amine: Sigma
Osmium: BDH
PBS: Sigma
Pepstatin (Merk Biosciences): stock solution of 100 mg/ml in HzO.
PFA (Paraformaldehyde): Polysciences 
Ponceau S: Sigma 
Potassium acetate: Sigma
Potassium dihydrogen phosphate (KH2P 0 4): BDH 
Potassium ferricyanide: Sigma 
Propylene oxide: Fisher 
Protease inhibitor mix: Sigma
Protein markers: Standard markers molecular weights 30-200 kDa (Sigma), 
Rainbow marker high and low molecular weights (Amersham)
Saponin (Sigma): 20% stock.
SDS (Sigma): 10% stock solution 
Silver nitrate: Sigma 
SOC media: Invitrogen 
Sodium acetate (acetate): Sigma 
Sodium azide (azide): Sigma 
Sodium cacodylate: TAAB 
Sodium carbonate: Fisons
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Sodium bicarbonate (NaHC03): Sigma
Sodium chloride (NaCl): Sigma
Sodium hydrogen phosphate (Na2H P04): Sigma
Sodium hydroxide (NaOH): Sigma
Sodium sulphate: BDH
Sodium thiosulphate: BDH
SYBR green: Finnzymes
TAAB resin: TAAB 
Tannic acid: TAAB 
TEMED: Sigma 
Tris Base: Sigma 
Triton-X: Sigma 
Trypsin: Sigma 
Tryptone: Sigma
TSA-kit (reagent and amplification reagent): Perkin Elmer 
Tween-20: Sigma
Yeast extract: Sigma
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2.2 Antibodies
2.2.1 Antibody production
Polyclonal antibodies were raised against human CLN6. Peptide synthesis and 
immunisation were performed by Eurogentec (Seraing, Belgium). Peptides were 
chosen according to the following criteria:
• Approximately 20 amino acids long
• Containing as many antigenic amino acids as possible (H, K, A, L, N, R)
• Located at hydrophilic regions in the protein
• Determined by BLAST not to be present in other proteins
• Located in regions less conserved across species
Peptides were EPO1293-MEATRRRQHLGATGG (residues 1-15) for 1746/1747 
and EPO1294-ARHGSVSADDEAAR (residues 28-39) for 1748/1749 coupled to 
KLH. A cysteine residue was added to force coupling to the C-terminal side of 
peptide EPO 1293 since this corresponds to the amino terminus of CLN6. First 
injection was in complete Freunds Adjuvant, subsequent injections (at day 14, 28 
and 58) with incomplete Freunds Adjuvant. Final bleed antisera were taken after 
three months.
2.2.2 Antibody purification
Peptides were coupled to NHS-activated sepharose in HiTrap affinity columns 
(Amersham Biosciences). Peptides were dissolved at 4 mg/ml in coupling buffer 
(0.2 M NaHC03, 0.5 M NaCl, pH 8.3). Columns were washed in ice-cold 1 mM 
HC1 using a Gilson Minipuls 3 pump. The peptide solution was injected onto the 
column and coupled for 2 hours at RT (room temperature). The columns were 
then washed with Buffer A (0.5 M ethanolamine, 0.5 M NaCl, pH 8.3) and 
Buffer B (0.1 M acetate, 0.5 M NaCl, pH 4) a number of times. Columns were 
stored in 10 mM Tris, pH 7.5 with 0.1% azide at 4°C.
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To purify the antibodies, columns were washed in Start buffer (0.5 M NaCl, 10 
mM Tris, pH 7.5, cold) and Elution buffer (100 mM glycine, pH 2.5, cold) and 
equilibrated in Start buffer. 8 ml aliquots of antisera were purified at a time. 
Samples were spun to pellet debris for 5 min at 1,000 rpm in a Sorval TC 
centrifuge (rotor H400). Samples were then applied onto the columns and 
pumped on a circular loop for 4 hours on ice. Columns were then washed with 10 
mM Tris, pH 7.5 followed by Start buffer until the effluent was clear. Six 1 ml 
fractions of eluted antibody in Elution buffer were collected. 100 pi 1 M Tris, pH 
8 was added to each to neutralise the Elution buffer. Samples were run on SDS- 
Page gels and stained with colloidal comassie to ascertain which fractions 
contained the purified antibody. These fractions (usually fractions 2 and 3) were 
pooled and aliquots of 50 p.1 were stored at -20°C.
The columns were washed and stored in 10 mM Tris, pH 7.5 with 0.1% azide at 
4°C.
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2.2.3 List of antibodies used
Name Description Application Dilution Source
1746p Human CLN6, 
rabbit polyclonal
IF, WB, IP IF 1:1,000; WB 
1:500, IP 3 pi A b / 2 
ml lysate
(Mole et al., 2004)
1747p Human CLN6, 
rabbit polyclonal
IF, WB, IP IF 1:1,000; WB 
1:500, IP 3 pi A b / 2 
ml lysate
(Mole et al., 2004)
1748p Human CLN6, 
rabbit polyclonal
(Mole et al., 2004)
1749p Human CLN6, 
rabbit polyclonal
(Mole et al., 2004)
Actin Rabbit
monoclonal
IF 1:500 Sigma
Calreticulin Rabbit polyclonal IF 1:50 ABR
IB5 CD 63, mouse 
monoclonal
IF 1:300 (Fraile-Ram os et 
al., 2001)
H4A3 Lamp-1, mouse 
monoclonal
IF 1:100 Hybridoma bank
EEA-1 Mouse
monoclonal
IF 1:100 BD Transduction 
Laboratories
GFP Sheep polyclonal IF 1:100 Biogenesis
PDI (RL90) Mouse
monoclonal
IF 1:50 AbCam
GM130 Mouse
monoclonal
IF 1:100 BD Transduction 
Laboratories
Gamma-actin Sheep polyclonal WB 1:500 Chemicon
Beta-tubulin Mouse
monoclonal
WB 1:500 Sigma
eIF4AIII
(hNMP65)
Mouse
monoclonal
WB 1:300 (Tange et al., 2005)
mtHSP70 Mouse
monoclonal
WB 1:1000 (Bhattacharyya et 
al., 1995)
Table 2.2.3.1: Primary antibodies
WB: W estern b lo tting , IF: Ind irect im m unofluorescence, IP:
immunoprecipitation
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Name Tag Application Dilution Source
Goat anti rabbit HRP WB 1:4,000 Jackson
Goat anti mouse HRP WB 1:4,000 Jackson
Donkey anti sheep FITC IF 1:100 Jackson
Donkey anti rabbit Cye 5 IF 1:200 Jackson
Goat anti rabbit Alexa 488 IF 1:400 Invitrogen
Goat anti rabbit Alexa 588 IF 1:400 Invitrogen
Goat anti mouse Alexa 488 IF 1:400 Invitrogen
Goat anti mouse Alexa 588 IF 1:400 Invitrogen
Goat anti mouse IR Dye 800 QuIF 1:1,000 Li-Cor
Goat anti rabbit IR Dye 800 QuIF 1:1,000 Li-Cor
Table 2.2.3.2: Secondary antibodies
WB: Western blotting, IF: indirect immunofluorescence, QuIF: quantitative 
immunofluorescence
2.3 Cloning and Molecular Biology
2.3.1 Restriction digest
The following template reaction set-up was used for all restriction digests:
Buffer 2 pi
DNA 1-3 pi
BSA 0.2 pi
Restriction enzyme 1 pi
h 2o
Final volume: 20 pi
Buffers, BSA and enzymes were supplied by Promega, enzymes were at 10 U/pl. 
Incubation time was 1 hr (2 hr if 2 enzymes were used and the buffer system in 
combination was less than 100% efficient for one of the enzymes) at 37°C.
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2.3.2 Ligation
A series of ligations (L) were set up for cloning inserts into vectors. Different 
ratios were used to optimise ligation of insert into vector as shown in figure 
2.3.2. Ligations were performed at 4°C overnight.
Oil) L 1 L 2 L 3 L 4 L 5 L 6
Vector 1 1 1 1 1 1
Insert 1 0.5 1.4 0 3 6
H20 6 6.5 5.6 7 4 0
Ligase 1 1 1 1 1 1
Buffer 1 1 1 1 1 1
Table: 2.3.2: Ligations
2.3.3 Site directed mutagenesis (with all primers)
Reagents were from the Quickchange II XL kit (Stratagen). 
Reactions were set up according to the following template:
lOx Reaction buffer 5 pi
10 ng/pl DNA 1 pi
10 ng/pl Forward Primer 12.5 pi
10 ng/pl Reverse Primer 12.5 pi
dNTPs 1 pi
Quicksolution 3 pi
H20 15 pi
Total volume 50 pi
1 pi Pfu Ultra HF DNA polymerase (2.5 U/pl) was added to the reaction and 
samples run in a MJ Research PTC-200 Peltier Thermal Cycler PCR machine on 
the following program:
95 °C 1 min
18 cycles of:
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95 °C 
60°C 
68 °C
50 sec
50 sec
1 min
followed by: 
68 °C 7 min
1 pi Dpn (10 U/pl) was added and the restriction digest performed for 1 hr at 
37°C. Samples were stored at 4°C.
2.3.4 Transformation
Competent cells (DH 5 alpha or XL-10 Gold from Quickchange II XL kit for 
site-directed mutagenesis) were thawed on ice and aliquoted into 45 pi per 
transformation under sterile conditions. 2 pi BME (Quickchange II XL kit) was 
added for 10 min. 10 pi ligation products or 2 pi site-directed mutagenesis 
products were added for 30 min on ice. Samples were heat shocked at 42°C for 
30 sec. After 2 min on ice, cells were rescued in 500 pi of either SOC media or 
NZY+ broth (1 g NZ amine, 0.5 g yeast extract, 0.5 g NaCl, at pH 7, add 1.25 ml 
1 M MgCl2, 1 ml 1 M M gS04, 2 ml 20% glucose, 1 1 final volume) for 1 hour at 
37°C with 250 rpm in an Eppendorf Thermomixer Compact. Samples were then 
plated on Agar plates (15 g/1 agar in LB, autoclaved), containing relevant 
antibiotics such as ampicillin, and left to grow overnight at 37°C or over the 
weekend at RT.
2.3.5 DNA and RNA preparations
2.3.5.1 Mini, Midi and Maxi DNA Preparations
DNA preparations were done with Qiagen Kits according to the manufacturer’s 
instructions. DNA was eluted in H20 and stored at -20°C.
48
2.3.5.2 Caesium chloride preparations
400 ml of LB (10 g tryptone, 5 g yeast extract, 10 g NaCl in 1 1 H20, pH 7, 
autoclaved) was inoculated with a starter culture and incubated overnight in a 
Kuehner ISF-l-W  shaking incubator. Samples were centrifuged for 20 min at
6.000 rpm in a Beckman HLA-1624 rotor. Pellets were resuspended in buffer PI 
(50 mM glucose, 25 mM Tris, pH 8, 10 mM EDTA, pH 8, autoclaved and stored 
at 4°C). Buffer P2 (0.2 M NaOH, 1% SDS, made fresh) was added for 10 min. 
Buffer P3 (3 M potassium acetate, stored at 4°C) was added and the samples 
centrifuged for 15 min at 9,000 rpm in the same rotor. Supernatants were poured 
through a tea strainer into ice-cold isopropanol. This was centrifuged for 15 min 
at 9,000 rpm. The supernatant was discarded and the pellet dissolved in 5.5 ml 
TE (10 mM Tris, pH 7.5, 1 mM EDTA). To this 550 pi of 5 mg/ml ethidium 
bromide was added followed by 6 g of CsCl. Samples were spun for 5 min at
4.000 rpm in a Sorvall H400 rotor to pellet debris and the optical density 
measured and adjusted to 1.55-1.56 with 1.1 g CsCl/ml TE if necessary. Cleared 
solutions were loaded into Beckman Quick-Seal centrifuge tubes and sealed. 
Tubes were spun at 100,000 rpm overnight in a Beckman ultracentrifuge in a 
TLN100 rotor at 20°C. Plasmid bands were removed from the tubes and the 
ethidium bromide extracted with water-saturated butanol until the solutions 
appeared clear. Two volumes of water were added and to this two total volumes 
of ethanol. Extra ethanol was added if necessary until a DNA precipitate was 
visible. Samples were spun at 9,000 rpm in JLA-16.250 rotor for 15 min at 4°C 
in glass tubes. Pellets were washed in 70 % ethanol and air-dried. Pellets were 
resuspended in H20  and the concentration measured in a GeneQuant Pro 
spectrophotometer. DNA was stored at -20°C.
2.3.5.3 RNA preparations
RNA preparations were done with Qiagen Kits according to the manufacturer’s 
instructions. Cells were lysed and passed through a QiaShredder and RNA 
extracted using an RNeasy mini kit. RNA was eluted in RNase free H20 and 
stored at -20°C.
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2.3.6 DNA sequencing
DNA sequencing was provided by the MRC Geneservice. Innoculated starter 
cultures were grown overnight in a shaking incubator in a total volume of 2 ml 
LB. 1 ml of sample was sent to the MRC Geneservice for sequencing. Sequences 
were analysed using programs DNA Star and DNA Strider.
2.3.7 Agarose gels
Gels contained 1% agarose in TAE (4.84 g Tris, 1 ml glacial acetic acid, 2 ml 0.5 
M EDTA, pH 8, total volume 1 1) and 4% ethidium bromide. Gels were run at 
100 mV for 30 min. DNA 1 kb ladder was used as a loading control.
2.3.8 List of constructs used
Construct Source
CLN6-HRP Yella Martin, Claudia Kitzmiiller
Sec24-GFP (Stephens et al., 2000)
GFP-cytochrome b(5) (Pedrazzini et al., 2000)
Table 2.3.8: Constructs used 
2.3.9 O-PCR
RNA was reverse transcribed into (complementary) cDNA in a Techne Genius 
PCR machine, according to the following protocol (all reagents were from 
Invitrogen):
total RNA 8 pi
random hexamers 1 p
10 mM dNTP mix lpl
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65°C for 5 min, 4°C for at least 1 min. The following were then added:
lOx RT buffer 2 pi
25 mM MgCl2 4 pi
0.1M D TT 2 pi
RNase OUT (40 U/pl) 1 pi
Superscript III RT (200 U/pl) 1 pi
25°C for 10 min, 50 °C for 50 minutes, 85°C for 5 min, 4°C. 1 pi RNase H was 
added at 37°C for 20 min. Samples were either used immediately or stored at 
-20°C.
Q-PCR was performed in an MJ Research DNA Engine Opticon 2 with the 
following reaction mixture for each sample. Samples were done in duplicates or 
triplicates.
SYBR Green 12.5 pi
DNA at 100 ng/pl 6.25 pi
Primer mix at 1.2 pM 6.25 pi
Conditions were:
95 °C 10 min
40 cycles of:
95 °C 10 sec
54°C 15 sec
72°C 15 sec
plate read
77°C 1 sec
plate read 
followed by:
72°C 10 min
melting curve 65 -  95°C, read every 0.5°C, hold 1 sec
72°C 8 min
Samples were analysed using Opticon Monitor 2 program and Microsoft Excel.
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2.3.10 Primers and siRNA
Primers:
CLN5 For GCC CCT TTC TGG TGT AAT CAA G
Rev TCC CAT TTT CCT TCC AGT GAA (Bessa et al., 2006) 
CLN6 For CCC ATT GCC ATG CTG GTA TTC CC
Rev GGC GGT GGT TGA CAG AGT CAC CC 
CLN8 Qiagen Quantitect validated primers Hs_CLN8_l_SG and
For CCA CCT GTC CAA CTT GAT CTT CCG G 
Rev CGG ACC AGC CCG CCT TAA GAG CAT CC 
GAPDH For CAG CCT CAA GAT CAT CAG C 
Rev GTC TTC TGG GTG GCA GTG AT 
Actin For GCG AGA AGA TGA CCC AGA T
Rev TGG TGG TGA AGC TGT AGC C 
For: forward primer, Rev: reverse primer
siRNAs were designed and chosen according to the guidelines on the Qiagen
website fwww.qiagen.corri) and verified bv BLAST sequence alignment:
CLN5-1 GG ACAGGT C AGTT CAT AAA
CLN5-2 AACTGCTGTCrGGTAAAAACA
CLN6-1 CCGGTCrCTTCCTCGGAAA
CLN6-2 CCAGAGACCGAGAGCATGA
CLN8-1 C A AGGT GT AT AGT A ACCT A
CLN8-2 CGCT AAT C ATT AAT CCAT A
Control ACGUGACACGUUCGGAGAA
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2.4 Cell culture
2.4.1 List of cell types/lines used
Cell line name Species T ransformed/Pri mary Source
HEK293 Human Transformed Culter lab
HeLa Human Transformed Culter lab
Human fibroblasts Human Primary Mole lab and others
Table 2.4.1: Cell types/lines used
2.4.2 List of fibroblast cells lines used
Name Type Mutation Protein Source
Hs68 Healthy
control
CRUK
BR3 Healthy
control
Peter C lingen , 
UCL
48BR Healthy
control
Peter C lingen, 
UCL
HF364Pa CLN6 I154del/c.829-
832delGTCG;
c.837delG
p.[Ilel54del]+[Val277fs] Kohlschutter,
Braulke
HF423Pa CLN6 c.316insC/c.316insC p. [ Arg 106fs]+[ Arg 106fs] GOS
HF471Pa CLN6 E72X/E72X p.[Glu72X]+[Glu72X] Boustany
HF476Pa CLN6 R5W; D83H Freehauf/
Boustany
Table 2.4 .2: Fibroblast cell lines used
2.4.3 Culture conditions
HEK293 and HeLa cells were cultured in MEM-a with glutamax. Fibroblasts 
derived from skin biopsies were cultured in D-MEM high glucose. All culture 
media was supplemented with 10% FCS and 1% gentamycin. Cells were grown
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at 37°C with 5% C 0 2 in Galaxy R C 0 2 incubators and split using trypsin/EDTA. 
Cell culture dishes were 3.5, 6, 9 or 14 cm (NUNC).
2.4.4 Transfection
Amaxa nucleofector and nucleofection kits were used for transient transfections. 
Subconfluent cells were trypsinised and counted in a Coulter Z2 cell counter. 0.5 
to 2 x 107 cells were used per nucleofection with kits as follows:
Cell line Kit Program
HEK293 Cell line V A-23
HeLa Cell line R 1-13
Table 2.4.4: Transfections
Cells were mixed with 100 pi nucleofector solution per nucleofection and 1-5 pg 
DNA or 4-10 pi siRNA and nucleofected in the supplied vials. Cells were 
rescued immediately after nucleofection in normal growth medium, seeded in 6 
or 9 cm dishes and cultured for times indicated.
2.4.5 Microinjection
All microinjections were performed by Dr. Claudia Kitzmiiller, UCL. DNA or 
siRNA was diluted to 0.1 pg /p l in H20. Cells were co-microinjected with 
Dextran Blue at 5 pg/pl to identify microinjected cells. Borosilicate glass 
capillaries (Harvard Apparatus) were pulled into needles using a Flaming/Brown 
Micropipette Puller (Sutter Instruments), settings were: heat = 447, pull = 35, 
velocity = 55, time = 250. Cells were grown to subconflucency on glass 
coverslips and the coverslips scored using a diamond scorer to ease identification 
of injected cells. Cells in the vicinity of the scored cross were injected using an 
Eppendorf Micromanipulator 5171.
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2.5 Protein work
2.5.1 Cell extracts
For immunoprecipitations, media was aspirated from culture dishes and cells 
placed on ice, washed x2 in cold PBS (137 mM NaCl, 2.7 mM Kcl, 10 mM 
KH2P 04, 2 mM Na2HP04, in 1 1 H20, pH 7.4, sterile), then lysed in either non­
denaturing lysis buffer (NDLB, 500 mM Tris-HCl, pH 7, 200 mM NaCl, 7.5 mM 
EDTA, 7.5 mM EGTA, 0.5% Triton-X, 0.25% NP-40, protease inhibitors) or 
NET lysis buffer (200 mM NaCl, 75 mM Tris-HCl, pH 7, 7.5 mM EDTA, 1% 
Triton X-100, protease inhibitors) as indicated. Lysates were scraped off the 
dishes using a rubber policeman and transferred into Eppendorf tubes and 
incubated on ice for 10 min. Lysates were centrifuged at 12,000 rpm for 10 min 
at 4°C in a Beckman Avanti 30 Centrifuge with a F2402H rotor. Supernatants 
were transferred to fresh tubes and total lysates immunoprecipitated as described 
below.
For Western Blotting, cells were trypsinised and washed x2 in PBS. Pellets were 
resuspended in NET buffer for 10 min on ice. Lysates were then centrifuged as 
described. To determine total protein content, Bio-Rad protein assay reagent was 
used according to protocol. Either 2 pi total lysates were diluted 1:10 or used 
neat. Of this between 1 and 10 pi were diluted in H20  (total volume 800 pi) and 
added to 200 pi protein assay reagent. A freshly prepared dilution series of 
bovine serum albumin (BSA) was used as a standard. Absorbance at 600 nm was 
measured using GeneQuant Pro and samples adjusted to a total concentration of 
lpg/pl in 3x non-reducing SDS-PAGE sample buffer (150 nM Tris-HCl, pH 6.8, 
2% SDS, 0.1% bromophenol blue, 10% glycerol).
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2.5.2 Immunoprecipitation and crosslinking
For crosslinking experiment, crosslinkers DSS, DSP and BS3 were weighted 
using a AND HM-200 balancing scale and made up to a stock solution of 25 mM 
in either desiccated DMSO or HEPES lysis buffer:
Crosslinker Cell-permeable Cleavable Buffer
DSS Yes No DMSO
DSP Yes Yes DMSO
BS3 No No HEPES lysis buffer
Table: 2.5.2: Cross-linkers
For cell-permeable crosslinkers, cells grown to confluency on 9 cm dishes were 
washed 3x in cold PBS and incubated with crosslinker in PBS (final 
concentration 25 pM) at room temperature for 30 min and quenched with Tris, 
pH 7.2, to a final concentration of 200 mM, for 15 min. Total lysates were 
obtained in NET buffer as described above.
For non-permeable crosslinkers, total cell extracts were obtained as described 
above, however HEPES lysis buffer (50 mM HEPES, pH 7.6, 200 mM NaCl, 1% 
Triton-X, protease inhibitors) was used as the presence of Tris quenches 
crosslinking activity. Cell lysates were incubated with crosslinker (final 
concentration 25 pM) for 30 min at room temperature and the reaction quenched 
by the addition of Tris, pH 7.2, to a final concentration of 200 mM, for 15 min.
For immunoprecipitation, lysates were either pre-cleared or incubated with 
primary antibody for 30 min at 4°C with rotation. For pre-clearing steps, sheep 
anti rabbit magnetic dynabeads were washed x2 in PBS with 0.1% BSA, x l in 
PBS, x l in lysis buffer. The beads were added to the lysates and incubated for 1 
hr at 4°C with rotation. Lysates were then transferred from the beads into fresh 
tubes and incubated with primary antibody as described. After incubation, 
washed beads were added to the lysate with primary antibody for 2 hr or 
overnight at 4°C with rotation. Beads were then washed x5 in NDLB or NET
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wash buffer (50 mM NaCl, 75 mM Tris-HCl, pH 7, 7.5 mM EDTA, 1% Triton- 
X) as indicated and resuspended in 30-50 pi l-3x non-reducing SDS-PAGE 
sample buffer. Samples were either stored at -20°C or immediately run on SDS- 
PAGE gels as described below.
2.5.3 SDS-PAGE
10% SDS-PAGE gels with 6% stacking gels were used in all experiments unless 
indicated otherwise. For a 0.75 mm separating gel: 1.5 ml H20 , 0.95 ml 1.5 M 
Tris-HCl, pH 8.8, 1.3 ml acrylamide, 37.5 pi 10% SDS, 37.5 pi 10% APS, 3.8 pi 
TEMED with a 6% stacking gel: 1.06 ml H20 , 0.5 ml 0.5 M Tris-HCl, pH 6.8, 
0.4 ml acrylamide, 20 pi SDS, 20 pi APS, 2 pi TEMED. Samples were stored at 
-20°C and reduced when indicated by addition of 3% beta-mercaptoethanol. 
Reduced and non-reduced samples were boiled for 5 min. Small gels were run 
using the Bio-Rad Mini-Protean 3 system (200 mV for 45 min) and large gels 
using the Bio-Rad Protean II xi Cell system (7-10 mA overnight at 4°C).
2.5.4 Coomassie staining 1 and 2
Gels were fixed for 1 hr in 2% acetic acid, 50% methanol. Colloidal coomassie 
reagent was diluted 1:5 in water and this stock solution stored in the dark. The 
stock solution was diluted 1:1 with methanol and gels stained in this for at least 1 
hr to overnight. Gels were rinsed briefly in 5% acetic acid, 25% methanol and 
then fully destained for no more than 1 hr in 25% methanol. Following this, gels 
were placed in water and photographed in a Bio-Rad GS800 calibrated 
densitomer scanner. Gels were subsequently dried onto 3 MM paper for storage.
For subsequent analysis by mass spec, gels were fixed for at least 20 min in 45% 
methanol, 1% acetic acid and 54% water. Gels were then stained for 12-18 hours 
in 17% ammonium sulphate, 34% methanol, 0.5% acetic acid, 0.1% Coomassie
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G250 and destained in water until the desired contrast was achieved. Bands were 
excised immediately (see Mass Spectrometry, chapter 2.5.7).
2.5.5 Silver staining
Gels were fixed in 50% methanol, 12% acetic acid for 2 hr to overnight followed 
by 3 x 20 min washes in 50% ethanol. Gels where then washed with 0.02% 
sodium thiosulphate for 1 min and washed 3 x 20 sec in water. Gels were then 
impregnated with 0.1% silver nitrate for 20 min and rinsed 2 x 20 sec in water. 
Gels were developed in 3% sodium carbonate, 0.0002% sodium thiosulphate, 
0.0093% formaldehyde-37 until the desired contrast was achieved. Gels were 
then washed 2 x 2  min in water and the staining stopped in 50% methanol, 12% 
acetic acid for 10 min. Following this, gels were washed with 50% methanol for 
20 min and finally rinsed and stored in 1% acetic acid. Gels were photographed 
in a Bio-Rad GS800 calibrated densitometer scanner and dried down onto 3 MM 
filter paper or bands cut out for analysis by mass spectromety (see 2.5.7).
2.5.6 Western blotting
Protein was transferred using the Bio-Rad Transblot SD Semi-dry Transfer Cell 
at 10 mV for 35 min onto BioScience Protran Nitrocellulose Transfer Membrane 
in Semi-dry transfer buffer (2.93 g glycine, 5.81 g Tris, 0.375 g SDS, 200ml 
methanol, final volume 1 1). Membranes were protein assayed with 0.2% 
Ponceau S and blocked for 1 hr or overnight at 4°C in 5% Marvel dry-milk 
powder in TBS-Tween (TBS (Tris-buffered saline, 61 g Tris, 87 g NaCl, final 
volum 1 1, pH 7.4) with 0.1% Tween-20). Primary antibody was diluted in TBS- 
Tween with 3% BSA and membranes incubated in this for 1 hr with shaking. 
Membranes were subsequently washed 3 x 5  min in TBS-Tween and incubated 
in secondary antibody diluted in TBS-Tween with 3% BSA for 1 hr. This was 
followed by washes for 30 - 45 min in TBS-Tween. Membranes were incubated 
with SuperSignal West Pico Chemiluminescent Substrate (Pierce) for 1 min and
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exposed to Hyperfilm ECL (Amersham Bioscience) or Biomax MR (Kodak) film 
and developed in a XOGraph Imaging Systems Compact X4 developer.
Films were scanned using a Bio-Rad GS800 calibrated densitometer scanner 
when indicated and the optical density of bands measured using Quantity One 
software.
2.5.7 Mass spectrometry 
Cutting bands:
Bands were cut in a laminar flow hood to avoid contamination. A fresh scalpel 
blade was used and dipped in methanol in between cutting individual bands. 
Bands were cut from the gel and placed in Eppendorf tubes, which had been 
washed with methanol and twice with water. The bands were subsequently 
washed twice with water and stored at -20°C until sample processing.
Maldi-Tof mass spectroscopy sequencing was performed by either Dr. Oliver 
Kleiner, UCL and Eisai or by Dr. Catherine Lilley, Cambridge.
2.5.8 Indirect immunofluorescence and quantitative 
immunofluorescence (OuIF)
Subconfluent cells grown on coverslips were fixed in 3% paraformaldehyde 
(PFA) for 15 min, washed xl in PBS with 50 mM ammonium chloride and 0.2% 
saponin and permeabilised in the same solution for 15 min. Coverslips were 
stored in PGAS (PBS with 0.2% gelatin, 0.02% azide, 0.02% saponin) for at 
least 5 min or overnight at 4°C. Antibodies were diluted in PGAS, coverslips 
were incubated in primary antibody for 1 hr, washed x3 in PGAS and incubated 
in secondary antibody in the dark for 30 min. This was followed by x3 washes in 
PGAS, x2 in PBS, x2 in H20 . Coverslips were mounted using Antifade Gold 
Reagent with DAPI or in Mowiol (for QuIF). Confocal pictures were taken using
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the 60x objective on a Biorad (Hercules) MRC 1024 confocal microscope and 
imported into Image J or Adobe Photoshop for visualisation without further 
modifications. Quantitative Immunofluorescence images were taken on the Li- 
Cor Odyssey imager and analysed using the supplied software and Microsoft 
Excel.
2.5.9 TSA staining of HRP containing cells
Coverslips of cell transfected with HRP chimeric constructs were fixed in PBS 
with 3% paraformaldehyde for 15 min, washed once and quenched for 15 min in 
PBS with 50 mM ammonium chloride. Coverslips were washed x2 with PBS and 
incubated 4 min in 1:50 TSA reagent in amplification reagent. The reaction was 
quenched for at least 30 sec in 0.2% azide in PBS. Coverslips were washed x2 in 
PBS and either mounted onto glass slides with Antifade Gold reagent or 
permeabilised with saponin as described above for further indirect 
immunofluorescence.
2.6 Electron microscopy
2.6.1 DAB reaction for HRP chimeras
Coverslips were fixed for 15 min in 2% paraformaldehyde / l .5% glutaraldehyde 
in 0.1 M sodium cacodylate (cacodylate). Cells were rinsed x2 in cacodylate 
followed by 3 x 5 min washes in 0.05 M Tris-HCl, pH 7.6 (Tris buffer). 250 pi 
DAB stock (3% stock in Tris buffer, stored at -20°C) was diluted in 10 ml Tris 
buffer and 7 pi hydrogen peroxide was added. Coverslips were incubated in 
DAB reaction mix for 30 min at room temperature in the dark. Coverslips were 
then washed 3 x 5  min in Tris buffer and rinsed x2 in cacodylate. This was 
followed by osmication and embedding as described below.
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2.6.2 Embedding
Coverslips were fixed for 15 min in 2% paraformaldehyde / l .5% glutaraldehyde 
in 0.1 M sodium cacodylate (cacodylate). Coverslips were washed x2 in 
cacodylate. This was followed by osmication in 1% osmium, 1.5% potassium 
ferricyanide for 1 hour at 4°C. After 3 washes in cacodylate, samples were stored 
at 4°C overnight. Coverslips were incubated for 45 min in 1% tannic acid in 0.05 
M sodium cacodylate followed by 5 min incubation in 1% sodium sulphate in 
0.05 M sodium cacodylate. Coverslips were rinsed with water and washed for 3 
min. This was followed by stepwise dehydration of the cells in increasing 
concentrations of ethanol: 2 x 5  min washes each in 70% ethanol, 90% ethanol 
and 100% ethanol. Epon was prepared according to the following recipe or 
multiples of it: 7.2 ml TAAB resin, 2.85 ml DDSA (Dodecenyl succinic 
anhydride), 4.95 ml MNA (Methylnadic anhydride), 0.3 ml DMP-30 (2,4,6 
Tri(Dimethylamenomethyl) phenol). Coverslips were transferred into a 50:50 
mix of propylene oxide and epon in aluminium dishes for 1 hour. The mix was 
replaced by neat epon for 2 x 2 hours. Coverslips were inverted onto capsules of 
polymerised epon and allowed to polymerise overnight in a Scientific Laboratory 
Supplies oven at 60°C. Coverslips were removed from the epon sticks by 
plunging into liquid nitrogen.
Ultrathin (60 nm) sections were cut, stained, an images taken on a Phillips 
EM420 electron microscope by Dr. Lucy Collinson, MRC LMCB.
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Results
Chapter 3 -  Setting up the Tools and Techniques
This chapter describes the tools and techniques developed to investigate the 
CLN6 protein. In order to answer the questions set out in the aims of this project, 
certain tools and techniques were required, most of which were not already 
available. The following questions were addressed in this context:
Can CLN6 be detected in W estern blotting and indirect 
immunofluorescence?
Can CLN6 be immunoprecipiated?
Is it possible to generate a chimeric construct of CLN6 and horseradish 
peroxidase for detection by indirect immunofluorescence and electron 
microscopy?
Can CLN6 protein levels be reduced using RNA interference?
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3.1 Western analysis
Four polyclonal antibodies to human CLN6 were previously raised in the 
laboratory. One of these, 1747p, was reported to detect endogenous CLN6 as a 
band of 30 kDa in Western blotting (Mole et al., 2004). All available CLN6 
antibodies were tested for use in Western blotting.
The antibodies had been raised against peptides specific to CLN6 as described in 
Materials and Methods, chapter 2.2.1. Briefly, peptide sequences shown in table 
3.1 were chosen for their antigenic properties and their non-conserved amino 
acids. Both are directed against regions in the N-terminus of CLN6 as shown in 
figure 3.1.1.
Peptide name Peptide sequence Residues
EP01293 MEATRRRQHLGATGG 1-15
EP01294 ARHGSVSADDEAAR 28-39
Table 3.1: Antibody peptides
 1 1 1 1-
10 20 30 40
1  CLN6human
1  M E A A T R R R Q L L G A A G G P  G V ^ ^ H a  f H q a R H G S V K A E D K D R  CLN6mouse 
1  M E A A * R  R R Q l | G A A G G P G  V A F L Q A R H G s B k A E O K O R  C L N 6 ra t
Figure 3.1.1: Sequence alignment of human, rat and mouse CLN6 
Non-conserved sequences are indicated in red and antibody peptide coverage 
indicated in blue (sequence alignment DNA Star).
Peptides were injected into rabbits according to the scheme set out in figure 3.1.2 
below. Final bleed plasma samples were collected and used in subsequent 
experiments as unpurified antisera, denoted by the letter f for final bleed. 
Antisera were further affinity purified against the original peptides to produce 
purified antibodies, denoted by the letter p for purified.
64
Peptide
Rabbit
EP01293 EP01294
1746 1747 1748 1749
« •  « • « •  « •
Final bleed 1746f 1747f 1748f 1749f
Affinity ± 1 1 1
purification ▼ ▼ T ▼
Purified 1746p 1747p 1748p 1749p
antibody
Figure 3.1.2: Schematic overview of production of CLN6 antibodies
Unpurified antisera and purified antibodies were tested in Western blotting on 
HEK293 cell total lysate. The dilution used for unpurified antisera was 1:100, for 
purified antibodies 1:500. The results of this are shown in figure 3.1.3 panel A. 
Overall, the unpurified antisera showed more background staining and a larger 
number of bands. This was expected as final bleed plasma may contain a number 
of endogenous antibodies. Unpurified antisera and purified antibodies for 1748 
and 1749 did not show any signal. It was therefore concluded that these did not 
contain antibodies that could detect epitopes of CLN6 by Western blotting. 
However, 1746 and 1747 detected a number of bands. The major band detected 
by both 1746f and 1746p was at 25 kDa with a minor band at 28 kDa. The latter 
corresponded to the major band detected by 1747f and 1747p. There was also a 
minor band at 34 kDa in 1747f and 1747p. To find out which bands were specific 
for CLN6, the purified antibodies were further tested in different cell types, 
including fibroblast cells from the CLN6 patient HF476Pa. This cell line has a 
mutation at amino acid position 5 (R5W), which is within the region covered by 
the peptide that 1746p and 1747p were raised against. It was therefore expected 
that these two antibodies at least should not be able to detect CLN6 in this 
sample, as any CLN6 protein produced would likely have an altered tertiary 
structure in this region.
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Panels B and C in figure 3.1.3 show Western blots of cell extracts from HEK293 
cells, HeLa cells, the healthy control fibroblast cell line BR3 and the CLN6 
patient fibroblast cell line HF476Pa. An antibody against tubulin was used as a 
control to detect tubulin by Western blotting, indicating the presence of cell 
extract and validating the Western blot procedure. The same amount of total 
protein was loaded in each lane, but differences in tubulin band intensity were 
observed between the different cell types. As expected, antibodies 1748p and 
1749p did not detect any bands. 1746p showed a major band at 25 kDa, which 
was present in all samples including cells from the CLN6 patient, and a minor 
band at 28 kDa, which was faint but absent in cells from the CLN6 patient. 
1747p detected a minor band at 34 kDa in all samples. There was also an 
additional minor band at 30 kDa, which was present in all samples and which ran 
as a doublet just above the major band. The major band at 28 kDa was absent in 
cells from the CLN6 patient, as marked in panel B in figure 3.1.3 by the star. 
Therefore, the band at 28 kDa corresponded to endogenous CLN6, consistent 
with published results.
1747p was chosen for use in subsequent Western blots as it detected CLN6 as its 
major band as well as showing less background signal than 1746p. It was further 
noted that different cell types contained different amounts of CLN6 as 
demonstrated by the intensity of the band detected by Western blotting. More 
CLN6 was detected in HEK293 cells than in HeLa cells and in turn more than in 
fibroblast cells. This information was used to subsequently choose cell lines most 
suited for different types of experiments.
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Figure 3.1.3: CLN6 Western blotting
(A) Final bleed antisera (f, dilution 1:100) and purified CLN6 antibodies (p, 
dilution 1 :500) were tested in Western blotting in HEK293 cells. Purified 
antibodies (B) 1746p, 1747p, (C) 1748p and 1749p were further tested in 
HEK293, HeLa and fibroblast cells from healthy control (BR3) and CLN6 
patient (HF476Pa). The band corresponding to CLN6 is denoted by the 
star.
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3.2 CLN6 Immunoprecipitation
The four purified CLN6 antibodies were tested for efficiency of 
immunoprecipitation of CLN6. Although 1748p and 1749p did not give a signal 
by Western blotting, they may be able to immunoprecipiate CLN6 as it is often 
the case that an antibody might recognise an epitope on a protein by one 
technique but not by another.
Figure 3.2 panel A shows an attempted immunoprecipitation of endogenous 
CLN6 from HEK293 total cell lysates by all four antibodies. 1747p was used to 
detect CLN6 by Western blotting. No CLN6 was detected using 1747p when 
either 1748p or 1749p were used to immunoprecipitate. 1746p and 1747p both 
immunoprecipitated a protein of 28 kDa, corresponding to the CLN6 band in the 
total cell lysate. Therefore, both 1746p and 1747p were able to 
immunopreciptiate endogenous CLN6 that could subsequently be detected by 
Western blotting using 1747p.
However, Western blotting using the 1746p antibody has previously shown the 
detection of an additional band at 25 kDa that was present in a patient with a 
mutation in CLN6. It was tested whether 1746p would also immunoprecipitate 
this band. Figure 3.2 panel B shows an immunoprecipitation using 1746p 
detected by Western blotting using both 1746p and 1747p. In both the total lysate 
before and after immunoprecipitation, 1746p detected a major band around 25 
kDa and a minor band at 28 kDa, the latter one being CLN6. However, in the 
immunoprecipitated sample, only the band corresponding to CLN6 was detected. 
This was confirmed by Western blotting using 1747p. This experiment showed 
that 1746p could immunoprecipitate CLN6 specifically, but not the additional 
protein of 25 kDa, which it detected in Western blotting.
It was decided to use 1747p as the preferred tool for immunoprecipitation of 
CLN6 as it was more specific in Western blotting than 1746p. A further 
experiment was conducted to ensure that CLN6 was binding specifically to the 
antibody and not non-specifically to the magnetic beads that the antibody was
68
bound to. Figure 3.2 panel C shows an immunoprecipitation with and without 
1747p. The CLN6 band was only detected when the 1747p antibody was present. 
From this experiment, it was concluded that immunoprecipitation of CLN6 by 
the 1747p antibody is specific.
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Figure 3.2: CLN6 Immunoprecipitation
(A) CLN6 was immunoprecipitated from HEK293 total cell lysate using the 
four purified polyclonal CLN6 antibodies. (B) CLN6 w as 
immunoprecipitated using the 1746p antibody and detected by Western 
blotting using 1746p and 1747p antibodies. (C) CLN6 was 
immunoprecipitated with and without addition of the 1747p antibody.
3.3 Indirect immunofluorescence
CLN6 has been reported to localise to the ER (Heine et al., 2004; Mole et al., 
2004). The four polyclonal antibodies were tested for use in indirect 
immunofluorescence (immunofluorescence) followed by detection by confocal 
microscopy. Although the 1748p and 1749p antibodies did not detect any signal 
in Western blotting, they were tested for use in immunofluorescence.
Figure 3.3.1 shows immunofluorescence in HEK293 cells using the four purified 
antibodies. Both 1746p and 1747p showed punctate staining throughout the 
cytosol as well as discontinous staining around the nucleus. This staining pattern 
is reminiscent of ER, consistent with published results (Heine et al., 2004; Mole 
et al., 2004). Antibodies 1748p and 1749p did not detect CLN6 by 
immunofluorescence. This is in contrast to published results showing reticular 
staining by immunofluorescence using 1749p (Mole et al., 2004).
To confirm the localisation of CLN6 staining as ER, the 1747p antibody was 
used for co-localisation with protein disulphide isomerase (PDI), an ER 
chaperone protein, in HEK293 and HeLa cells. Figure 3.3.2 shows partial co­
localisation of CLN6 with PDI in both cell types. This confirms the previously 
published localisation of CLN6 where co-localisation of endogenous and 
overexpressed CLN6 with different antibodies against PDI had also been 
observed (Heine et al., 2004; Mole et al., 2004).
From these experiments it was concluded that 1746p and 1747p were reliable 
antibodies for detection of CLN6 by immunofluorescence. It was decided to use 
1747p as the preferred antibody for investigating CLN6 as it was able to detect 
CLN6 by Western blotting as well as immunofluorescence with less non-specific 
background than 1746p.
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1748p 11749p
Figure 3.3.1: CLN6 Immunofluorescence
Purified CLN6 antibodies were tested for their ability to detect CLN6 in 
HEK293 cells. 1746p and 1747p were used at dilutions of 1:1,000, 1748p  
and 1749p were used at 1 :100. Bar, 10 pm.
A
I  Merge
Figure 3.3.2: CLN6 shows partial co-localisation with Protein 
Disulphide Isomerase
CLN6 (green) was co-localised with the ER-resident protein PDI (red) in 
(A) HEK293 and (B) HeLa cells. Bar, 10 pm.
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3.4 CLN6-HRP chimera
GFP-tagged wild-type and mutant constructs of CLN6 are very useful tools for a 
variety of experiments, including immunofluorescence, Western blotting and 
immunoprecipitation. However, for localisation studies using transmission 
electron microscopy, horseradish peroxidase-chimera constructs are a useful 
alternative. The electron dense reaction product of horseradish peroxidase can be 
detected without the use of antibodies.
The enzyme horseradish peroxidase (HRP) is a plant glycoprotein that can 
oxidise several cellular substances and form covalent cross-links between 
proteins (Hayat, 1993; Stahmann, 1977). HRP reacts with hydrogen peroxide in 
the following reaction:
HRP + H20 2 -> HRP H20 2
(HRP-H20 2) + (CHR)H2 -> HRP + 2H20 + CHRj
After HRP forms a complex with hydrogen peroxide, this reacts with a 
chromogen (CHR) to form HRP, water and a precipiate of the chromogen 
(Hayat, 1993). There are a number of different chromogens that can be used to 
react with HRP. Diaminobenzidine (DAB) and its derivatives are used in light 
and electron microscopy (Graham and Karnovsky, 1966). An HRP-chimera is 
therefore a powerful tool for localisation studies. HRP has been shown to stay 
enzymatically active when fused to chimeric proteins (Hopkins, 1985) as well as 
after fixation. Furthermore, the DAB reaction product does not diffuse out of the 
compartment it was generated in (Connolly et al., 1994).
To construct the CLN6-HRP chimera, HRP was fused to the C-terminus of 
CLN6 as this protrudes into the lumen of the ER (Heine et al., 2004). Therefore, 
the DAB reaction product would be retained within the ER in the locality of the 
CLN6 protein.
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The CLN6 gene was excised from pcDNA3.1/NT-GFP-TOPO-CLN6 (Mole et 
al., 2004) using the restriction enzymes NheI and Notl. This gave fragments of 
1019 bp and 6093 bp with the following overhangs: g/ctagc-CLM5-gc/ggccgc. 
The Nhel-Notl fragment containing CLN6 was then cloned into the mammalian 
expression vector pCI-neo (Promega), which had been pre-cut with Nhe I and 
Notl. This yielded the new construct CLN6-pCI-neo with the open reading frame 
of CLN6 located at 1137-2073 bp. Next, the stop codon of CLN6 was mutated 
and a new restriction site generated to allow cloning of the gene encoding ssHRP 
at the C-terminus of CLN6, resulting in the construct CLN6-pCI-neo-mut. The 
primers used for this are shown in figure 3.4.1 panel A.
The pSRa.ssHRP construct (Connolly et al., 1994) was digested with HindYll 
and the cohesive ends of the fragment removed with Endonuclease I. The 
fragment was then digested with £cc>RI and ligated into the precleaved CLN6- 
pCI-neo-mut vector, resulting in the construct CLN6-HRP-pCI-neo. Following 
this, a stop codon was generated at the 3’ end of CLN6-HRP and an additional 
guanine residue inserted at the 5 ’end of HRP to correct the reading frame. The 
primers used for these mutageneses are shown in figures 3.4.1 panels B and C. 
The sequence of the resulting construct pCLN6-HRP-pCI-neo, named CLN6- 
HRP, depicted in figure 3.4.2 panel A, was verified by sequencing analysis.
The CLN6-HRP construct was tested by overexpression in HeLa cells. 
Transfected cells were detected using TSA reagent from Perkin Elmer. This 
system utilises HRP to catalyse the deposition of fluorophore-labeled tyramide 
amplification reagent in fixed cells. The fluorophore labels are deposited 
adjacent to the HRP molecules (Perkin Elmer TSA Fluorescence Systems 
Handbook). In figure 3.4.2 panel B, partial co-localisation of TSA-detected 
CLN6-HRP with both the CLN6 antibody and the ER marker PDI can be seen. It 
was concluded that the construct was active and localised to regions within the 
ER. The results using this construct are described in chapter 4.2.
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Sequence of CLN6
Translation
Mutagenesis primer 
New translation
New restriction site
B
Sequence of CLN6- 
Translation
Mutagenesis primer
New translation
Sequence of CLN6- 
Translation
Mutagenesis primer
New sequence of CLN6
New translation
GTC AGC AGT CGG CAT TAA
val ser ser arg his Stop
GTC AGC AGT CGG CAT ATA
val ser ser arg his leu
AGA GTG GTC AAC TCT AAT
a r g Hi m in ■ asm
G GTC AAC TCT AAT
a r g v a l f a | Bri N a s n
CGG CAT TTA AAG GGG AAT
arg his leu lys gif ■
CGG CAT TTA AAG GGG GAA
CGG CAT TTA AAG GGG GAA
arg his leu lys m glu
AAG GGC
AAG GGG 
lys gly
EcoRI
AAT TCT GCA GAT ATC CAG CAC
AAT TCT GCA GAT ATC CAG G
asn ser ala asp ile gin his
TGG CGG CCG CTT CCC TTT
trp arg pro |L@n pro pha
TGG CGG CCG CTT CCC
Stop
TCC AGT TAA CGC CGA CTT
Ser ser STOP arg arg leu
TTC CAG TTA ACG
TTC CAG TTA ACG CCG ACT
phe gin leu put pro thr
Figure 3.4.1: Mutagenesis primers used in CLN6-HRP cloning
(A) Removal of stop codon in CLN6 sequence of CLN6-pCI-neo:
The stop codon in the CLN6 sequence was removed and a new restriction site (EcoRI) generated to allow cloning of the ssHRP sequence onto 
the 3’end of CLN6, following a short linker sequence.
(B) Addition of stop codon to CLN6-HRP:
The end of HRP was mutated to generate a stop codon.
(C) Mutation of HRP to correct reading frame:
The insertion of a guanine at position 2079 was necessary to correct the reading frame of HRP
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Figure 3.4.2: CLN6-HRP show s partial co-localisation with 
CLN6 and PDI
(A) Depiction of the CLN6-HRP construct in pcl-neo, with restriction sites 
used in making the construct indicated.
(B) HeLa cells were transiently transfected with CLN6-HRP. Cells were 
fixed 24 hours after nucleofection and stained for active HRP with TSA 
reagent (red) and co-localised with (A) CLN6 (green) and (B) the ER 
protein PDI (green). Bar, 10 pm.
3.5 CLN6 RNAi
RNA interference (RNAi) is the process of silencing gene expression. This 
mechanism has been shown to provide protection against invasion by mobile 
genetic elements such as transposons and viruses. It can also act to regulate gene 
expression at the transcriptional or post-transcriptional level. This process has 
been described in plants, invertebrates and vertebrates (Fire, 1999; Fire et al., 
1998; Matzke and Birchler, 2005; Montgomery and Fire, 1998).
Endogenously occurring or artificially introduced double-stranded (ds) RNA 
molecules are processed into 2 1 - 2 3  nucleotide (nt) RNA fragments by proteins 
of the Dicer family of RNase III nucleases (Bernstein et al., 2001). These 
resulting short interfering (si) RNA molecules target complementary mRNAs for 
degradation through interaction with the RNA-induced silencing complex 
(RISC) (Caplen et al., 2001; Elbashir et al., 2001; Hammond et al., 2000; 
Nykanen et al., 2001). RNAi is a potent tool that can be used to silence genes, 
allowing the investigation of the resulting loss-of-function phenotype.
Two siRNAs targeting different regions of the CLN6 messenger RNA (mRNA) 
were chosen as described in Materials and Methods, chapter 2.3.10. Figure 3.5.1 
depicts a BLAST alignment of CLN6 mRNA and the two CLN6 siRNAs. No 
perfect matches with other human mRNAs were found using this alignment.
CLN6-1 siRNA 1 CCGGTCTCTTCCTCGGAAA 19
CLN6 mRNA 25 CCGGTCTCTTCCTCGGAAA 43
CLN6-2 siRNA 1 CCAGAGACCGAGAGCATGA 19
111111111111111! 111 
CLN6 mRNA 1102 CCAGAGACCGAGAGCATGA 1120
Figure 3.5.1: Alignment of CLN6 mRNA (gi 1478999) and CLN6 siRNAs
The efficiency of protein depletion using these siRNAs was tested in HeLa cells. 
In an initial experiment, cells were transfected with each siRNA separately as
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well as with a mix of both. Samples were taken at 48 hours and the remaining 
cells transfected in a second round of siRNA treatment. Mock samples were 
transfected without the addition of siRNA. Figure 3.5.2 panel A shows the results 
of this experiment. CLN6 protein levels were reduced by each siRNA 
individually as well as by a mix of the two. One and two rounds of siRNA 
treatment were effective at reducing CLN6 protein levels as detected by Western 
blotting. In a further experiment, shown in panel B, a control non-silencing 
siRNA (Qiagen) was used as an additional control. This confirmed that CLN6 
protein levels were reduced by siRNA treatment specific to CLN6 but not by 
non-specific siRNA treatment. Immunofluorescence of the same experiment, 
figure 3.5.3, shows reduced CLN6 staining in the CLN6 depleted cells (CLN6-1, 
CLN6-2, CLN6-1/CLN6-2 mix) in comparison to the control siRNA treated 
cells. Faint background staining could still be detected in siRNA treated cells. It 
is unclear whether this indicates very low residual levels of CLN6 or non­
specific background staining.
It is possible to use quantative reverse-transcription polymerase chain reaction 
(Q-PCR) to verify a reduction in the mRNA levels in siRNA-treated cells 
compared to mock-treated cells. The results of Q-PCR analysis of CLN6 siRNA 
are shown in figure 3.5.2 panel C. This shows an average reduction of CLN6 
mRNA levels to 18.5% after siRNA treatment with a CLN6-1/CLN6-2 siRNA 
mix compared to mock treatment. The housekeeping gene GAPDH was used as 
an internal control. For subsequent experiments it was decided that use of 
Western blotting and immunofluorescence to show effective knock-down was 
preferable as this reflected protein levels as opposed to mRNA levels.
It was concluded that both siRNAs designed against CLN6 were effective in 
reducing CLN6 proteins levels and that optimum reduction of protein was 
achieved using a mix of both siRNAs. This mix was therefore used in subsequent 
experiments. Experiments investigating the effects of CLN6 siRNA treatment are 
further discussed in chapter 6.
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WB: CLN6
WB: Tubulin
First round | Second round
WB: CLN6 
WB: Actin
C
Quantitative PCR siRNA CLN6
□ Mock ■ siRNA CLN6
Figure 3.5.2: CLN6 siRNA
(A) CLN6 was depleted using siRNA in HeLa cells using 2 rounds of 
nucleofection with CLN6 siRNA constructs CLN6-1, CLN6-2 and a mix of 
both. Mock sam ples were nudeofected without siRNA. (B) CLN6 was 
depleted (2 rounds) in HeLa cells including a non-silencing control siRNA.
(C) Quantitative PCR show s a reduction in CLN6 mRNA levels to 18.5% 
after siRNA treatment, n=4.
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CLN6-1
CLN6-2 CLN6 mix
Figure 3.5.3: CLN6 siRNA Immunofluorescence 
CLN6 w as knocked-down using siRNA in HeLa cells (figure 3.4.1, panel 
B) using 2 rounds of nudeofection with CLN6 siRNA. 
Immunofluorescence show s reduction of CLN6 staining in CLN6-1, CLN6- 
2 and mix siRNA compared to the control siRNA. Bar 10, pm.
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6.3 Chapter 3 Summary
In chapter 3, the tools and methods to investigate CLN6 were established and 
characterised. A number of techniques were now available for future 
investigation:
CLN6 could be detected by W estern blotting. CLN6 could be 
immunoprecipiated, which would allow a search for interacting proteins. It could 
also be detected by indirect immunofluorescence, which would allow further 
characterisation of its location and co-localisation with other proteins and 
cellular markers. The construction of the CLN6-HRP chimera made it possible to 
further localise CLN6 at the subcellular level using transmission electron 
microscopy. The effect of loss of CLN6 could be investigated using RNAi 
treatment and a cellular phenotype established.
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Chapter 4 -  CLN6 localisation
This chapter describes a detailed investigation of the subcellular location of the 
CLN6 protein. As the immunofluorescence pattern of endogenous CLN6 appears 
less tubular than classic ER marker staining and co-localisation with ER markers 
is only partial, it was proposed that CLN6 may be located within specific regions 
of the ER, which would perhaps implicate it in one of the many functions of the 
ER. It was also considered whether CLN6 could exit the ER and traffic to the 
lysosome, the site of the accumulated storage material in vLINCL, and have a 
specific function there. Furthermore, suggestions have been made that mutant 
CLN6 may be degraded faster than wild-type CLN6. Proteasomal inhibitors were 
used to investigate whether wild-type and/or mutant CLN6 are degraded by ER 
associated degradation (ERAD).
The following questions were addressed in this chapter:
Is there co-localisation between CLN6 and markers of specific functions 
of the endoplasmic reticulum as analysed by immunofluorescence 
microscopy?
Does the CLN6-HRP chimera show a distribution in a specific region of 
the endoplasmic reticulum at the ultra-structural level?
Is there a change in protein levels or in distribution of CLN6 in the cell 
upon treatment with lysosomal or proteasomal inhibitors?
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4.1 CLN6 co-localisation study within the endoplasmic reticulum 
using immunofluorescence microscopy
The endoplasmic reticulum is a very versatile organelle and serves a multitude of 
purposes in the cell. Some parts of the ER are spatially segregated and have 
different functions, such as the smooth and rough ER, contact sites with other 
organelles and the transitional ER or ER exit sites. In more detail, an example of 
spatial segregation is the necessity for contact sites between the ER and 
mitochondria for the sequestration of cytosolic calcium by the mitochondria. A 
marker for this mitochondria-associated ER sub-domain is the autocrine motility 
factor receptor (AMF-R), which has been localised to a smooth sub-domain of 
the ER that is in direct contact with mitochondria (Wang et al., 2000).
By establishing whether CLN6 co-localises with markers of specific functions of 
the ER, which are spatially segregated, it may be possible to elucidate the 
function of CLN6.
Upon careful examination of recent literature, two proteins were identified with 
immunofluorescence staining patterns similar to CLN6. These were Sec24, a 
component of ER exit sites, and the organised smooth ER marker cytochrome 
b(5). Immunofluorescence images showed very punctate staining for both these 
proteins. Furthermore, these proteins are involved in and thus can serve as 
markers for distinct processes taking place in the ER.
First, it was investigated whether CLN6 co-localises with the ER exit site 
component Sec24. This protein is located in a complex with Sec23 and together 
with Sari and the Sec 13/31 complex forms the COPII coat involved in exit from 
the ER to the Golgi (Antonny and Schekman, 2001; Barlowe et al., 1994). 
Immunofluorescence of Sec23/Sec24 in HeLa cells has been shown to be very 
punctate with large clusters of punctae in the perinuclear region and more 
dispersed punctae in the periphery of the cells (Shimoi et al., 2005). It was 
proposed that CLN6 was located in ER exit sites where it could have a specific 
function.
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A Sec24-GFP construct (Stephens et al., 2000) was overexpressed in HeLa cells 
and cells stained with antibodies against GFP and CLN6. Figure 4.1.1 shows the 
results of this experiment. Sec24-GFP staining appeared as distinct and sparse 
punctae throughout the transfected cells as well as clustered in perinuclear 
regions. CLN6 staining was punctate throughout the cells. Some punctae 
appeared in close proximity, however no co-localisation was observed between 
Sec24-GFP and CLN6. From this experiment, it was concluded that CLN6 was 
not located in ER exit sites.
Next it was investigated whether CLN6 co-localises with the ER isoform of 
cytochrome b(5). Cytochrome b(5) acts as an electron transfer component in 
many oxidative reactions, such as anabolic metabolism of fats and steroids, 
catabolism of xenobiotics and the reduction of methemoglobin (reviewed in 
(Schenkman and Jansson, 2003)). Cytochrome b(5) is found in a membrane- 
bound form and a soluble form, the latter being present in red blood cells where 
it maintains the reduced state of haemoglobin (Hegesh et al., 1986). The 
membrane-bound form of cytochrome b(5) exists in two isoforms, one localised 
mainly in the ER and the other one in the mitochondrial outer membrane 
(D'Arrigo et al., 1993; Ito, 1980; Lederer et al., 1983). Overexpression of 
cytochrome b(5) in yeast and mammalian cells leads to a proliferation of the ER 
into structures called organised smooth ER (OSER) (Koning et al., 1996; 
Pedrazzini et al., 2000; Vergeres et al., 1993). As reported in (Snapp et al., 2003) 
these OSER structures are formed through low affinity interactions when several 
ER-resident proteins are overexpressed. It is unclear as to what the function of 
OSER is. Suggestions have been made that it is involved in sub- 
compartmentalisation of the ER, sequestration of lipophilic drugs and 
accumulation of misfolded membrane proteins, such as mutant peripheral myelin 
protein-22 in Charcot-Marie-Tooth syndrome and mutant torsin A in early onset 
torsion dystonia (Dickson et al., 2002; Hewett et al., 2000; Snapp et al., 2003). In 
(Snapp et al., 2003), the authors show that at low levels of expression of 
endogenous or overexpressed cytochrome b(5) the protein is located throughout 
the ER. The immunofluorescence pictures of low levels of GFP-cytochrome b(5) 
expression closely resemble the staining of CLN6. At higher levels of expression
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of cytochrome b(5), bright oval structures appear near the nuclear envelope or in 
the periphery of the cells, which are positive for other ER markers such as PDI. 
Overexpression of cytochrome b(5) thus induces the sequestration of components 
of the peripheral ER into a newly formed, distinct sub-compartment. As the 
immunofluorescence patterns of cytochrome b(5) and CLN6 looked very similar 
in distribution, it was proposed that CLN6 could be preferentially recruited by 
cytochrome b(5) into the newly forming OSER structures. This would provide a 
clue to whether CLN6 had a function in an inducible, smooth sub-compartment 
of the ER or in the maintenance of ER structure.
The GFP fusion construct of cytochrome b(5) (Pedrazzini et al., 2000) was 
overexpressed in HeLa cells and the cells stained for CLN6. The results of this 
experiment are shown in figures 4.1.2 - 4.1.5. Figure 4.1.2 shows very low levels 
of expression of GFP-cytochrome b(5). The staining for both CLN6 and GFP- 
cytochrome (5) appeared very punctate. There was some degree of co­
localisation, similar to that seen between PDI and CLN6 (see chapter 3.2). At 
slightly higher levels of overexpression, shown in figure 4.1.3, the staining for 
GFP-cytochrome b(5) appeared more reticular, showing a larger extent of the 
classic tubular structure of the ER. There was less co-localisation between GFP- 
cytochrome b(5) and CLN6. It appeared that both proteins were in the same 
compartment and the CLN6 punctae occupied regions of the tubules stained for 
GFP-cytochrome b(5). Very high levels of overexpression are shown in figure
4.1.4. Here, GFP-cytochrome b(5) appeared in bright, large oval OSER 
structures. CLN6 was partially sequestered into these structures, showing 
significant co-localisation, although not to the same extent as GFP-cytochrome 
(b), as the former remained visible to a higher degree in the periphery of the cell 
than the latter. The peripheral staining of CLN6 was above non-specific 
background levels, indicating that some protein remained in regions of the ER 
not incorporated in OSER. To test the possibility that CLN6 is specifically 
recruited to OSER, a triple labelling of highly overexpressed GFP-cytochrome 
b(5) with CLN6 and the ER marker PDI was performed (figure 4.1.5). Both 
CLN6 and PDI were partially sequestered into the OSER structures. This data 
suggests that there is no preferential recruitment or exclusion of CLN6 into
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newly forming OSER structures. There was no indication that CLN6 has a 
function in this process.
The experiments described in this section showed that CLN6 is not a component 
of ER exit sites or implicated the conversion of ER into OSER when this is 
induced by overexpression of cytochrome b(5). An alternative approach to 
investigate whether CLN6 was located in a sub-compartment of the ER at the 
ultra-structural level was attempted using the CLN6-HRP construct.
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CLN8
Figure 4.1.1: CLN6 show s no co-localisation with Sec24-GFP 
Sec24-G FP w as overexpressed in HeLa cells. Coverslips were stained with 
anti-GFP (green) at 1 :100 and anti-CLN6 (red) at 1:1,000. Bar, 10 pm.
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Figure 4.1.2: CLN6 shows partial co-localisation with GFP- 
cytochrome b(5) (low expression levels)
GFP-cytochrome b(5) (green) was overexpressed in HeLa cells. Coverslips 
were stained with anti-CLN6 (red) at 1:1,000. Cells shown are an example 
of low levels of expression of GFP-cytochrome b(5). Bar, 10 |im.
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Figure 4.1.3: CLN6 show s very little co-localisation with GFP- 
cytochrome b(5) (low to medium expression levels) 
GFP-cytochrome b(5) (green) was overexpressed in HeLa cells. Coverslips 
were stained with anti-CLN6 (red) at 1:1,000. Cells shown are an example 
of low to medium levels of expression of GFP-cytochrome b(5). Bar, 10 pm.
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Figure 4.1.4: CLN6 show s co-localisation with GFP- 
cytochrome b(5) in OSER structures (high expression levels) 
GFP-cytochrome b(5) (green) was overexpressed in HeLa cells. Coverslips 
were stained with anti-CLN6 (red) at 1:1,000. Cells shown are an example 
of high levels of expression of GFP-cytochrome b(5). Bar, 10 |im.
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Figure 4.1.5: CLN6 and PDI co-localise with GFP-cytochrome 
b(5) in OSER structures
GFP-cytochrome b(5) (green) w as overexpressed in HeLa cells. Coverslips 
were stained with anti-CLN6 (red) at 1:1,000 and anti-PDI (blue) at 1:50. 
Bar, 10 pm.
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4.2 CLN6-HRP distribution within the endoplasmic reticulum
The design and cloning of the CLN6-HRP chimera were described in chapter
3.4, and it was further shown by using TSA reagent that the HRP was 
enzymatically active. While the staining in some overexpressed cells looked 
reticular, as expected for a protein residing in the ER, other cells showed TSA 
positive structures that resembled large punctae (chapter 3, figure 3.4.2). To 
clarify whether the CLN6-HRP construct localised to the same regions of the ER 
as endogenous CLN6, further co-localisation studies by immunofluorescence 
microscopy were conducted.
Figure 4.2.1 shows two confocal microscopy sections of a cell overexpressing 
CLN6-HRP, stained with TSA and an antibody against CLN6. Co-localisation in 
panel A was seen mainly in the perinuclear regions and around the nuclear ring. 
CLN6-HRP staining was continuous around the nuclear ring, whereas the 
antibody staining against CLN6 was non-continuous and co-localisation was 
therefore not complete. It has previously been observed that overexpression of 
CLN6 results in continuous staining of the nuclear ring, in contrast to that of 
endogenous CLN6 (Mole et al., 2004). This data indicates that expression levels 
determine the localisation of CLN6 within the ER. Less co-localisation was seen 
in panel B in the peripheral regions of the cell although both the TSA staining of 
CLN6-HRP and the antibody staining to CLN6 were visible. Figure 4.2.2 shows 
further co-localisation of CLN6-HRP with CLN6 antibody staining (panel A) as 
well as with antibody staining to the ER marker calreticulin (panel B). Co­
localisation in both experiments was extensive in perinuclear regions but only 
partial in peripheral regions. The TSA staining of CLN6-HRP furthermore 
appeared aggregated in contrast to the antibody staining of endogenous CLN6, 
which as usual appeared punctate throughout the cell. To investigate whether this 
aggregated staining seen by TSA staining showed that the CLN6-HRP construct 
had mis-localised to a different, more spherical organelle, co-localisation with 
the late endosomal/lysosomal markers CD63 and Lamp-1 was performed. The 
results of this experiment are shown in figure 4.2.3. No co-localisation was 
observed between markers of late endocytic structures and the aggregated TSA
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staining of CLN6-HRP. These results indicated that CLN6-HRP was in the ER, 
and yet its localisation was not quite the same as that of endogenous CLN6, 
consistent with previous results using other overexpressed CLN6 constructs 
(Mole et al., 2004). Furthermore, the overexpressed construct occasionally 
aggregated into larger punctae, which do not represent the distribution of 
endogenous CLN6. There was no evidence of striking organisational change of 
the ER when these punctae were visible.
The results of the immunofluorescence analysis of the CLN6-HRP construct 
confirmed that CLN6-HRP was in the ER, although not distributed exactly like 
endogenous CLN6. The distribution of the CLN6-HRP chimeric protein at the 
ultra-structural level was therefore investigated. In this initial experiment, 
HEK293 cells were nucleofected with CLN6-HRP and the DAB reaction 
performed. The samples were embedded, ultrathin sections cut and photographs 
taken on the Phillips EM420 electron microscope by Dr. Lucy Collinson of the 
MRC, LMCB. The results are shown in figures 4.2.4 and 4.2.5. The cells in both 
figures showed electron-dense DAB reaction material throughout the ER, 
particularly in and near the membranes as indicated by yellow stars. This was 
consistent with the localisation of endogenous CLN6 and of overexpressed 
CLN6-HRP as found by immunofluorescence microscopy. Figures 4.2.4 panel B 
and 4.2.5 panel C further show DAB reaction material throughout the nuclear 
envelope, which also was consistent with the results of the immunofluorescence 
microscopy. Interestingly, there appears to be an ER exit site cluster near the 
nuclear envelope, indicated in the figure 4.2.4 panel C by the label ERES. This is 
also positive for DAB reaction material, indicating the presence of CLN6-HRP 
in this region of highly specialised ER. However it was previously shown (figure 
4.1.1) that there was no co-localisation between endogenous CLN6 and the ER 
exit site marker Sec24. This is a further indication that CLN6-HRP may not 
localise to the same regions of the ER as endogenous CLN6, but rather is 
distributed throughout the entire ER.
It was noted, that the number of cells positive for electron-dense DAB reaction 
material was much lower than had been predicted by the transfection efficiency
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observed by immunofluorescence (30%). It is unclear why this occurred as the 
detection of DAB reaction material by electron microscopy is more sensitive 
than the detection by TSA staining. Furthermore, the cells that were transfected 
developed large vacuoles, especially apparent in the cell depicted in figure 4.2.5. 
It is possible that in order to detect the CLN6-HRP construct by DAB reaction, a 
significant overexpression is necessary, which may be lethal for the cells.
In conclusion, it was not possible to determine whether CLN6 is located in a sub­
compartment of the ER using CLN6-HRP. It may be that the enzymatic activity 
of HRP is not optimal for this particular construct, and further work will be 
necessary if this construct is to be used for localisation studies. Future work to 
optimise the use of this construct might involved the use of different size linkers 
between the protein and the HRP domain, as the linker used in this construct is 
very short. It may also be possible to move the HRP domain to a different region 
within the CLN6 protein, although this may prevent correct folding. However, it 
must protrude into the lumen of the ER to ensure the DAB reaction product does 
not diffuse into the cytoplasm.
Furthermore, since the construct was made, it was reported that regions within 
the C-terminal domain are implicated in CLN6 homodimerisation (Heine, et al. 
2006, in press). Although there is no evidence that dimerisation is required for 
the localisation or the function of the protein, it is possible that the addition of 
the HRP domain at the C-terminus of the protein may prevent it from localising 
correctly.
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Figure 4.2.1: CLN6-HRP and CLN6 are both located in the ER 
CLN6-HRP was overexpressed in HeLa cells. Coverslips were stained with 
TSA (red) at 1:50 and anti-CLN6 (green) at 1:1,000. (A) and (B) are 
confocal sections of the sam e cell. Bar, 10 pm.
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Figure 4.2.2: CLN6-HRP partially co-localises with CLN6 and 
Calreticulin
CLN6-HRP was overexpressed in HeLa cells. Coverslips were stained with 
TSA (red) at 1:50 and (A) anti-CLN6 (green) at 1:1,000 and (B) anti- 
Calreticulin (green) at 1:100. Bar, 10 pm.
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Figure 4.2.3: CLN6-HRP does  not co-localise with the late 
endosomal/lysosomal markers CD63 and Lamp-1 
CLN6-HRP was overexpressed in HeLa cells. Coverslips were stained with 
TSA (red) at 1:50 and (A) anti-CD63 (green) at 1:300 and (B) anti-Lamp-1 
(green) at 1 iOO. Bar, 10 [im.
Figure 4.2.4: CLN6-HRP throughout the ER in HEK293 cells - 
EM cell 1
CLN6-HRP w as overexpressed in HEK cells and the DAB reaction 
performed. Cells were embedded, semi-thin sections cut and images taken 
by Dr. Lucy Collinson, MRC, LMCB. DAB positive reaction product can be 
seen  throughout the tubules of the ER and around the nuclear envelope. 
ER = endoplasmic reticulum, N = nucleus, NE = nuclear envelope, yellow 
star indicates tubules containing DAB reaction product.
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AFigure 4.2.5: CLN6-HRP throughout the ER in HEK293 cells - 
EM cell 2
CLN6-HRP was overexpressed in HEK cells and the DAB reaction 
performed. Cells were embedded, semi-thin sections cut and images taken 
by Dr. Lucy Collinson, MRC, LMCB. DAB reaction product can be seen  
throughout the ER, in the nuclear envelope and in the ERES. ER = 
endoplasmic reticulum, LD = lipid droplet, N = nucleus, V = vacuole, NE = 
nuclear envelope, ERES = ER exit site, yellow stars indicate tubules 
containing DAB reaction product.
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4.3 CLN6 trafficking in response to lysosomal and proteasomal 
inhibitors
Both wild-type and mutant forms of CLN6 have been reported to be located in 
the ER, and it has been proposed that mutant CLN6 is degraded at an increased 
rate (Mole et al., 2004). Proteins are degraded either in the lysosome or by the 
proteasome in the cytosol. It would seem logical that mutant forms of CLN6, at 
least, are degraded by the ER-associated degradation (ERAD) process. In this 
process misfolded proteins are retro-translocated into the cytosol, where they are 
ubiquitinated and degraded by the proteasome complex. If CLN6 is degraded by 
ERAD, then inhibiting the proteasome complex may stabilise CLN6 within the 
ER, at sites of retro-translocation or at the proteasome.
Furthermore, as the pathological effect of vLINCL caused by mutations in CLN6 
can be observed in lysosomes, it could be that some CLN6 traffics from the ER 
to the lysosome and performs a specific function there. Although no trafficking 
motifs have been identified in the sequence of CLN6 to date, non-classical and 
indeed non-vesicular traffic could allow this protein to be located in more than 
one organelle. It might be that the majority of CLN6 is located in the ER and 
small amounts traffic to the lysosome, which would be difficult to detect by 
immunofluorescence microscopy at steady-state. If this was indeed the case, 
inhibition of lysosomal hydrolases might stabilise CLN6 and allow its 
visualisation in the lysosome.
It was therefore decided to use lysosomal or proteasomal inhibitors on 
endogenous and mutant CLN6. The system chosen for this experiment were 
fibroblast cell lines from healthy control individuals and from patients with 
mutations in CLN6 as these provide a naturally occurring disease model. It was 
proposed that if wild-type and mutant CLN6 were degraded by the proteasome, 
the use of proteasomal inhibitors should stabilise protein levels. If wild-type or 
mutant CLN6 did traffic from the ER to the lysosome, then the use of lysosomal 
inhibitors should stabilise the protein in this organelle. The results could then be 
visualised using Western blotting and immunofluorescence microscopy.
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Three fibroblast cell lines were chosen for this experiment. The healthy control 
cell line BR3 and the cell lines from CLN6 patients, HF364Pa and HF471Pa. 
Patient HF364Pa was heterozygous for p.[Ilel54del]+[Val277fsX5] and one of 
these alleles, which was assumed to be non-functional, could be detected by 
Western blotting. Patient HF471Pa was homozygous for p.[Glu72X] and at 
steady-state, no protein could be detected.
The lysosomal inhibitors used were leupetin and pepstatin. Leupeptin is a 
reversible inhibitor of trypsin-like proteases and cystein proteases. Pepstatin is a 
reversible inhibitor of aspartic proteases such as cathepsin D, pepsin and renin. 
MG-132 was used to inhibit the proteasome. This is a reversible inhibitor of the 
degradation of ubiquitin-conjugated proteins by the 26S complex of the 
proteasome (Calbiochem Product information). Fibroblast cells were grown to 
approximately 80% conflucency and the inhibitors added every 24 hours 
(leupeptin, pepstatin) or every 12 hours (MG-132) for 48 hours. At this stage, the 
cells treated with MG-132 had started to die. The cell bodies were swollen while 
the peripheral parts of the cells had shrunk to filamentous protrusions. Cell 
numbers were reduced compared to cells mock treated with DMSO. The 
experiment was stopped and analysed at this point.
Figure 4.3.1 shows the results from this experiment. Panel A shows a Western 
blot of cell lysates from the mock- and inhibitor-treated cells. Tubulin was used 
as a loading control. The intensity of the bands detected by the CLN6 antibody 
seemed to decrease upon inhibitor treatment in both the control cell line as well 
as cells from patient HF364Pa. No bands were detected with the CLN6 antibody 
in the cell line from patient HF471Pa. Densitometric analysis shown in panel B 
revealed that levels of CLN6 were indeed decreased upon inhibitor treatment. In 
the control cell line, CLN6 levels were reduced to 66% when treated with 
lysosomal inhibitors and reduced to 50% when treated with proteasomal 
inhibitors. In the cell line from patient HF364Pa, levels were reduced to 33% 
when either inhibitor was used. This data showed that using lysosomal or 
proteasomal inhibitors did not stabilise the levels of CLN6 in the cell and in fact
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resulted in less CLN6 being present. It is however unclear why treatment with 
inhibitors would lead to such a drastic decrease in protein levels.
The localisation of CLN6 following lysosomal or proteasomal inhibition was 
evaluated. Panel C of figure 4.3.1 shows immunofluorescence staining of CLN6 
in the control cell line BR3 after mock treatment with DMSO and treatment with 
lysosomal or proteasomal inhibitors. Although the fluorescence intensity appears 
increased upon treatment with MG-132, this is most likely due to the change in 
cell shape in response to the inhibitor. Compared to the DMSO treated cells, no 
change in localisation of CLN6 was observed when either inhibitor was used and 
the discontinous nuclear ring was still clearly visible.
From this experiment, a number of conclusions were drawn. This experiment did 
not support the proposed theory that wild-type or mutant CLN6 were degraded 
by the proteasome. However, the treatment with MG-132 affected the cells quite 
severely. Less severe treatment using MG-132 or other proteasomal inhibitors 
would need to be tested before it would be possible to conclusively state that 
CLN6 was not degraded by ERAD. The proposed theory that CLN6 could traffic 
to the lysosome could also not be supported by this data as no change in 
localisation was observed upon lysosomal inhibitor treatment, although protein 
levels surprisingly were decreased. It was therefore concluded that CLN6 does 
not exit the ER and traffic to the lysosome.
Future experiments should be conducted using a range of concentrations of 
lysosomal and proteasomal inhibitors, as well as different time-points. Controls 
must be included to validate whether the inhibitors worked correctly. These 
should be ER membrane proteins, which are known to be degraded by either 
ERAD or in the lysosome. Therefore, the results for CLN6 could then be 
compared to a stabilisation of these control proteins following inhibitor 
treatment. It must further be ascertained that proteins are not degraded by other 
pathways. It is possible that when proteasomal inhibitors are used, misfolded 
proteins accumulate in the cytosol and are degraded by the autophagic pathway. 
Therefore, a combination of both lysosomal and proteasomal inhibitors should
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also be used. Once optimal conditions are established, it may then be possible to 
conclude whether CLN6 is degraded by ERAD and/or traffics to the lysosome.
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Rgure 4.3.1: Lysosomal and proteasomal inhibitor assay  
Fibroblast cell lines from healthy controls (BR3) and CLN6 patients 
(HF364Pa, HF471Pa) were treated with Pepstatin/Leupeptin (P/L) or MG- 
132 (MG) or with DMSO (-) for 48 hours. (A) Total cell lysates were 
analysed by Western blotting for CLN6 and the loading control marker 
tubulin. (B) Western blots were scanned using a Bio-Rad densitometer 
and the optical density of the bands determined using Quantity One 
software. CLN6 density values were normalised to tubulin and displayed 
graphically. (C) Immunofluorescence of CLN6 in control cell line BR3.
Bar, 10 pm.
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4.4 Chapter 4 Summary
In chapter 4, the subcellular localisation of CLN6 was investigated. It was shown 
that CLN6 did not co-localise with ER exit sites nor was it preferentially 
recruited into OSER when formation of this was induced by overexpression of 
cytochrome b(5). The CLN6-HRP construct was shown to localise to the ER, but 
under the conditions used it was not possible to detect any sub-localisation at the 
ultra-structural level. Under the conditions used, neither lysosomal nor 
proteasomal inhibitors stabilised levels of wild-type or mutant CLN6, and no 
change in localisation of the protein was observed when cells were treated with 
either inhibitor.
To conclude, it was not possible to locate CLN6 in a sub-compartment of the ER 
or in the lysosome, and it was not possible to ascertain whether wild-type or 
mutant CLN6 are degraded by ERAD.
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Chapter 5 -  CLN6 interactors
This chapter describes the search for proteins that interact with CLN6. It was 
proposed that by finding proteins that bind to CLN6 it would be possible to make 
a prediction about its function and perhaps implicate it in one of the many 
functions of the ER. Co-immunoprecipitation experiments have in the past been 
employed successfully to identify interactions between proteins including 
proteins located in the ER membrane. An example of this is the identification of 
the Derlin-l/VIMP complex, which binds to the ATPase p97 in the ER 
membrane and retro-translocates misfolded proteins during ERAD (Lilley and 
Ploegh, 2004; Ye et al., 2004). The ability to immunoprecipitate endogenous 
protein is a great advantage as it allows the analysis of a protein in its natural 
intracellular environment. It was therefore decided to employ this method to 
search for proteins that co-immunoprecipitate with endogenous CLN6.
Endogenous CLN6 could be immunoprecipitated, as described in chapter 3.2. To 
identify interacting partners, the following questions were addressed:
Could proteins be co-immunoprecipitated with CLN6?
Could these proteins be identified using mass spectrometry?
Could any of the identified proteins be confirmed as interactors of CLN6?
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5.1 Co-immunoprecipitation 1
The initial co-immunoprecipitation experiment was conducted using the same 
conditions that had been employed while testing the technique. Briefly, cells 
were lysed in NDLB (non-denaturing lysis buffer) (Roberts et al., 2003).
NDLB
500 mM Tris, pH 7 
200 mM NaCl 
0.5% Triton-X 
0.25% NP-40
7.25 mM EDTA and EGTA 
Table 5.1.1: Non-denaturing lysis buffer
Although detection of CLN6 by Western blotting after immunoprecipitation was 
very successful, a band of the correct molecular weight was much more difficult 
to detect by coomassie or silver staining when comparable amounts of starting 
material were used. The experiment was scaled up and successful results 
obtained when 55 x 15 cm diameter cell culture dishes of confluent HEK293 
cells were used. These were immunoprecipitated as described in Materials and 
Methods, chapter 2.5.2. Briefly, cells were lysed and the lysate cleared by 
centrifugation. The lysate was then “pre-cleared” by incubation with magnetic 
beads without antibody. This step was undertaken in order to immunoprecipitate 
proteins that bound non-specifically to the magnetic beads. The lysate was then 
incubated with anti-CLN6 antibody conjugated to magnetic beads. Co- 
immunoprecipitated material was dissociated from the antibody and beads using 
20% SDS (Woods et al., 2002). Both eluted sample and material remaining 
bound to the beads were boiled in sample buffer, run on an SDS-PAGE gel and 
bands detected by silver staining by Dr. Oliver Kleiner, UCL. The resulting gel is 
shown in figure 5.1.1. The eluted sample was split between two lanes because 
the volume was too large to run in a single lane. A few distinct bands were 
visible that were present in the eluted sample and had not remained bound to the 
antibody or beads. These were marked and excised by Dr. Kleiner. The band of 
the molecular weight corresponding to CLN6 (band 7) was excised from the
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beads sample as there was more material available for sequencing. The bands 
were analysed by Maldi-Tof mass spectrometry as described in Materials and 
Methods, chapter 2.5.7. Table 5.1.2 shows the highest scoring predicted proteins 
for each band. The raw sequencing data can be found in Appendix B. Predicted 
proteins that were of a different molecular weight to the estimated molecular 
weight of the band on the gel were discounted.
Band Predicted protein Accession number
2 DEAD box polypeptide 48 gi_7661920
2 Beta-tubulin gi_18088719
3 Gamma-actin gi_7441428
5 PPR repeat domain 2 gi_20127634
7 CLN6 gi_8923532
Table 5.1.2: Sequencing results from co-immunoprecipitation 1
In this experiment, it was proposed that CLN6 would co-immunoprecipitate with 
CLN6, as the protein can dimerise, together with interacting proteins. It was then 
investigated whether the identified proteins could be detected in a co- 
immunoprecipitation with CLN6 using specific antibodies and Western blotting.
For technical reasons it was not possible to sequence band 1.
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Figure 5.1.1: Silver stain of CLN6 co-immunoprecipitation 1 
Gel and silver stain by Dr. Oliver Kleiner, UCL.
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5.1.1 Band 2
DEAD-box polypeptide 48 also known as human nuclear matrix protein (hNMP) 
265 or Eukaryotic Translation Initiation Factor 4A (eIF-4A) is a nuclear protein 
proposed to be involved in mRNA processing (Holzmann et al., 2000). Figure
5.1.1.1 shows no enrichment of this protein by Western blotting after 
im m unoprecipitation of CLN6. hNMP265 did therefore not co- 
immunoprecipitate with CLN6.
Beta-tubulin was the second predicted protein for band 2. In figure 5.1.1.1, a 
Western blot using an antibody specific for beta-tubulin showed no enrichment 
of this protein after CLN6 was immunoprecipitated. Beta-tubulin therefore did 
not bind to CLN6.
5.1.2 Band 3
Gamma-actin is distinct from beta-actin in its residues at the N-terminus. This 
area was covered by one of the peptides sequenced in this experiment, which 
increased the confidence that the identification of this band was correct. 
However, figure 5.1.2.1 shows no enrichment of gamma-actin by Western 
blotting after immunoprecipiation of CLN6. Therefore, gamma-actin did not 
interact with CLN6.
5.1.3 Band 5
Pentatricopeptide repeats (PPR) are found in proteins that are involved in RNA 
processing. Repeats of the PPR a-helical motifs have been proposed to form a 
superhelix, which has a luminal space into which an RNA molecule can fit. 
Members of this family are spread extensively throughout the plant kingdom. In 
plants they are mainly located in chloroplasts but members of this family can 
also be found in eukaryotes. One particular PPR protein is usually associated 
with one organelle only, such as the mitochondria or the nucleus (Blatch and
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Lassie, 1999). It was not possible to predict which protein containing a PPR 
motif was identified by mass spectrometry. Therefore, no further steps were 
undertaken to search for this particular interaction partner. Moreover, as there is 
no indication that CLN6 may have a role in RNA processing, it seemed unlikely 
that this was a real candidate.
5.1.4 Band 7
Mass spectrometry confirmed CLN6 to be the band of the correct molecular 
weight as shown by Western blotting. This confirmed the ability of the antibody 
to detect CLN6 by Western blotting, and it showed that CLN6 was indeed 
immunoprecipitated successfully. A small amount of CLN6 was eluted in 20% 
SDS. This may indicated that endogenous CLN6 dimerises as has been reported 
for the overexpressed protein (Heine et al., 2004). However, this experiment is 
not conclusive proof as the protein was not sequenced from a higher molecular 
weight dimeric complex.
The first attempt to co-immunoprecipitate proteins with CLN6 was unsuccessful. 
The use of a large amount of starting material in the experiment probably 
resulted in significant non-specific binding to the antibody and to the magnetic 
beads. It was subsequently decided to optimise the technique and use chemical 
cross-linking reagents to identify proteins interacting with CLN6 to allow less 
starting material to be used.
Ill
WB: CLN6 
WB: hNMP65 
WB: beta-tubulin
Figure 5.1.1.1: CLN6 d o es  not co-immunoprecipitate 
hNMP65 or beta-tubulin
HEK293 cells were immunoprecipitated with CLN6 antibody and samples 
Western blotted with antibodies to CLN6, hNMP65 and beta-tubulin. Left 
lane: total input material, right lane: material following immunoprecipitation 
of CLN6.
WB: CLN6
WB: gamma-actin
Figure 5.1.2.1: CLN6 does not co-immunoprecipitate gamma- 
actin
HEK293 cells were immunoprecipitated with CLN6 antibody and samples 
Western blotted with antibodies to CLN6 and gamma-actin. Left lane: total 
input material, right lane: material following immunoprecipitation of CLN6.
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5.2 Co-immunoprecipitation 2
The use of chemical cross-linkers strengthens the physical bond between proteins 
that interact. During the time of this investigation, this method was used to show 
that overexpressed CLN6 can homodimerise, that this dimerisation is facilitated 
by N- and C-terminal regions of the protein and that CLN6 does not 
heterodimerise with CLN8 (Heine et al., 2004)(Heine, et al., 2006, in press). It 
was proposed that the use of similar conditions would enhance the binding of 
interacting proteins to CLN6, making it easier to co-immunoprecipitate them. 
Three different cross-linking reagents were used for subsequent experiments. 
These are shown in table 5.2.1. Two were capable of permeating cell membranes 
and one was cleavable allowing release of protein that bound to and co- 
immunoprecipitated with CLN6.
Name Cell-permeable Cleavable
DSS + -
DSP + +
BS3 - -
Table 5.2.1: Cross-linking reagents for co-immunoprecipitation
The lysis buffers used in this experiment were different to the one used in 
previous experiments. For permeable cross-linkers, NET buffer was used to lyse 
the cells as this was more efficient in immunoprecipitating CLN6. For non- 
permeable cross-linkers cells were lysed in HEPES buffer as suggested by the 
manufacturer of the cross-linkers, as the presence of Tris quenches their activity. 
Furthermore, after the pre-clearing step, lysates were incubated only with CLN6 
antibody, followed by the addition of the magnetic beads, as opposed to 
incubation with the antibody conjugated to the beads as previously used. This 
change was introduced to increase the efficiency of antibody binding to CLN6 
and decrease the chance of the antibody-bead complex aggregating. Table 5.2.2 
shows the constituents of NET and HEPES lysis buffers:
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NET buffer
75 mM Tris-HCl, pH 7
200 mM NaCl
7.5 mM EDTA
1% Triton-X
Table 5.2.2: NET and HEPES lysis bufi
HEPES lysis buffer
50 mM HEPES, pH 7.6
200 mM NaCl
1% Triton-X
ers used in co-immunoprecipitation 2
Control samples included immunoprecipitation without the addition of cross­
linkers and without the addition of CLN6 antibody. The immunoprecipitated 
samples were run on a large 10% SDS-Page gel and stained using the coomassie 
blue method 2 described in Materials and Methods, chapter 2.5.4. Figure 5.2.1 
shows the results of this experiment. Bands were chosen for sequencing 
according to the following criteria:
• Not present in samples where no primary antibody was used
• Present in sample with non-cleaveable cross-linker but not in sample 
without cross-linker (cross-linking should shift the molecular weight of a 
co-immunoprecipitated complex)
• Present in sample without cross-linker but not in sample with non- 
cleavable cross-linker
Bands were excised as described in Materials and Methods, chapter 2.5.7. Bands 
were sequenced by Dr. Catherine Lilley, Cambridge. Unfortunately, all of the 
bands except one were contaminated with keratin. The only band that could be 
sequenced was band 2. The raw sequencing data can be found in Appendix B. 
The highest scoring possible protein for this band was mitochondrial heat shock 
protein 75 (mtHSP75), gi_292059. This is a chaperone protein located in the 
mitochondrial inner matrix membrane that has been implicated in the folding of 
nascent nuclear and mitochondrial proteins and is a member of the HSP70 family 
of proteins (Bhattacharyya et al., 1995; Mizzen et al., 1989; Mizzen et al., 1991). 
A monoclonal antibody against mtHSP75 can detect this protein by Western 
blotting. It was also shown to cross-react with other members of the HSP70 
family, namely HSC70 and HSP70, in two-dimensional gel electrophoresis 
(Bhattacharyya et al., 1995). As shown in figure 5.2.2, this antibody against
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mtHSP75 does not detect a band after co-immunoprecipitation with CLN6, 
confirming that this protein does not interact with CLN6.
Co-immunoprecipiation 2 was therefore unsuccessful in identifying interacting 
partners of CLN6. As it was very unfortunate that most of the bands were 
contaminated by keratin, it was decided to repeat the experiment and collaborate 
with a different laboratory to perform the mass spectrometry sequencing.
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#  <y> <y> <§> * °
Figure 5.2.1: Coomassie stain of co-immunoprecipiation 2
WB: CLN6
WB: mtHSP75
Figure 5.2.2: CLN6 d o es  not co-immunoprecipitate 
mitochondrial HSP75
HEK293 cells were immunoprecipitated with CLN6 antibody and samples 
Western blotted with antibodies to CLN6 and mtHSP75. Left lane: total 
input material, right lane: material following immunoprecipitation of CLN6.
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5.3 Co-immunoprecipitation 3
The experimental conditions used in co-immunoprecipitation 3 were the same as 
those used in co-immunoprecipitation 2. However, the after running the sample 
on a large 10% SDS-Page gel, the gel was staining using silver staining as 
described in Materials and Methods, chapter 2.5.5. Figure 5.3.1 shows the results 
of this. Bands were identified according to the same criteria outlined above in 
chapter 5.2. Sequencing was performed by Dr. Oliver Kleiner, Eisai. The raw 
sequencing data can be found in Appendix B. Unfortunately, it was only possible 
to identify proteins from two of the bands as there was not enough material 
present in the other bands for protein to be detected using this method. These are 
shown in table 5.3.1.
Band Predicted protein Accession number
3 HSP70, N-terminal domain gi_6729803
5 Beta-actin gi_4501885
Table 5.3.1: Sequencing results of co-immunoprecipitation 3
HSP70 is a member of the HSP70 family of proteins, which also contains 
mtHSP75, identified in co-immunoprecipitation 2. HSP70 is located in the 
cytoplasm and the nucleus where it assists the folding of nascent polypeptides 
(Bhattacharyya et al., 1995; Frydman et al., 1994). The antibody recognising 
mtHSP75 cross-reacts with HSP70 (Bhattacharyya et al., 1995). In figure 5.2.2 it 
was shown that this antibody does not detect a band after co- 
immunoprecipitation of CLN6, indicating that CLN6 does not interact with 
mtHSP75 or HSP70.
In co-immunoprecipitation 1, gamma-actin was identified as a proposed 
interactor of CLN6, although it was shown in figure 5.1.2.1 that this interaction 
could not be confirmed. Figure 5.3.2 shows that an antibody against alpha, beta 
and gamma actin does not detect a band after co-immunoprecipitation of CLN6. 
The faint doublet of bands that is visible in the co-immunoprecipitation lane 
when the actin antibody was used for Western blotting is a contamination as the
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same bands were visible when the CLN6 antibody was used. Therefore, CLN6 
does not interact with alpha, beta or gamma actin.
Co-immunoprecipitation 3 was unsuccessful in identifying interaction partners of 
CLN6. It was extremely unfortunate that most of the bands identified in this 
experiment could not be identified due to technical reasons.
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Figure 5.3.2: Silver stain of co-immunoprecipitation 3
WB: CLN6
Figure 5.3.3: CLN6 does  not co-immunoprecipitate actin 
HEK293 cells were immunoprecipitated with CLN6 antibody and samples 
Western blotted with antibodies to CLN6 and actin (alpha, beta and 
gamma). Left lane: total input material, right lane: material following 
immunoprecipitation of CLN6.
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5.4 Chapter 5 Summary
In this chapter, proteins that interact with CLN6 were investigated. A number of 
potential interacting proteins were identified, but none of them could be 
confirmed to be true interactors. Many technical problems were encountered. 
Endogenous CLN6 can be easily detected by Western blotting after 
immunoprecipitation. However, this was not the case for detection by coomassie 
or silver staining. The use of large amounts of protein for co- 
immunoprecipitation resulted in proteins being identified that had most likely 
bound non-specifically to the antibody or the magnetic beads. The use of 
chemical cross-linkers was introduced to reduce the amount of protein needed for 
co-immunoprecipitation. However, under the experimental conditions used, this 
did not prove successful either. In conclusion, it was not possible to identify 
proteins that interact with CLN6 using this method. Further optimisation will be 
necessary if interactors of CLN6 are to be identified. This will be addressed in 
chapter 7.
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Chapter 6 -  siRNA screen of vLINCL proteins
In order to elucidate the cellular mechanisms underlying NCL pathology, many 
recent publications have made use of cell lines from NCL patients or animal 
models. Fibroblast cell lines from CLN6 patients were used to show that the 
levels of MnSOD were increased in these cells compared to healthy control cells 
(Heine et al., 2003) and microarray data on fibroblast cell lines has implicated 
changes in a number of cellular pathways to be involved in CLN6 pathology 
(Teixeira et al., 2006). In order to investigate cellular changes due to loss of 
functional proteins in the vLINCL family, it was considered using such a model 
system. However, it was not possible to obtain fibroblast cell lines from CLN5 
patients. Furthermore, as fibroblast cell lines are primary cell lines, they are 
subject to natural variation between individuals. Moreover, these cell lines can be 
thought of as having adapted to the mutant vLINCL proteins, as there is no 
evidence of pathological events in these cells. It was therefore decided to use a 
simpler, transformed cell system to analyse the immediate cellular events 
occurring in response to loss of functional vLINCL proteins.
Chapter 6 describes the results of RNA interference experiments of the vLINCL 
proteins CLN5, CLN6 and CLN8. The aim of this screen was to model and 
identify early events in response to depletion of functional proteins as well as to 
investigate whether these events were similar for the different proteins in the 
vLINCL group.
RNAi targeting of CLN6 was optimised previously and described in chapter 3. 
RNAi against the two remaining vLINCL proteins CLN5 and CLN8 was 
designed and tested. A combined screen of RNAi depletion of all three vLINCL 
proteins was performed. The questions addressed in this chapter therefore were: 
Can CLN5 and CLN8 protein levels be successfully reduced using 
siRNA?
What are the effects of siRNA depletion of the vLINCL proteins CLN5, 
CLN6 and CLN8?
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6.1 siRNA against CLN5 and CLN8
Two siRNAs each were chosen for targeting CLN5 and CLN8. Figure 6.1 panel 
A depicts a BLAST alignment of the respective mRNAs and siRNAs. No exact 
matches between the siRNAs and any other human mRNA sequences were 
found. As there were no antibodies available to endogenous CLN5 and CLN8, 
quantitative reverse-transcription (Q-) PCR was used to analyse the efficiency of 
the siRNAs to reduce mRNA levels. Experiments were performed in the same 
way as described for siRNA against CLN6. Briefly, HeLa cells were 
nucleofected for two rounds of siRNA treatment, with recovery of 48 hours after 
each nucleofection. Samples nucleofected without addition of siRNA were used 
as mock-treated control samples.
Unfortunately, difficulties with Q-PCR of CLN8 mRNA were encountered. Two 
different primer sets were tested but these did not give any signal under 
conditions used for Q-PCR of CLN5 and CLN6 mRNA. To trouble-shoot, the 
following were tested: different annealing temperatures, different concentration 
of primers and template. The primers did detect an amplicon of the expected size 
in conventional PCR when the annealing temperature was lowered, however it 
was not possible to obtain any signal by Q-PCR when the same temperature was 
used. It was consequently decided to proceed with the siRNA screen nonetheless 
and use a mixture of both siRNAs to CLN8. However, it cannot be said for 
certain that CLN8 is indeed depleted successfully in any of the experiments 
presented below. In the event that better reagents could be obtained and used in 
the future, RNA was extracted from all samples and stored.
Q-PCR analysis for CLN5 siRNA showed that both siRNAs reduced mRNA 
levels. It was decided to use a mixture of both in subsequent experiments. Figure
6.1 panel B shows the reduction in mRNA levels to an average of 22% with 
siRNA targeting CLN5 compared to mock-treated cells. For comparison, the 
same figure also shows the reduction of CLN6 mRNA to an average of 18.5% in 
samples treated with siRNA against CLN6 (same data presented in figure 3.5.2).
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For all subsequent experiments, mixtures of two siRNAs for each gene were used 
against CLN5, CLN6 and CLN8.
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A
CLN5-1 SiRNA 1 GGACAGGTCAGTTCATAAA
M I N I M I  M I N I M I
19
CLN5 mRNA 1168 GGACAGGTCAGTTCATAAA 1186
CLN5-2 SiRNA 1 AACTGCTGTCTGGTAAAAACA
M M M I M M I  M M M M i
21
CLN5 mRNA 544 AACTGCTGTCTGGTAAAAACA 564
CLN8-1 SiRNA 1 CAAGGTGTATAGTAACC TA
M M M M M M M M M I
19
CLN8 mRNA 3016 CAAGGTGTATAGTAACCTA 3034
CLN8-2 siRNA 1 CGCTAATCATTAATCCATA
M M M M M M M M M I
CGCTAATCATTAATCCATA
19
CLN8 mRNA 959 977
B
Quantitative PCR siRNA CLN5 and CLN6
1.2 --------------------------------------------------------------------------------
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Figure 6.1: siRNA CLN5, CLN6 and CLN8
(A) BLAST alignment of siRNA sequences against CLN5 and CLN8 and 
their respective mRNAs (CLN5 mRNA gi 5729711, CLN8 mRNA gi 
31083052).
(B) CLN5 and CLN6 were depleted in HeLa cells using two rounds of 
siRNA of a mix of two siRNAs for each protein. Quantitative PCR was 
performed using the housekeeping gene GAPDH as an internal control. 
The graph shows a depletion to 22% of mRNA levels for CLN5 and 18.5% 
mRNA levels for CLN6 compared to mock transfected cells, CLN5 n=2, 
CLN6 n=4. It was not possible to quantitate depletion of CLN8.
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6.2 siRNA against CLN5. CLN6 and CLN8
A fter two rounds of siRNA treatm ent, cells were analysed by 
immunofluorescence to visualise gross changes in organelle morphology. 
Quantitative immunofluorescence (QuIF) was subsequently used to examine 
whether the protein levels of any of the organelle markers used were altered. 
QuIF is described in Materials and Methods, chapter 2.5.8. Briefly, samples were 
plated into 96-well plates and incubated with organelle markers under the same 
conditions used for standard immunofluorescence. Secondary antibodies were 
used at 800 nm wavelength in combination with a DNA stain fluorescing at 700 
nm wavelength. Plates were scanned using the Li-Cor Odyssey scanner, which 
can detect dyes at two different wavelengths. Integrated fluorescence intensity 
was measured. Samples were normalised to the cell number as counted by DNA 
stain. Values for siRNA treated samples were displayed in comparison to mock 
samples whose integrated fluorescence intensity was set to 100%. Each 
experiment was performed independently three times. QuIF was performed twice 
independently for each experiment, with two repeats for each separate QuIF.
The following organelle markers were used in this analysis:
Marker Subcellular location
Lamp-1 late endosome/lysosome
CD63 late endosome/lysosome
EEA-1 early endosome
PDI endoplasmic reticulum
GM130 ds-Golgi
Table 6.1: Organelle markers used in siRNA screen
It was proposed that siRNA targeting of CLN5, CLN6 or CLN8 may have 
similar effects, as mutations in any of these proteins result in the vLINCL 
phenotype. It was further hypothesised that there may be an effect on late 
endocytic/lysosomal compartments when these proteins were depleted, as it is 
here that the storage material accumulates.
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6.2.1 Lamp-1
Immunofluorescence microscopy showed a clear change in the phenotype of 
Lamp-1-positive structures upon treatment with siRNA to CLN5, CLN6 and 
CLN8. Lamp-1-positive structures in mock-treated cells were small punctae, 
which appeared widely dispersed throughout the cells. Cells treated with siRNA 
to any of the vLINCL proteins showed a variety of changes in the appearance of 
Lamp-1 positive structures and typical examples of these changes are shown in 
figure 6.2.1.1. These structures were generally enlarged and appeared ring- 
shaped with Lamp-1 staining on the perimeter of the compartment as can clearly 
be seen in the picture of siRNA targeting CLN5, left hand panel. Often the 
structures appeared brighter, as can be observed in the picture of siRNA to 
CLN6, left hand panel. Sometimes the compartments were more clustered in the 
perinuclear region as shown in the picture of siRNA to CLN8, right hand panel. 
These changes were present to similar degrees in siRNA of all three vLINCL 
proteins. The changes were also observed when the siRNAs were used 
individually, indicating that there is a consistent effect due to protein depletion, 
which is not due to an off-target effect of individual siRNAs.
As the Lamp-1-positive structures often appeared to be brighter in cells treated 
with siRNA, QuIF was used to test if there was a quantitative change in 
fluorescence intensity of this marker. Figure 6.2.1.2 shows that there was no 
statistically significant change in integrated fluorescence intensity after siRNA 
treatment.
As the immunofluorescence of Lamp-1 in cells treated with siRNA against 
CLN8 looked very similar to that seen with siRNA against CLN5 and CLN6, 
confidence was gained that the depletion of CLN8 by siRNA was successful.
To determine whether the phenotype observed by immunofluorescence with 
Lamp-1 was due to a direct effect on this marker protein when the vLINCL 
proteins were depleted, another late endosomal/lysosomal marker, CD63, was 
used.
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6.2.2 CD63
Immunofluorescence microscopy showed a similar change in phenotype of 
CD63-positive structures to the one observed for Lamp-1-containing structures. 
The results of this are shown in figure 6.2.2 panel A. While CD63-positive 
structures in mock-treated cells were small, puntate and dispersed throughout the 
cells, structures in cells treated with siRNA against the vLINCL proteins 
appeared enlarged and clustered in the perinuclear regions.
QuIF of CD63 did not show any statistically significant changes in integrated 
fluorescence intensity after siRNA treatment, as shown in figure 6.2.2 panel B.
As CD63 and Lamp-1 are both markers for late endosomal/lysosomal 
compartments, these data confirmed that the changes observed were most likely 
due to an effect on the morphology of these compartments occurring as a result 
of decreased levels of the vLINCL proteins.
Interestingly, similar results for these compartments have been observed by other 
members of the laboratory in response to siRNA against the JNCL protein CLN3 
(C. Kitzmuller, personal communication).
6.2.3 EEA1
As shown in figure 6.2.3, no changes were observed in EEA1-positive structures 
after siRNA treatment. Immunofluorescence microscopy showed small, 
dispersed early endosomes in mock and siRNA treated cells. QuIF did not show 
a statistically significant change in integrated fluorescence intensity after siRNA 
treatment.
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6.2.4 PDI
As shown in figure 6.2.4, no changes were observed in PDI staining after siRNA 
treatment. Immunofluorescence microscopy showed reticular and punctate ER 
staining with clearly visible nuclear envelopes in mock and siRNA treated cells. 
QuIF did not show a statistically significant change in integrated fluorescence 
intensity after siRNA treatment.
6.2.5 GM130
A change in phenotype of GM 130-positive structures was observed after 
treatment with siRNA targeting CLN6 and CLN8 but not with siRNA targeting 
CLN5. The results of the immunofluorescence microscopy are shown in figure
6.2.5.1 panel A. GM130 staining gave ribbons of varying length in the 
perinuclear region, some short and some longer. Figure 6.2.5.2 panel A shows 
typical images of cells that were counted as containing short GM130-postive 
ribbons (shorter than 5 p,m) and cells counted as containing long GM 130- 
positive ribbons (longer than 5 p,m). Mock-treated cells tended to have short and 
long ribbons as did CLN5-depleted cells. However, more cells had long GM 130- 
positive ribbons when they were treated with siRNA against CLN6 and CLN8. 
An initial attempt was made to quantify this and 3 x 50 cells were counted for 
each sample. Each cell was counted as containing either short or long ribbons. 
Figure 6.2.5.2 panel B shows a graph of cells containing predominantly short or 
long GM 130-positive ribbons. While in mock and CLN5-depleted cells around 
20% of the cells contained long GM 130-positive ribbons, CLN6-depleted cells 
contained just over 50% and CLN8-depleted cells around 65% of long GM130- 
positive ribbons. The differences observed upon depletion of CLN6 and CLN8 
were statistically significant.
QuIF did not show a statistically significant change in integrated fluorescence 
intensity after treatment with siRNA, as shown in figure 6.2.5.1.
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These results were further investigated by targeting specific cells directly using 
microinjection. HeLa cells were nucleofected for the first round of siRNA 
treatment as described previously. Specific cells were then microinjected with 
water in mock-treated cells and siRNA against CLN5, CLN6 or CLN8. This was 
performed by Dr. Claudia Kitzmiiller. The results of this experiment are shown 
in figure 6.2.5.3. Microinjected cells are denoted with a star. Twenty 
microinjected cells were counted for each sample. All cells that were 
microinjected with water or siRNA against CLN5 showed short cis-Golgi 
ribbons. 50% of cells that were microinjected with siRNA against CLN6 and 
CLN8 showed long ds-Golgi ribbons. These results are consistent with previous 
results and confirm that cells depleted of CLN6 and CLN8 but not of CLN5 
contain more long ds-Golgi ribbons.
This data indicates that there is a change in the morphology of the czs-Golgi, as 
shown by GM130 staining when cells were treated with siRNA against CLN6 
and CLN8 but not CLN5. GM130 localises to the c/s-Golgi membrane where it 
is thought to have a structural role as well as being implicated in facilitating 
vesicle docking (Barr et al., 1997; Nakamura et al., 1997; Nakamura et al., 
1995). There were no previous reports of Golgi abnormalities in vLINCL 
patients. Therefore, it was unexpected that the morphology of the ds-G olgi 
should change in response to CLN6 or CLN8 depletion. Both CLN6 and CLN8 
are located in the ER (Heine et al., 2004; Lonka et al., 2000; Mole et al., 2004), 
and CLN8 has also been reported in the ER-Golgi intermediate compartment 
(Lonka et al., 2000). It is possible that depletion of these proteins would have an 
effect on the cz's-Golgi as there is a close relationship between the two organelles. 
It is unclear whether a change in Golgi morphology could be due to a direct 
effect on the organelle or due to an event in the ER, which could consequently 
lead to a secondary event affecting the Golgi. As CLN5 is reported to be located 
in lysosomes (Isosomppi et al., 2002; Vesa et al., 2002), it is consistent that 
siRNA against this protein would therefore not have an effect on the c/s-Golgi.
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Figure 6.2.1.1: Lamp-1 staining of siRNA treated cells against 
CLN5, CLN6 and CLN8
HeLa cells were mock transfected and treated with siRNA against CLN5, 
CLN6 and CLN8. Immunofluorescence of Lamp-1 shows enlarged structures 
in siRNA treated samples. Bar, 10 pm.
Lamp-1 QuIF siRNA CLN5, CLN6 and CLN8
CLN5 CLN6 CLN8
Figure 6.2.1.2: QuIF Lamp-1
HeLa cells were mock transfected and treated with siRNA against CLN5, 
CLN6 and CLN8. QuIF shows levels of integrated intensity compared to 
mock. There was no statistically significant change between mock and siRNA 
samples as determined by two-sample t-test (see  appendix A).
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Figure 6.2.2: CD63 staining of siRNA treated cells against 
CLN5, CLN6 and CLN8
HeLa cells were mock transfected and treated with siRNA against CLN5, 
CLN6 and CLN8. (A) Immunofluorescence of CD63 shows enlarged 
structures in siRNA treated samples. Bar, 10 pm. (B) QuIF shows levels of 
integrated intensity compared to mock. There was no statistically significant 
change between mock and siRNA treated samples as determined by two- 
sample t-test (see appendix A).
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Figure 6.2.3: EEA1 staining of siRNA treated cells against CLN5, 
CLN6 and CLN8
HeLa cells were mock transfected and treated with siRNA against CLN5, CLN6 
and CLN8. (A) Immunofluorescence of EEA1 shows no difference between 
mock and siRNA treated cells. Bar, 10 nm. (B) QuiF shows levels of integrated 
intensity compared to mock. There was no statistically significant change 
between mock and siRNA treated samples as determined by two-sample t-test 
(see  appendix A).
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Figure 6.2.4: PDI staining of siRNA treated cells against CLN5, 
CLN6 and CLN8
HeLa cells were mock transfected and treated with siRNA against CLN5, 
CLN6 and CLN8. (A) Immunofluorescence of PDI shows no difference 
between mock and siRNA treated cells. Bar, 10 nm. (B) QuiF shows levels of 
integrated intensity compared to mock. There was no statistically significant 
change between mock and siRNA treated cells as determined by two-sample 
t-test (see appendix A).
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Figure 6.2.5.1: GM130 staining of siRNA treated cells against 
CLN5, CLN6 and CLN8
HeLa cells were mock transfected and treated with siRNA against CLN5, 
CLN6 and CLN8. (A) Immunofluorescence of GM130 shows short Golgi 
ribbons in mock and CLN5 depleted cells and long Golgi ribbons in CLN6 and 
CLN8 depleted cells. Bar, 10 pm. (B) QuiF shows levels of integrated intensity 
compared to mock. There was no statistically significant change between 
mock and siRNA treated samples as determined by two-sample t-test (see  
appendix A).
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Figure 6.2.5.2: Golgi structures in siRNA treated cells against 
CLN5, CLN6 and CLN8
(A) Examples of Golgi structures counted as short, bar 5 pm, and long, bar 10 
pm. (B) Number of cells containing short and long Golgi ribbons (3 x 50 cells 
counted per sam ple).p-values were determined by two-sample t-test 
compared to mock (see  appendix A). One star p > 0.05, two stars p > 0.01.
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Figure 6.2.5.3: GM130 staining of cells microinjected with siRNA 
against CLN5, CLN6 and CLN8
HeLa cells were nucleofected for the 1st round of siRNA treatment and then 
microinjected with water (mock) and siRNA against CLN5, CLN6 or CLN8 for 
the 2nd round treatment by Claudia Kitzmuller. Immunofluorescence of 
GM130 show s short Golgi ribbons in mock and CLN5 depleted cells and long 
Golgi ribbons in CLN6 and CLN8 depleted cells. Star indicates microinjected 
cells as detected by co-microinjection with dextran blue.
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6.3 Chapter 6 Summary
The siRNA screen of CLN5, CLN6 and CLN8 revealed two interesting changes 
in organelle morphology. There was an effect on the size and distribution of late 
endosomes and lysosomes in response to siRNA targeting all three proteins. The 
compartments became enlarged and more clustered in the perinuclear region. In 
response to siRNA against CLN6 and CLN8 but not CLN5 there appeared to be 
a specific effect on the structure of the cis-Golgi with more ribbons tending to be 
long on depletion of CLN6 and CLN8.
Future work within the laboratory will ensure the continuation of this project. 
Future work will focus on establishing more detailed knowledge of the different 
responses to depletion of CLN5, CLN6 and CLN8. These results will be put into 
a wider context by comparison with results from experiments of siRNA targeting 
of other NCL genes. Particular attention will focus on lysosomal morphology, as 
this may be a common feature of all or most NCLs, and on Golgi morphology, as 
this may be a mechanism specific to a subset of NCLs.
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7. Discussion
7.1 Summary of findings
The aims of this project were to establish the tools and techniques necessary to 
analyse the CLN6 protein and to utilise these to investigate its subcellular 
location, to identify proteins that interact with CLN6 and to elucidate the early 
cellular responses to loss of functional vLINCL proteins, CLN5, CLN6 and 
CLN8.
It was first shown that a number of different techniques can be utilised to analyse 
CLN6. The endogenous protein can be detected by Western blotting, indirect 
immunofluorescence and immunoprecipitation using the purified peptide 
antibody 1747p. A construct of CLN6 fused to horseradish peroxidase (HRP) 
was cloned for localisation studies by indirect immunofluorescence and electron 
microscopy. CLN6 protein and mRNA levels could be successfully depleted 
using siRNA specific to CLN6 mRNA and this depletion assessed by Western 
blotting, indirect immunofluorescence and Q-PCR.
The subcellular localisation of CLN6 was investigated. CLN6 has been reported 
to be localised in the ER (Heine et al., 2004; Mole et al., 2004) and findings in 
this project were consistent with this. However, CLN6 did not co-localise with 
markers of ER exit sites or become specifically recruited into organised smooth 
ER structures when formation of these was induced by overexpression of GFP- 
cytochrome b(5). Furthermore, it was not possible to detect CLN6 within a sub- 
domain of the ER by indirect immunofluorescence or electron microscopy using 
the CLN6-HRP construct. The levels of wild-type or mutant CLN6 were not 
stabilised using proteasomal or lysosomal inhibitors, and the location of the 
proteins within the cell did not change under the conditions used. It was therefore 
not possible to locate CLN6 within a sub-compartment of the ER or in the 
lysosome and it was also not possible to show that wild-type or mutant CLN6 are 
degraded by ERAD.
CLN6 has been reported to exist as a dimer using overexpression and chemical 
cross-linking (Heine et al., 2004). Co-immunoprecipitation of endogenous CLN6
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supported this, when a large amount of starting material was used. However, it 
was not possible to identify and confirm that other proteins bind to CLN6, even 
when different conditions including chemical cross-linkers were used.
Depletion of CLN5, CLN6 and CLN8 showed changes in the size and 
distribution of late endocytic compartments, resulting in enlarged structures 
positive for the late endosomal/lysosomal markers Lamp-1 and CD63, which 
were clustered in perinuclear regions. A change in the structure of the cis-Golgi 
was also observed in response to siRNA against CLN6 and CLN8 but not CLN5, 
resulting in an increase in cells with long ribbons positive for the cis-Golgi 
marker GM130. No changes were detected in early endosomal or ER structures 
in response to siRNA.
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7.2 Localisation of CLN6
Proteins that are located within the ER can be involved in one or more of its 
different functions. A localisation within a specific sub-compartment of the ER 
may be indicative of these functions. During this project, data became available 
about the localisation of overexpressed CLN6 in neurons (Heine, et al. 2006, in 
press), which shows CLN6 in PDI-positive as well as in PDI-negative structures. 
This staining pattern further suggests that CLN6 is located within distinct regions 
of the ER, as has been previously reported for non-neuronal cells (Mole et al., 
2004). It could also indicate a localisation for CLN6 specific to neuronal cells. If 
this was the case, it might implicate that CLN6 has an additional function in 
neurons.
7.2.1 Co-localisation study within the endoplasmic reticulum using 
immunofluorescence microscopy
CLN6 was proposed to be located within specific regions of the ER, as the 
immunofluorescence pattern of endogenous CLN6 appears less tubular than 
classic ER staining and co-localisation with ER markers is only partial (Mole et 
al., 2004). The immunofluorescence pattern of the ER exit site marker Sec24 is 
very similar to the one observed for CLN6, as it appears as distinct punctae 
distributed throughout the ER (Shimoi et al., 2005). CLN6 could have a function 
in recruitment of other NCL proteins to ER exit sites and thus regulate their 
trafficking through the ER. However, no co-localisation between endogenous 
CLN6 and overexpressed Sec24 was observed. It therefore seems unlikely that 
CLN6 is located in ER exit sites and that it has a function in COPII vesicle 
recruitment or cargo selection.
The immunofluorescence pattern of low overexpression of GFP-cytochrome b(5) 
closely resembles the immunofluorescence pattern of CLN6 (Snapp et al., 2003). 
Organised smooth ER (OSER) structures, formation of which can be induced by 
overexpression of cytochrome b(5), have been implicated in diseases such as 
Charcot-Marie-Tooth syndrome and early onset torsion dystonia (Dickson et al.,
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2002; Hewett et al., 2000). It is possible that similar structural defects of the ER 
exist in CLN6 patients, however, no data has been published to date. Therefore it 
was investigated whether CLN6 is preferentially recruited into OSER, since this 
may suggest a role for CLN6 in the maintenance of ER structure. There was no 
indication that CLN6 was recruited into OSER structures preferentially to the ER 
marker PDI, indicating that CLN6 becomes incorporated into OSER by bulk 
recruitment of ER membrane. This data therefore indicates that CLN6 does not 
have a role in the formation of OSER. However, it may be possible that it has 
another function in the maintenance of the structural integrity of the ER.
7.2.2 CLN6-HRP distribution within the endoplasmic reticulum
The experim en ts using the CLN6-HRP construct by indirect 
immunofluorescence indicated that the construct localises to the ER but most 
likely not in the same distribution pattern as endogenous CLN6. At the ultra- 
structural level, the construct was located throughout the entire ER. It is therefore 
difficult to directly compare the localisation results of the overexpressed 
construct to those of the endogenous protein. Modification of the construct will 
be necessary and suggestions for this were made in chapter 4.2.
7.2.3 CLN6 trafficking in response to lysosomal and proteasomal 
inhibitors
The use of lysosomal inhibitors did not show a change in the localisation of wild- 
type or mutant CLN6, suggesting that CLN6 does not exit the ER. This indicates 
that CLN6 does not have a function in the lysosome but that it most likely has a 
function in the ER that impacts on lysosome function. This data is consistent 
with published results about the location of CLN6 in the ER (Heine et al., 2004; 
Mole et al., 2004).
The use of proteasomal inhibitors did not show a stabilisation of the protein 
levels of wild-type or mutant CLN6. It was proposed that mutant or misfolded 
CLN6 at least should be degraded by ERAD as is the case with many misfolded
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proteins such as wild-type and mutant forms of the cystic fibrosis transmembrane 
conductance regulator (CFTR) (Sun et al., 2006; Zhang et al., 2001). However, 
this data showed that wild-type and mutant CLN6 used in the experiment were 
not degraded by ERAD. It is of course possible that the mutant protein misfolds 
and aggregates in the ER. However, no changes in the appearance of the ER, 
such as increased amounts of OSER, have been observed at the ultra-structural 
level when these cells were analysed by electron microscopy (data not shown).
There is no data published about the half-life of wild-type CLN6, although 
siRNA experiments show a reduction in protein levels after two days of 
treatment with siRNA, suggesting that the protein is actively turned over in this 
time period. It would therefore be expected that two days of treatment with 
proteasomal inhibitors should show an increase in protein levels if the protein 
was degraded by the proteasome. However, as discussed in chapter 4.3, the cells 
were severely affected by the treatment with the inhibitor. There was also no 
positive control in this experiment, such as another protein known to be degraded 
by ERAD, whose protein levels were increased after inhibitor treatment. It would 
therefore be necessary to optimise the conditions and repeat the experiment in 
order to elucidate the degradation of wild-type and mutant CLN6, and technical 
suggestions for this have been described in chapter 4.3.
7.2.4 Future work
The ER is a very versatile organelle and its structure and specialised functions 
differ between cell types. The following experiments are proposed to further 
investigate the localisation of endogenous CLN6:
The localisation of endogenous and overexpressed CLN6 could be further 
investigated using indirect immunofluorescence in different cell types. These 
experiments should include the use of specialised cell types such as polarised 
cells, hepatocytes with a large proportion of smooth ER, and neurons or 
neuroblastoma cell lines. This would help clarify whether there is a differential 
distribution of CLN6 in different cell types.
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Further co-localisation studies could be performed using other markers for 
different ER functions. This could be done in different cell types to further 
investigate whether CLN6 has a differential distribution dependent on cell type.
The CLN6-HRP construct should be further improved. Technical suggestions for 
this were described in chapter 4.2. If the construct could be expressed more 
efficiently, it may be possible to clarify its location within the ER at the ultra- 
structural level. This would help to elucidate the location and function of CLN6.
The proteasomal inhibitor treatment of fibroblast cell lines from CLN6 patients 
should be repeated. The concentration of the inhibitor should be optimised to 
minimise cell death and positive controls included in the experiment.
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7.3 CLN6 binding partners
It was proposed that by identifying proteins that interact with CLN6 it might be 
possible to elucidate its function. There are different approaches to analyse this, 
such as yeast-two-hybrid screens, GST-pull down experiments and others. 
Immunoprecipitation of the endogenous protein was successful. It was therefore 
decided to use this technique as it captures the protein in its natural intracellular 
environment. However co-immunoprecipitation of CLN6 with other proteins 
proved very challenging. Two different approaches were used. The first one used 
a large amount of starting material, as it was difficult to detect CLN6 by silver 
staining when less starting material was used. This method successfully 
identified CLN6 as the protein of the correct molecular weight detected by 
Western blotting. It further indicated that CLN6 may bind to itself which has 
been reported for the overexpressed protein (Heine et al., 2004). However, other 
proteins identified by this method could not be confirmed as interactors of 
CLN6. The large amount of starting material most likely resulted in non-specific 
binding of these proteins to the antibody or the magnetic beads. The amount of 
starting material was reduced and chemical cross-linkers used to strengthen the 
physical interaction between CLN6 and proteins that bind to it, as this technique 
had been used to show the dimerisation of overexpressed CLN6 (Heine et al., 
2004). Interestingly, a dimer of endogenous CLN6 could never be detected by 
Western blotting even after cross-linking (data not shown). It is possible that 
only a small population of endogenous CLN6 dimerises, making it difficult to 
detect the dimeric complex. It was further reported that regions in both the bl­
and C-termini of the protein are implicated in dimerisation (Heine, et al., 2006, in 
press). As the antibody recognises the first fifteen amino acids of the N-terminal 
of the protein, it may be that the ability of the antibody to detect the dimer is 
greatly reduced due to steric interference.
It was also not possible to identify and confirm interacting proteins when 
chemical cross-linkers were used. It is possible that the amount of starting 
material used in the second and third co-immunoprecipitations experiments was 
too low, which could be further optimised by using increasing amounts of cells.
146
However, other technical difficulties were encountered. The contamination of 
most bands in the second co-immunoprecipitation experiment with keratin meant 
that although interacting proteins may have been present in the bands, they could 
not be identified. In the third co-immunoprecipitation experiment there was no 
contamination but only two bands could be identified. However HSP70 has been 
shown by Western blotting not to be enriched after co-immunoprecipitation of 
CLN6, as the antibody that recognises mtHSP75 cross-reacts with HSP70. It was 
further shown that CLN6 does not interact with alpha, beta or gamma actin using 
an antibody that detects all three isoforms.
From these data it is clear that this technique must be optimised if interactors are 
to be successfully identified using this method. In this context, the following 
could be tested:
The amount of starting material used in combination with cross-linkers should be 
further optimised. Different numbers of cells should be used to find the lowest 
amount necessary that would allow positive identification of bands while 
keeping the amount of non-specific binding to a minimum.
Different detergents could be used to test if other interacting proteins can be 
identified. Some proteins are easily solubilised in one detergent but not in 
another or require the addition of other reagents to be successfully detected. For 
example, the ER protein ribophorin I can only be detected when 0.6% SDS is 
added to the Triton-X lysate (de Virgilio et al., 1998)(C. Kitzmiiller, personal 
communication). Furthermore, proteins that are post-translationally modified 
might be more difficult to detect. For example, proteins that are glycosylated are 
often seen as a smear of many bands when detected by Western blotting, as is the 
case for CLN3 (Storch et al., 2004)(C. Kitzmiiller, personal communication). It 
might be possible that these smears are more difficult to see than distinct bands 
when visualised by silver staining. In the case of glycosylated proteins, the co- 
immunoprecipitated samples could be deglycosylated prior to running them on 
gels.
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If CLN6 interacts with other NCL proteins, it may be very difficult to detect this 
interaction using endogenous proteins, as some NCL proteins, such as CLN3, are 
expressed at very low levels (C. Kitzmiiller, personal communication). Indeed 
CLN6 and CLN5 are the only human NCL proteins that have been reported to be 
detected at their endogenous expression levels (Bessa et al., 2006; Mole et ah,
2004). Although CLN6 has been reported not to interact with CLN8 (Heine, et 
ah, 2006, in press), it is possible that CLN6 could interact with other NCL 
proteins and perhaps have a function in their transit through the ER. These 
interactions may be better investigated using overexpressed NCL proteins to 
facilitate their detection. However, there are disadvantages associated with 
overexpressing proteins for this purpose. If proteins are expressed at high levels 
to ease their detection, it is possible that they aggregate or do not integrate into 
their intracellular environment correctly. This is especially true if proteins are 
tagged, as the addition of the tag may prevent correct folding or integration into 
multimeric complexes (Bauer and Kuster, 2003). Thus interactions may be 
detected which occur as a result of overexpression. It would therefore have to be 
proven that interactions detected this way are physiologically relevant.
It is also possible that CLN6 does not bind to another protein. It could bind to 
lipids, which could be tested using a lipid overlay assay. Furthermore it may 
form a channel and therefore only bind to itself. In this case the properties of 
dimeric or multimeric CLN6 should be further investigated.
In conclusion, there are many possibilities to optimise the co- 
immunoprecipitation of endogenous CLN6 with interacting proteins. Future 
work should certainly focus on this, as elucidation and clarification of proteins 
that bind to CLN6 would greatly further the understanding of its function.
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7.4 siRNA screen of vLINCL proteins
7.4.1 Lamp-1 and CD63
Depletion of the vLINCL proteins showed an increase in the size and a 
redistribution into perinuclear regions of late endocytic compartments positive 
for Lamp-1 and CD63. It was postulated that there may be an effect on late 
endocytic structures in response to reduced protein levels, as this is the site of the 
accumulation of storage material. It was surprising that this effect was so 
immediate and so striking as the onset of vLINCL symptoms in patients does not 
occur until late infancy. From this it can be postulated that a change in the 
structure and distribution of the lysosome is present throughout the development 
of vLINCL patients, long before the onset of symptoms. In fact, it was recently 
reported that in the brains of OCL6 sheep, the South Hampshire sheep model of 
CLN6, neurodegeneration occurs before the onset of symptoms (Oswald et al.,
2005).
The question that then arises is how this change in size and distribution of the 
late endocytic compartments is caused and how it relates to the accumulation of 
storage material and the pathological effect on the neurons in patients. It is likely 
that a change in size and distribution of the lysosomes is accompanied by a 
defect in function, which could result in an accumulation of undegraded material 
in the lysosomes. However, as the onset of pathological changes in not 
immediate and only a sub-set of cell types are affected by this, it can be assumed 
that most cells can tolerate the structural lysosomal defect. Two different 
possibilities can be considered to explain the neuropathology:
It can be postulated that the change in size and distribution of the lysosomes and 
the accumulation of the storage material may not necessarily be the cause of the 
neurodegeneration, and that neuronal cell death may occur via a cell-type 
specific effect related to an effect on lysosome function. Indeed glial activation 
in the South Hampshire OCL6 sheep was observed independently of the storage
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material (Oswald et al., 2005). However, it is also possible that neurons are 
simply more susceptible to metabolic changes and are therefore more affected by 
the storage accumulation and the effect on lysosome function. It can therefore be 
postulated that the pathological effect of the storage is first observed in the 
neurons and that the patients do not live long enough for pathological changes to 
occur in other cell types.
The following questions could be addressed to further elucidate this:
Is the lysosomal function compromised at the same time as the changes in size 
and distribution are observed? It has been reported that the activities of cathepsin 
D, beta-hexosaminidase, arylsulfatase A and TPP-I were normal in fibroblast cell 
lines from CLN6 patients (Heine et al., 2004; Sohar et al., 1999). It would 
therefore be expected that the activities of these enzymes would also be 
unaffected after siRNA treatment. However, in brain samples from CLN3 
patients the levels of TPP-I were reported to be increased although it was 
indicated that some of this was enzymatically inactive. Therefore other 
lysosomal hydrolases should be tested after depletion of CLN5, CLN6 and CLN8 
to clarify this question as a defect in lysosomal hydrolase activity would result in 
an accumulation of undegraded material as has been reported for many LSDs 
(Futerman and van Meer, 2004).
Is there a change in pH? Elevated lysosomal pH levels have been reported for 
fibroblast cell lines from CLN5, CLN6 and CLN8 patients (Holopainen et al., 
2001). It could therefore be expected that the pH of lysosomes in cells depleted 
of the vLINCL proteins should also increase. Changes in cytoplasmic pH have 
been shown to influence the distribution and size of lysosomes. As the 
cytoplasmic pH was lowered, lysosomes moved towards the cell periphery and 
became smaller (Heuser, 1989). It is possible that depleting cells of CLN5, 
CLN6 or CLN8 results in an increase in intra-lysosomal pH and the change in 
size and distribution of lysosomes occurs as a secondary event. Therefore, 
lysosomal pH should be monitored to establish the earliest cellular events that 
occur after depletion of vLINCL proteins.
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Is there an accumulation of autofluorescent material? Autofluorescence was not 
observed in any of the siRNA experiments conducted. However, it may be that 
autofluorescent material would accumulate over time. For this an inducible 
RNAi system where cells are stably transfected with an RNAi vector that can be 
activated over longer periods of time would be necessary. It could then be 
possible to follow the accumulation of autofluorescent material over time and 
correlate this with any other cellular changes that might occur.
Are the effects similar in neurons from the vLINCL mouse models? In order to 
find out if the changes observed in the siRNA experiments are physiologically 
relevant, it would be possible to test whether neurons from the nclf, the mnd and 
the Cln5-/- mouse models show similar changes in late endocytic structures.
Another important implication can be drawn from the siRNA experiments. The 
effect on late endocytic structures was the same when siRNA was used against 
the vLINCL proteins CLN5, CLN6 and CLN8 as well as against CLN3 (C. 
Kitzmiiller, persona l com m unication). This may indicate a functional 
relationship between these and potentially between other NCL proteins on a 
common pathway. To further investigate this, the following experiment could be 
performed:
Is there an additive effect when more than one NCL protein is targeted by 
siRNA? The use of combinations of siRNAs against two or more proteins at the 
same time could answer this question. It may be postulated that if proteins are 
involved in the same cellular pathway, then depleting one should have the same 
effect as depleting more than one, as this pathway would already be disturbed. 
However, if there was an additive effect, this may indicate an involvement in 
separate pathways. It would however have to be taken into consideration that 
NCL proteins could have more than one function, as has been suggested for 
CLN3 (C. Kitzmiiller, R. Haines, S. Mole, personal communication). Therefore, 
additional effects upon protein depletion may still indicate that the proteins are 
involved in the same cellular pathway but that they also have other functions that 
are not related.
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7.4.2 GM130
In response to depletion of CLN6 and CLN8 but not CLN5, there was a change 
in the structure of cfs-Golgi ribbons, resulting in an increase of long GM 130- 
positive structures. This result is interesting because it shows for the first time a 
difference in cellular phenotype between the ER located vLINCL proteins and 
the lysosomal vLINCL protein CLN5. There are no reports of abnormal Golgi in 
vLINCL patients to date, however it is unclear whether this has been investigated 
in detail. It therefore remains to be determined how this phenomenon contributes 
to the vLINCL phenotype. The following could be addressed to elucidate this in 
greater detail:
Is there a change in rate of collapse/reassembly of the cz's-Golgi when CLN6 and 
CLN8 are depleted? The Golgi can be formed de novo from constituents of the 
ER. These leave the ER via ER exit sites and mature into ERGIC structures, 
which then fuse to form the cfs-Golgi (Altan-Bonnet et al., 2004; Puri and 
Linstedt, 2003). If CLN6 or CLN8 had a function in Golgi biogenesis or 
maintenance, there may be changes in the collapse or reassembly of the Golgi 
when the proteins are depleted. This could be assayed using the drug brefeldin A 
(BFA), which inhibits Sari, a key protein involved in the formation of ER exit 
sites, and relocalises most Golgi proteins to the ER upon drug treatment (Altan- 
Bonnet et al., 2004; Peyroche et al., 1999). After the drug is removed, the rate of 
reassembly of Golgi components can then be measured. The dynamics of this 
could be compared between mock and CLN6- or CLN8-depleted cells. This 
would help to establish if CLN6 or CLN8 have a function in the formation or 
maintenance of the Golgi.
Is there a change in actin recruitment at the Golgi? Actin filaments have been 
implicated in the positioning and morphology of the Golgi complex as well as in 
retrograde traffic from the Golgi to the ER (Valderrama et al., 1998; Valderrama 
et al., 2001). The Rho GTPase Cdc42 has been implicated in regulating actin 
assembly on Golgi membranes and microinjection of a constitutively active 
Cdc42 mutant resulted in longer cfs-Golgi ribbons (Matas et al., 2005). These
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closely resemble the long ribbons seen upon depletion of CLN6 and CLN8. 
However, it was shown in chapter 5.3 that CLN6 does not interact directly with 
alpha, beta or gamma actin. It is possible that CLN6 interacts with a protein that 
in turn interacts with actin. It is further possible that CLN8 binds to actin. Both 
beta- and gamma-actin have been reported to localise to Golgi structures and 
COPI-coated vesicles (Valderrama et al., 2000). It could therefore be postulated 
that CLN6 and CLN8 are involved in an actin-mediated process of retrograde 
traffic or maintenance of Golgi structure, a disruption of which could result in 
the morphological changes observed after depletion of CLN6 and CLN8. To 
further investigate this, actin dynamics at the Golgi after siRNA treatment could 
be analysed.
Is there a change in the rate of protein traffic through the Golgi? The structural 
changes observed after depletion of CLN6 and CLN8 may directly influence the 
rate at which proteins traffic through the ER. The rate of traffic through the Golgi 
varies greatly and can be in the range of 1 min to 60 min (Altan-Bonnet et al., 
2004). A structural change could have an effect on the rate of traffic of all 
proteins or perhaps of a subset of proteins. This could be assayed using time- 
lapse microscopy following the trafficking of tagged overexpressed proteins. 
This experiment would establish whether depletion of CLN6 or CLN8 have a 
direct effect on protein trafficking through the Golgi. It would be particularly 
interesting to follow the trafficking of other NCL proteins to test whether 
depletion of CLN6 or CLN8 has a direct effect on this. This could further the 
understanding of the relationship of different NCL proteins to each other.
Is there a change in the rate of lipid traffic through the Golgi? CLN8 has been 
reported to belong to the TLC family of proteins and has been implicated in lipid 
metabolism (Winter and Ponting, 2002). It is possible that depletion of CLN8 
results in a disturbance of lipid metabolism that leads to a change in Golgi 
structure. Dilated trans-Golgi structures have been reported in Tangier disease 
(Robenek and Schmitz, 1991). This disorder is caused by mutations in the 
adenosine triphosphate (ATP)-binding cassette transporter A 1 (ABCA1), which 
is implicated in lipid trafficking, and manifests with the storage of cholesteryl
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esters in reticuloendothelial tissues and peripheral neuropathy (Kolovou et al.,
2006). These defects are thought to be caused by low plasma levels of high- 
density lipoprotein cholesterol (HDL-C). It has been reported that ABCA1 plays 
a role in the trafficking of cholesterol and phospholipids from the Golgi and late 
endosomes to the plasma membrane (Neufeld et al., 2004; Orso et al., 2000). 
Interestingly, late endosomes but not lysosomes of fibroblast cell lines from 
Tangier disease patients have been shown by electron microscopy to be enlarged 
(Neufeld et al., 2004; Robenek and Schmitz, 1991). Similarly, it may be possible 
that the depletion of CLN8 may have an effect on lipid trafficking or 
homeostasis. Abnormalities in sphingo- and phospholipid profiles have been 
reported in brain tissue from CLN8 patients (Hermansson et al., 2005). This 
should be further investigated. Fluorescently labelled lipids or lipid analogues 
could be used to analyse lipid trafficking and intracellular distribution upon 
depletion of CLN8. Although no involvement of CLN6 in lipid metabolism has 
been proposed to date, it is possible that CLN6 may have a function in this as 
depletion of CLN6 shows the same effect on the Golgi as depletion of CLN8, 
and experiments should therefore be performed on both proteins. It is however 
possible that CLN6 and CLN8 affect the Golgi through different mechanisms 
that result in the same phenotype. Elucidation of this would provide an 
understanding of whether CLN6 and CLN8 are involved in lipid metabolism or 
trafficking and establish whether this is involved in the vLINCL disease 
phenotype.
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7.5 Possible functions of CLN6
As CLN6 is a protein of unknown function, the processes it is involved in are 
unknown. Examining the data presented in this thesis, the following mechanism 
of action for CLN6 can be proposed:
The CLN6 protein has a role in trafficking of other proteins and/or lipids through 
the ER and/or a role in Golgi to ER or ER to Golgi trafficking
7.5.1 Trafficking of proteins or lipids
CLN6 could be involved in the traffic of other proteins through the ER. This 
could especially be the case for other NCL proteins, such as CLN3 and CLN5. It 
is also possible that CLN6 has a function in trafficking certain lipids. If the 
function of CLN6 is compromised, then these proteins or lipids may traffic more 
slowly or aberrantly. It is feasible that the functions of CLN6 and CLN8 are 
interlinked, even if they do not interact directly. Thus, if one is mutated, this 
might have an effect on the other protein. The result of this could be that the 
proteins or lipids being trafficked are disturbed in their homeostasis. 
Abnormalities in lipid profiles have indeed been reported in CLN8 patients 
(Hermansson et al., 2005). Furthermore if CLN6 and CLN8 affect the trafficking 
of the lysosomal proteins CLN3 and CLN5 this could explain the lysosomal 
phenotype observed in vLINCL.
7.5.2 Golgi to ER or ER to Golgi traffic
As there is a change in the structure of the cw-Golgi when CLN6 is depleted, it is 
possible that this protein has a functional link with the Golgi. This could either 
be through an actin-mediated pathway or through a lipid trafficking pathway. 
The same can be proposed for CLN8. If these proteins are mutated or depleted, 
the Golgi could be directly affected. This could then either lead to a secondary 
effect in the lysosome through a change in the rate of trafficking of lysosomal
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components, especially CLN3 and CLN5, or of lipid components. It is also 
possible that retrograde traffic from the ER to the Golgi is affected when CLN6 
is not present. This may lead to disturbances in lipid trafficking and perhaps in an 
accumulation of proteins in the cis-Golgi, unable to be retrieved to the ER. This 
may explain the increase in long Golgi ribbons observed upon depletion of 
CLN6 and CLN8. It may also indicate a secondary effect on traffic from the 
Golgi to the lysosome.
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7.6 Summary and Conclusions
As part of the thesis it was investigated whether CLN6 is located within a sub­
compartment of the ER, whether CLN6 binds to other proteins and what cellular 
responses occur when the vLINCL proteins CLN5, CLN6 and CLN8 are 
depleted. It was not possible to locate CLN6 within a sub-compartment of the 
ER, however it was shown that CLN6 does not traffic to the lysosome. Wild-type 
and mutant CLN6 were not found to be degraded by ERAD. It was not possible 
to identify proteins that bind to endogenous CLN6 in co-immunoprecipitation 
experiments other than CLN6 itself. After depletion of CLN5, CLN6 and CLN8 
a change in the size and distribution of late endocytic compartments was 
observed, which indicates that these compartments are affected immediately 
when the vLINCL proteins are absent. Furthermore, in response to depletion of 
CLN6 and CLN8 but not CLN5, an increase in the number of cells with long cis- 
Golgi ribbons was observed, indicating a difference in the cellular response to 
depletion of the ER-resident vLINCL proteins CLN6 and CLN8 and the 
lysosomal vLINCL protein CLN5.
The tools and techniques to analyse the CLN6 protein have been established and 
will provide a basis for future investigation. Using a derivative of the CLN6- 
HRP construct, it may be possible to locate CLN6 at the ultra-structural level and 
draw conclusions about its localisation within the ER. The identification of 
proteins that bind to CLN6 will provide an insight into the function of the 
protein, and this should be further investigated applying complementary 
techniques to these used here, especially with regard to interactions between 
CLN6 and other NCL proteins. Using RNAi experiments it was successfully 
shown that loss of the vLINCL proteins has an immediate effect on late 
endocytic compartments, implicating this as one of the earliest steps that occur in 
vLINCL pathogenesis and possibly a common phenomenon in NCL. The 
challenge for future investigations will be to further dissect the mechanism that 
leads to the effect on late endocytic compartments. It will also be necessary to 
establish whether there is a functional link between events in the Golgi and in 
late endocytic compartments when CLN6 or CLN8 are absent. The identification
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of the early cellular events that occur in the different types of vLINCL will 
enhance the understanding of this disease and the mechanisms that causes it.
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Table 9.1: t-tests (paired student’s t-test, two-tail)
6.2.1.2 LAMP-1
mock cln5 mock cln6 mock cln8
Mean 3.284246 3.105688 3.284246 2.975449 3.284246 3.798384
Variance 2.663816 1.887616 2.663816 1.547451 2.663816 7.471355
Observations 6 6 6 6 6 6
Pearson Correlation 0.989937 0.782007 0.92782
Hypothesized Mean Difference 0 0 0
df 5 5 5
tStat 1.30804 0.74319 -0.92422
P(T<=t) one-tail 0.123882 0.245395 0.198892
t Critical one-tail 2.015048 2.015048 2.015048
P(T<=t) two-tail 0.247764 0.490789 0.397783
t Critical two-tail 2.570582 2.570582 2.570582
6.2.2 CD63
mock cln5 mock cln6 mock cln8
Mean 2.121395 2.701549 2.727395 3.20645 2.727395 3.320224
Variance 0.981188 0.860395 0.981188 2.161642 0.981188 2.563173
Observations 6 6 6 6 6 6
Pearson Correlation 0.871649 0.827399 0.945039
Hypothesized Mean Difference 0 0 0
df 5 5 5
t Stat 0.129277 -1.37073 -1.96348
P(T<=t) one-tail 0.451089 0.114395 0.053406
t Critical one-tail 2.015048 2.015048 2.015048
P(T<=t) two-tail 0.902178 0.22879 0.106811
t Critical two-tail 2.570582 2.570582 2.570582
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6.2.3 EEA-1
mock cln5 mock cln6 mock cln8
Mean 0.475347 0.416073 0.475347 0.494079 0.475347 0.431482
Variance 0.008999 0.02833 0.008999 0.129084 0.008999 0.055198
Observations 6 6 6 6 6 6
Pearson Correlation 0.477169 0.136497 0.45804
Hypothesized Mean Difference 0 0 0
df 5 5 5
tStat 0.976859 -0.12786 0.513509
P(T<=t) one-tail 0.186751 0.451621 0.314737
t Critical one-tail 2.015048 2.015048 2.015048
P(T<=t) two-tail 0.373503 0.903242 0.629473
t Critical two-tail 2.570582 2.570582 2.570582
6.2.4 PDI
mock cln5 mock cln6 mock cln8
Mean 6.559477 7.960006 6.559477 6.12629 6.559477 5.650781
Variance 25.97112 24.50633 25.97112 23.8874 25.97112 19.33915
Observations 6 6 6 6 6 6
Pearson Correlation 0.929626 0.831113 0.905317
Hypothesized Mean Difference 0 0 0
df 5 5 5
tStat -1.81513 0.364881 1.02324
P(T<=t) one-tail 0.064608 0.365063 0.176562
t Critical one-tail 2.015048 2.015048 2.015048
P(T<=t) two-tail 0.129217 0.730125 0.353125
t Critical two-tail 2.570582 2.570582 2.570582
183
6.2.5.1 GM130
mock cln5 mock cln6 mock cln8
Mean 0.156731 0.227194 0.156731 0.124116 0.156731 0.195906
Variance 0.007134 0.003088 0.007134 0.000939 0.007134 0.012461
Observations 6 6 6 6 6 6
Pearson Correlation 0.366052 -0.4708 0.210006
Hypothesized Mean Difference 0 0 0
df 5 5 5
t Stat -2.09523 0.779325 -0.76742
P(T<=t) one-tail 0.045149 0.235523 0.238744
t Critical one-tail 2.015048 2.015048 2.015048
P(T<=t) two-tail 0.090298 0.471047 0.477488
t Critical two-tail 2.570582 2.570582 2.570582
6.2.5.2 GM130 ribbons short and long
mock CLN5 mock CLN8 mock CLN6
Mean 37.33333 40.33333 37.33333 18.33333 37.33333 23.33333
Variance 6.333333 6.333333 6.333333 2.333333 6.333333 8.333333
Observations 3 3 3 3 3 3
Pearson Correlation 0.684211 -0.56362 0.802955
Hypothesized Mean Difference 0 0 0
df 2 2 2
t Stat -2.59808 9.127305 14
P(T<=t) one-tail 0.060845 0.005896 0.002532
t Critical one-tail 2.919986 2.919986 2.919986
P(T<=t) two-tail 0.12169 0.011792 0.005063
t Critical two-tail 4.302653 4.302653 4.302653
Appendix B -  Co-immunoprecipitation sequencing data
Table 9.2 : Co-immunoprecipitation 1 raw data
Band Predicted protein Accession number Peptides matched Probability
2 DEAD box polypeptide 48 gi_7661920 10 1.0e+000
2 Beta-tubulin g i j  8088719 4 8.5e-008
3 Gamma-actin gi_7441428 5 5.7e-001
5 PPR repeat domain 2 gi_20127634 5 7.7e-001
7 CLN6 gi_8923532 3 1.0e-002
Data analysed in ProFound by Dr. Oliver Kleiner, UCL. Probability was computed as the normalised probability that a protein in a 
database is the protein being analysed.
Table 9.3: Co-immunoprecipitation 2 raw data
Band Predicted protein Accession number Peptides matched Probability score
2 mtHSP75 gi_292059 2 91
Data analysed in Mascot by Dr. Catherine Lilley, Cambridge. Score is -10xLog(P), where P is the probability that the observed match is a 
random event. Protein scores greater than 67 are significant (p < 0.05).
Table 9.4: Co-immunoprecipitation 3 raw data
Band Predicted protein Accession number Peptides matched Probability score
3 chain A, HSP70 42 kDa ATPase N-terminal domain gi_6729803 9 81
5 beta-actin gi_4501885 7 74
Data analysed in Mascot by Dr. Oliver Kleiner, Eisai. Score is -10xLog(P), where P is the probability that the observed match is a 
random event. Protein scores greater than 67 are significant (p < 0.05).
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